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Abstract  
Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health 
problems in Malawi. Coinfections are widespread and there is possibility of important 
interactions between these two pathogens with consequences for LF control and elimination. 
There is little available evidence on co-infection and interaction of LF and HIV infections and 
the study set out to investigate associations and interactions between these two pathogens 
and determine possible consequences for LF control and elimination through annual mass 
drug administration (MDA).   
This thesis presents results from adult study participants in two rural sites in Karonga district, 
northern Malawi, a region endemic for both LF and HIV. Stored blood samples and data from 
two geographically separate studies were used. One was a clinical trial of anti-filarial agent 
dosing regimens in Songwe in the northern part of the district (the Songwe clinical trial), and 
the other a whole population annual HIV sero-survey with longitudinal follow up data from the 
southern part of the district (the Karonga Health and Demographic Surveillance System or 
KHDSS).  The main objectives were: 
1. To determine the prevalence of LF and HIV co-infections as quantified by the Og4C3 
ELISA in a large cross-sectional study in Karonga district, rural northern Malawi. 
2. To investigate whether higher and/or more frequent doses of albendazole and 
ivermectin were more effective in eliminating Wuchereria bancrofti microfilariae than 
the World Health Organisation (WHO) approved standard regimen. 
3. To determine the relationship of circulating filarial antigen (CFA) and microfilaria count 
(MF) by HIV status.  
4. To monitor the impact of Mass Drug Administration (MDA) on LF antigenaemia by HIV 
status by following a cohort of LF antigen positive individuals identified in objective 
one. 
5. To assess the contribution of insecticide treated bed nets (ITNs) to changes in CFA. 
These objectives were met through three filarial research studies using data from two distinct 
geographical locations: Study 1, cross-sectional assessment of the relationship of HIV and 
markers of LF infection; Study 2, clinical trial of anti-filarial dosing regimens and Study 3, 
longitudinal assessment of the impact of MDA on LF antigenaemia by HIV status.  
In study 1 (cross-sectional assessment), 1,851 consecutive adult volunteers from the Songwe 
area of Karonga district were screened for HIV and LF infection. Overall CFA prevalence was 
24.1% (447/1851) while CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% 
(351/1487) in HIV-negative participants (p=0.57). Geometric mean concentrations (GMC) of 
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CFA were 859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean 
ratio (GMR) 0.85, 95% CI 0.49-1.50.  In addition, a further 7,863 adults from the KHDSS part 
of the district had an overall CFA prevalence of 23.8% (1875/7863), a CFA prevalence of 
20.9% (86/411) in HIV-positive and 24.0% (1789/7452) in HIV-negative participants (p=0.15) 
at baseline. GMC CFA was 630 and 839 Ag/ml respectively (GMR 0.75, 95% CI 0.60-0.94). 
In the HIV-positive group, antiretroviral therapy (ART) use was associated with a lower CFA 
prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95% CI 0.24-0.76). Prevalence of 
CFA decreased with duration of ART use, 15.2% 0-1 year (n=59), 13.6% >1-2 years (n=44), 
10.0% >2-3 years (n=30) and 0% >3-4 years treatment (n=9), p<0.01 χ2 for linear trend.   
In study 2 (clinical trial), seventy individuals with confirmed circulating LF antigen had 
microfilarial counts >80 microfilariae/ml and were randomised as part of a controlled open 
label clinical trial. The clinical trial compared three modified treatment groups to standard 
dosage of ivermectin and albendazole in adults. Participants were followed up every six 
months for two years for repeat microfilarial counts and safety assessments. All treatment 
groups achieved a significant reduction of microfilariae levels by 12 and 24 months of follow 
up. Doubling the standard dose and giving it twice yearly showed a non-significant tendency 
towards faster and more complete clearance. There were no serious adverse reactions.  
In study 3 (longitudinal assessment), the cohort was derived from study 1 and comprised of 
1722 baseline CFA positive individuals who had a follow up blood sample and a random 
sample of 939 baseline CFA negative individuals. Of the 1722 baseline CFA positive 
individuals, 524 (30.4%) remained CFA-positive, a clearance rate of 325/1000 person years 
of follow up while all but two of the 939 CFA-negative individuals at baseline remained 
negative at follow up, an incidence of 1/1000 person years of follow up. Using logistic 
regression, two doses of annual MDA was independently associated with decreased CFA 
positivity while bed net ownership and HIV status were not associated with CFA positivity. In 
the HIV-positive subgroup, ART use did not show any association with CFA positivity at follow 
up. 
This is the first investigation of this magnitude into HIV and LF co-infection in Malawi and it 
adds significantly to existing knowledge in the field. The cross-sectional study of two distinct 
LF-exposed populations confirms that there is no evidence that HIV infection has an impact 
on LF epidemiology that will interfere with LF control measures. A significant association of 
ART use with lower CFA prevalence merits further investigation to understand this apparent 
beneficial impact of ART. At follow up, MDA effectively reduced CFA prevalence and worm 
burden and the effectiveness of MDA treatment is unaffected by HIV co-infection and ART 
status.    
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 Introduction to the Thesis 
This chapter provides a background to the study, a summary of the justification and rationale 
to the study, the aims and objectives as well as a summary of the study design and main 
methods used in the study. The layout of the thesis is desciribed in the last section of this 
chapter.  
1.1 Background to the study 
1.1.1 Lymphatic filariasis control 
Lymphatic filariasis (LF), a helminth infection caused by the mosquito-borne filarial 
nematodes, Wuchereria bancrofti, Brugia malayi and Brugia timori, is a major public health 
problem in the tropics and according to the World Health Organisation (WHO) is the second 
leading cause of permanent and long-term disability globally after mental illness [1]. At the 
launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, an 
estimated 1.3 billion people in 73 endemic countries were at risk of LF and 120 million people 
were infected, with 91% of cases caused by W. bancrofti and 40 million of them disfigured and 
incapacitated by chronic manifestations of the disease [2, 3]. Currently, 856 million people in 
52 countries worldwide remain threatened by LF and require preventive chemotherapy [4]. 
The GPELF aims to eliminate LF through annual mass drug administration (MDA) using 
single-dose ivermectin 150 µg/kg and albendazole 400 mg annually for 4–6 years to affected 
populations living in areas in Africa that are also endemic for onchocerciasis [5, 6]. Rapid and 
sustained clearance is desirable for public health impact and the ideal annual dosing regimens 
remain unclear with documented ‘hot spots’ of new transmission remaining in areas that have 
received MDA and reports of individuals who remain microfilaria (mf) positive despite 
treatment [7].   
1.1.2 Frequency and dosing of mass drug administration  
Higher annual doses or more frequent dosing regimens might have the potential to achieve a 
successful and accelerated outcome of mass treatment programmes. This could be at a lower 
overall cost to national programmes by achieving critical programmatic milestones much 
earlier [8]. However, available data to guide and support such a large programmatic shift are 
limited and no data are available from HIV endemic areas. A randomised clinical trial in Egypt 
reported that multi-dose diethylcarbamazine (DEC) and albendazole treatment was more 
effective than single dose treatment [9]. The efficacy of ivermectin was shown to be higher 
when given twice yearly in French Polynesia [10]. Small studies in Haiti and Mali have shown 
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higher and biannual dosing to be more effective than the standard dose regimen in 
suppressing microfilariae [11, 12].   
1.1.3 Helminths and HIV co-infection is common  
Human Immunodeficiency Virus (HIV) infection is another major public health problem and 
leading cause of morbidity and mortality worldwide. Approximately 35 million people are 
infected with HIV worldwide and although Africa accounts for 14% of the population in the 
world, sub-Saharan Africa remains the region most heavily affected, accounting for 70% of all 
HIV infections worldwide [13]. Helminth and HIV co-infection are widespread in sub-Saharan 
Africa, including Malawi and there is substantial geographic and social overlap in their 
distribution leading to opportunities for HIV, parasite and drug interactions at both individual 
and population scales [14].    
1.1.4 Mixed evidence of interactions between helminths and HIV 
Several studies have examined the interaction of different helminths infections with HIV and 
have reported conflicting results. Some have found no association between helminth 
infections or treatment and HIV, while others have found evidence that treatment of helminth 
infections is associated with improvement in markers of HIV disease progression. A cohort 
study of HIV positive patients from Ethiopia reported that treatment of intestinal worms 
significantly decreased HIV plasma viral load in co-infected individuals [15]. This finding was 
supported by a systematic review of three randomized controlled trials that evaluated the effect 
of different interventions (praziquantel, albendazole, and DEC) on different helminth infections 
(schistosomiasis, soil-transmitted helminths, and W. bancrofti) respectively, which reported 
significant benefit of deworming on both plasma HIV-1 RNA and CD4 counts [16]. Similar 
findings were also reported in another prospective observational study from Ethiopia which 
found that intestinal helminths were associated with an increased HIV viral load which reduced 
significantly after treatment [17].  
While the impact of helminth infection on HIV disease has received considerable attention, 
there is limited data on how co-infection with HIV might influence the dynamics of helminth 
infection and the studies that have investigated this relationship have been less clear [18]. A 
prospective study of HIV-1 and intestinal helminth co-infected adults in Zambia that assessed 
the impact of antihelminthic treatment of on plasma concentrations of HIV-1 RNA did not find 
an overall association between treatment of intestinal helminth infections and reduction in viral 
load in co-infected adults [19]. Similarly, Webb et al in their review article examined the 
epidemiological and immunological evidence for HIV and helminth interactions and found 
limited and inconsistent evidence of any important interactive effects [20].  
17 
 
1.1.5 LF and HIV co-infection  
At the outset of this research there were few studies reported that had investigated LF and 
HIV co-infection. A cross-sectional study undertaken in Tanga region of Tanzania reported a 
positive association between HIV and W. bancrofti circulating filarial antigen (CFA) infection 
detected by the immunochromatographic rapid card test (ICT) [21]. A more detailed 
immunologic evaluation of a subpopulation of this cohort did not provide any evidence for an 
interaction between HIV and W. bancrofti infections, in terms of an association between W. 
bancrofti co-infection and HIV viral load, CD4% and CD4/CD8 ratio and, an association 
between HIV infection and CFA intensity or cytokine levels in response to filarial antigen 
stimulation [22]. Evaluation of the effect of diethylcarbamazine (DEC) treatment, a common 
drug of choice that kills both the microfilariae and some of the adult worms of W. bancrofti 
infection, found a significant decrease in HIV viral load in Tanzanian individuals co-infected 
with HIV and LF 12 weeks after treatment with DEC, indicating possible benefit of LF treatment 
in managing HIV progression [23]. In urban southern India, no quantitative difference in W. 
bancrofti CFA levels was found in a study of HIV-positive and HIV-negative patients [24]. 
Another study from the same cohort compared HIV replication and progression in HIV-positive 
patients with and without W. bancrofti infection and found no differences in HIV disease 
progression between the groups after treatment with DEC and albendazole  in contrast to 
previously reported findings from a similar study from Tanzania [23]. 
The results from these two studies are divergent and mainly focused on the effects of helminth 
or filarial infection on the markers of HIV infection. Turning this around, the impacts of HIV 
infection on W. bancrofti infection are less clear. At the outset of the study, there were no 
available data on this interaction and thus a lack of clarity for LF control programmes on 
whether and how to change the current mass drug administration (MDA) approaches in HIV 
endemic areas. Further clinico-epidemiological investigations were needed in order to better 
understand how LF and HIV infections interact and to either provide reassurance that the 
current approach to control LF is acceptable in HIV endemic areas and if not, to identify targets 
for change.  
1.2 Justification and rationale to the study 
Understanding the inter-relationship between HIV and lymphatic filariasis is essential for 
ensuring effective intervention strategies. A better understanding of this relationship will 
ensure that HIV will not present roadblocks to LF control in populations where HIV prevalence 
is high and will assist in identifying areas for public health action. In addition, establishing the 
efficacy of anti-filarial drug doses may help drive the search for alternative treatment 
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approaches for LF. This study therefore aimed to investigate the interaction of HIV infection 
and lymphatic filariasis in northern Malawi, an area where HIV and LF prevalence rates are 
high and control programs are underway. It tested various doses and frequencies of 
albendazole and ivermectin for LF control. It also aimed to investigate the impact of HIV on 
the success of annual treatment with microfilaricidal drugs and the effect of other concurrent 
measures including insecticide treated nets and HIV treatment programmes. The data 
generated from this study will add to the body of scientific knowledge on these major public 
health problems and provide key data for LF control programs operating in regions of high HIV 
prevalence, data that at present are lacking. 
1.3 Aim and objectives 
The aim of the study was to assess the interaction between lymphatic filariasis and HIV that 
might affect the success of lymphatic filariasis elimination programmes in areas with a 
generalised HIV epidemic.  
Objectives: 
1. To determine the prevalence of LF and HIV co-infections as quantified by the Og4C3 
ELISA in a large cross-sectional study in Karonga district, rural northern Malawi. 
2. To investigate whether higher and/or more frequent doses of albendazole and 
ivermectin are more effective in eliminating W. bancrofti microfilariae than the WHO–
approved standard regimen. 
3. To determine the relationship of CFA and microfilaria count (MF) by HIV status. 
4. To monitor the impact of Mass Drug Administration (MDA) on LF antigenaemia by HIV 
status by following a cohort of antigen positive individuals identified in objective one. 
5. To assess the contribution of insecticide treated bed nets (ITNs) to changes in 
circulating filarial antigen (CFA).  
1.4 Study summary and methods  
This thesis presents results from adults in two rural sites in Karonga district, northern Malawi, 
a region endemic for both LF and HIV. Two geographically separate studies (see Figure 1 and 
Figure 4) were used: one was a clinical trial of anti-filarial agent dosing regimens in Songwe 
in the northern part of the district (the Songwe clinical trial), and the other a whole population 
annual HIV sero-survey with longitudinal follow up data from the southern part of the district 
(the Karonga Health and Demographic Surveillance System or KHDSS).  
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Figure 1: Map of Karonga District Showing Songwe and KHDSS Areas 
 
Three filarial research studies were undertaken using stored blood samples and data from the 
two distinct geographical locations:  
1. Study 1, cross-sectional assessment of the relationship of HIV and markers of LF 
infection. 
2. Study 2, clinical trial of anti-filarial dosing regimens.  
3. Study 3, longitudinal assessment of the impact of MDA on LF antigenaemia by HIV 
status.  
1.5 Role in the research  
The work included in this thesis is entirely my own. As the trial coordinator for the Songwe 
clinical trial, I oversaw all aspects of the day-to-day running and coordination of the trial, 
including its design, procurement of equipment, supervision of a team of five people, door-to-
door data collection, night blood sample collection, laboratory work and analysis for the trial. I 
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randomised and selected stored blood samples from the KDHSS and the clinical trial for 
retesting and conducted the laboratory work with the assistance of a lab technician, following 
standard operating procedures (SOPs). The statistical and geospatial analysis are also my 
own work.  
1.6 Thesis Layout 
Chapter 1 provides a general introduction of the thesis including a summary of the justification 
and rationale to the study, the aims and objectives as well as a summary of the main methods 
and layout of the thesis. 
Chapter 2 reviews general and local literature on LF and HIV coinfections and provides a 
comprehensive study and interpretation of this literature. It particularly provides a detailed 
account of lymphatic filariasis that includes historical perspective, burden of the disease, life 
cycle and vectors of the parasites, clinical manifestations, diagnostic methods, treatment, LF 
and HIV coinfection, and public health approaches to LF control and elimination.  
Chapter 3 presents a detailed description of the methodology employed in this study. The 
chapter first describes the Karonga Prevention Study (KPS) in Karonga, northern Malawi. It 
then outlines the relevant Karonga Prevention Study studies within which this thesis is nested, 
including their linkage to each other. For the study to make sense, the timelines of the various 
interventions related to LF control in the district are summarised. The chapter then gives a 
detailed description of the methods for each of the filarial research studies that make up this 
thesis. For each the study design, characteristics and selection of the populations studied, 
description of the information collected from the participants, the variables used, and sample 
size considerations are described. Common methods across all the studies are presented 
separately and these include a description of laboratory methods, data handling and 
management, statistical analyses, mapping methods and analyses and ethical considerations.  
Chapter 4 presents the study findings of each of the three filarial research studies that make 
up this thesis. It is divided into three sections corresponding to the three filarial research 
studies. The first section presents the cross-sectional analysis of the relationship between LF 
and HIV infections. The second section describes the Songwe clinical trial participants and 
the microfilarial clearance in the different arms while the third and last section presents results 
of samples taken before and after a period of mass drug administration including participant 
characteristics at baseline and follow up, CFA clearance rates and an analysis of the impact 
of bed net ownership and an HIV subgroup analysis.  
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Finally, chapter 5 examines and gives details of the main findings and discusses these in the 
light of the existing evidence from elsewhere, summarises the conclusions of this thesis and 
provides suggestions for future work. It also provides alternative explanations of the findings 
and summarises and acknowledges the main limitations of the study. Finally, it draws 
generalisations from the important findings and implications for public health, makes 
recommendations for LF control programmes and outlines areas for further research.  
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 Literature Review  
This chapter presents a comprehensive study and interpretation of the existing literature on 
lymphatic filariasis and HIV coinfections. It provides a detailed and critical analysis of the 
available literature and identifies relevant previous research and methods on the subject area. 
It also identifies and demonstrates controversies and knowledge gaps in the existing literature 
on the subject area and justifies the rationale for the research question and study. It begins 
with a description of the methodology that was used to conduct the search for the existing 
literature on the subject area followed by a detailed account of the two main sections of the 
chapter. 
The first section gives a detailed account of the existing general literature on lymphatic 
filariasis that includes historical perspective, burden of the disease, life cycle and vectors of 
the parasites, clinical manifestations, diagnostic methods, treatment, LF and HIV coinfection, 
and public health approaches to LF control and elimination. 
The second section, the Malawian national context, gives a detailed account of the local 
context and available literature on lymphatic filariasis and LF and HIV coinfection. 
2.1 Literature search methods 
A comprehensive and systematic approach was used to conduct the search for the relevant 
existing literature on the research topic. The research question for the study – Is there an 
interaction between lymphatic filariasis and HIV that might affect the success of lymphatic 
filariasis elimination programmes in areas with a generalised HIV epidemic? – was used to 
derive key components of the subject area and the following key search terms and synonyms 
that were used for searching the literature: filariasis, filarial infection, lymphatic filariasis, 
elephantiasis, Wuchereria bancrofti, helminths, parasites, worms, nematodes, HIV, HIV-1, 
HIV-2, HIV/AIDS, Human Immunodeficiency Virus, AIDS, Acquired Immunodeficiency 
Syndrome, control, elimination, coinfection, interaction, relationship and association. 
These key search terms were used in combination or isolation, to conduct the literature search 
using the searching option on the chosen databases or search engines. The ‘AND’ and ‘OR’ 
Boolean operators were used to combine the search terms together. The ‘OR’ Boolean 
operator was used to combine synonyms of the key components of the subject area while the 
‘AND’ Boolean operator was used to combine the key components of the subject area. Other 
search tools that were used to help with the literature search were truncation and use of 
wildcards. 
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The literature search was performed on the following electronic healthcare databases: 
PubMed, Scopus and the Cochrane library. Other sources of information used were books, 
search engines, reference lists of key articles, authors and journals of key articles, and grey 
literature (conference papers and abstracts, theses, reports and unpublished research).  
2.2 Lymphatic filariasis 
2.2.1 Introduction 
Lymphatic filariasis is a parasitic helminth infection caused by the mosquito-transmitted filarial 
nematodes W. bancrofti, B. malayi and B timori with most cases (91%) and all cases in Africa 
caused by W. bancrofti [2, 25]. The parasites are transmitted to humans via the bite of an 
infected mosquito vector and cause damage to the lymphatic system which leads to swellings 
in the legs, arms, breast and genitalia and significant disability and disfigurement of the 
affected individuals [26]. LF is a major public health problem worldwide affecting 120 million 
people in 72 endemic countries with an estimated at-risk population of 1.39 billion people [27]. 
It is one the leading causes of long-term disability and an estimated 40 million of the LF-
infected people suffer from the chronic, debilitating and stigmatising clinical manifestations of 
LF, mostly lymphoedema or elephantiasis (15 million people) and scrotal hydrocoele (25 
million people) [2]. LF is classified as one of the world’s Neglected Tropical Diseases (NTDs), 
a diverse group of diseases that thrive mainly among the poorest and deprived populations of 
the world in Africa, Asia and Latin America [27]. 
The World Health Assembly (WHA) meeting in 1997 urged member states through the 
adoption of resolution WHA 50.29 which called for LF endemic countries to eliminate the 
disease as a public health problem [28]. In response to this resolution and the significant global 
LF burden, WHO launched the Global Programme to Eliminate Lymphatic Filariasis (GPELF) 
in the year 2000 with the goal to eliminate LF by 2020 through interruption of transmission of 
the filarial parasite using MDA and management and prevention of disabilities associated with 
the disease [2].  
2.2.2 Life cycle and vectors of LF parasites 
Anopheles and Culex mosquito vectors transmit LF from person to person. Anopheles 
gambiae s.l. and Anopheles funestus, which are also the principal vectors of malaria, transmit 
the disease in rural areas of Africa while Culex quinquefasciatus is the main vector in urban 
and peri-urban areas [27, 29]. The human phase of the life cycle (Figure 2) begins when the 
mosquito takes a blood meal and deposits infective larvae of microfilariae onto the human 
skin. The infective larvae of microfilariae enter the human body, their definitive host, via the 
mosquito bite wound. They migrate to the lymphatic system mostly in the inguinal and genital 
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areas where they reside and develop into male and female adult worms that are 4-8 cm long. 
The adult worms have a lifespan of 5-8 years during which they mate and produce thousands 
of sheathed microfilariae. The worms live in mutual symbiosis with Wolbachia endobacteria 
which are essential for growth, development and maturation of the filarial parasites and also 
responsible for inflammatory disease pathogenesis [30]. 
The microfilariae resemble tiny worms and measure about 100-150µm in length. They 
periodically migrate into the bloodstream at night and peaks between 9 pm and 4 am, a 
phenomenon called nocturnal periodicity. This period coincides with the period of most active 
feeding by the mosquito vectors. The mosquito phase of the life cycle begins when the 
mosquito vector that is the intermediate host, ingests the microfilariae during a blood meal on 
an infected human. Inside the mosquito, the microfilariae migrate to the thoracic muscles 
where they develop into three larval stages in about 10-14 days. The third-stage larvae then 
migrate to the head and proboscis of the mosquito and may infect other humans when the 
mosquito takes a blood meal again.  
 
Figure 2: Lymphatic Filariasis Life Cycle 
(Source: Public Health Image Library, CDC [http://phil.cdc.gov]) 
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2.2.3 Clinical manifestations 
LF infection is generally acquired in childhood but clinical signs and symptoms usually appear 
several years later in life. Most infected individuals remain asymptomatic and never develop 
clinical manifestations of LF, while a small proportion of infected individuals will develop clinical 
signs and symptoms. Males are more often infected than females and have the most severe 
forms of clinical manifestations of LF. Treatment options are discussed in more detail in 
section 2.2.5 below.  
Asymptomatic infection 
Asymptomatic individuals have adult worms and microfilaraemia but do not exhibit any clinical 
signs and symptoms of LF. 
Acute LF manifestations 
These include periodic attacks of adenolymphangitis (local inflammation of skin, lymph nodes 
and lymphatic vessels), fever and malaise. They are caused by the body’s immune response 
to the parasite and secondary bacterial infection of the skin and lymph system, facilitated by 
partial loss of the body’s immune response and damage of the lymphatic system (Figure 3). 
Chronic LF manifestations 
These include hydrocoele in males, lymphoedema, elephantiasis and chyuria (Figure 3). 
Hydrocoele is the fluid collection and swelling of the scrotum. Lymphoedema is the fluid 
collection and swelling mostly affecting the legs, arms, breasts and genitalia. Elephantiasis is 
the hardening and thickening of the skin which is caused by frequent secondary bacterial 
infections of the skin and lymph system. Chyuria is the presence of chyle or milky white 
lymphatic fluid in urine that makes urine appear white.  
Tropical pulmonary eosinophilia 
LF infection may also manifest a condition called tropical pulmonary eosinophilia syndrome. It 
is characterised by cough, shortness of breath and high levels of immunoglobulin E (IgE) and 
antifilarial antibodies. 
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Figure 3: Clinical Manifestations of LF 
(Source: Neglected Tropical Diseases – Sub-Saharan Africa) 
2.2.4 Diagnostic methods 
Clinical diagnosis 
Clinical diagnosis of LF can be made in any patient from an endemic area with a history of 
unilateral or bilateral lymphoedema of the limbs or hydrocoele in males associated with 
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thickening of skin and repeated episodes of fever and pain in the affected organs  in the 
absence of other obvious causes of oedema such as congestive cardiac failure or diseases of 
the lymphatic system [31]. 
Ultrasound scanning 
Adult filarial worms residing in the lymphatics can be detected by ultrasound scanning of the 
appropriate area, usually scrotal lymphatics in males and breast lymphatics in females. The 
worms are visualised rapidly moving on the scan, a phenomenon referred to as the filarial 
dance sign (FDS) [32]. This diagnostic technique is expensive and not suitable for mass or 
routine diagnosis of LF [31]. 
Detection of microfilariae 
Identification of microfilariae by microscopy on a blood smear from an infected individual is 
considered as the standard method to diagnose active LF infection [33]. The blood requires to 
be collected at night usually between 10pm and 2am because the microfilariae are only 
present in the blood circulation at night (nocturnal periodicity). There are four common 
methods for microfilarial detection: 
Thick blood smear 
A 20-60µL finger-prick blood sample volume is applied on a microscope glass slide, dried 
overnight, fixed and stained with Giemsa stain and later examined for microfilariae under a 
microscope. This method has low sensitivity due to small blood sample volume used and loss 
of microfilariae during preparation of the slide [34]. 
Knott’s concentration method 
A 1mL venous blood sample collected in an anticoagulant-containing tube is mixed with 10mL 
2% formalin that acts as a preservative and lysing solution. The mixture is left to stand for 15 
minutes and later centrifuged. The supernatant is discarded, and the remaining sediment is 
later examined for microfilariae under a microscope. A drop of methylene blue may be added 
to the sample to aid examination [34]. 
Counting chamber method 
A 100µL finger-prick blood sample volume is transferred to a tube containing 0.3% acetic acid 
that acts as a preservative and lysing solution. The mixture is shaken gently and later 
transferred to a Sedgewick Rafter counting chamber and examined for microfilariae under a 
microscope [34].  
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Membrane filtration method 
A venous blood sample volume of 1-5mL is collected in an anticoagulant-containing tube and 
mixed with a red blood cell lysing solution. The mixture is then filtered through a 5µM pore 
size Nucleopore filter held within a leak-proof reusable filter holder. The filter is later removed 
using forceps and placed on a glass slide and examined for microfilariae under a microscope 
[34].  
Alternative methods to microscopy are assays for circulating filarial antigens and antibodies 
and ultrasound scanning for detecting adult filarial worms. There are two assays for detecting 
filarial antigens currently available, the Og4C3 enzyme-linked immunosorbent assay (ELISA) 
and the immunochromatographic card test (ICT). These tests  have high sensitivity ranging 
from 96 to 100% and a specificity of 99% unlike microscopy for microfilariae detection which 
has a low and variable sensitivity [31]. 
Og4C3 ELISA 
This test kit is W. bancrofti specific and manufactured by TropBio Pty Ltd. (Queensland, 
Australia). It yields quantitative results (see laboratory methods section) but its use is limited 
and not suitable for mass or routine diagnosis because it requires a well-equipped laboratory 
as well as skilled laboratory personnel [34]. 
ICT 
This is a rapid card test manufactured by Binax (Scarborough, USA) and is also specific for 
W. bancrofti. It yields qualitative (positive/negative) results (see laboratory methods section) 
and is used extensively for mass and routine diagnosis and is ideal for field settings because 
it uses finger-prick blood, is easy to administer, has high sensitivity and yields results in a short 
time [34].  
Anti-Bm14 IgG4 assay 
The filariasis CELISA anti-Bm14 IgG4 assay (Cellabs Pty Ltd., Manly, Australia) is a filarial 
antibody IgG4-specific ELISA kit with plates that are coated with the recombinant Bm14 
antigen [35]. This antigen reacts with sera from patients with bancroftian filariasis and is highly 
sensitive (over 90%) [35]. Its limitation is cross reactivity with sera from other helminths 
parasites [34]. 
2.2.5 Treatment of lymphatic filariasis 
Treatment of LF is generally aimed at preventing, reversing or halting the progression of 
disease and to interrupt transmission of the parasite [36]. 
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Non-drug treatment of clinical manifestations 
This is targeted at alleviating the suffering and decreasing the disability in lymphatic filariasis 
patients [37]. It is achieved by providing training and support for improved hygiene including 
daily washing of the affected areas with soap and clean water, elevating and exercising of the 
swollen limbs to increase lymph flow, disinfecting wounds and treatment of secondary 
infections, and increases access to hydrocoelectomy [37]. 
The drugs and how they work 
Diethylcarbamazine (DEC), ivermectin and albendazole are the three drugs currently in use 
for the treatment and control of LF [38]. These drugs are given orally either alone or in 
combinations.  
a. Diethylcarbamazine 
This drug is a synthetic derivative of piperazine that is mainly microfilaricidal but also 
possesses some macrofilaricidal effects [39]. It acts by inhibiting arachidonic acid metabolism 
in microfilariae and making them more susceptible to host immune attack [38]. It rapidly 
reduces microfilariae after administration and this effect is sustained several months 
afterwards before the filarial load begins to increase again [38]. DEC also reduces circulating 
filarial antigenaemia, but this effect is variable probably because of its limited macrofilaricidal 
effects. It has no effect on already established lymphatic damage or chronic manifestations 
but can halt the development of chronic manifestations and is therefore recommended for 
treatment of asymptomatic microfilariae or antigen positive LF patients [38]. 
Common side effects include fever, headache, malaise, muscle, and joint pains. DEC is 
contraindicated in individuals co-infected with onchocerciasis due to severe adverse reactions 
and symptom progression especially in onchocercal eye disease. It is also contraindicated in 
pregnancy. 
b. Ivermectin 
Ivermectin, a macrocyclic lactone, is a broad-spectrum anti-parasitic drug of the avermectin 
group of compounds that is mainly microfilaricidal and has no macrofilaricidal effects [38]. It 
acts by inhibiting nerve and muscle function of the parasite. The recommended dosage is 150-
400µg/kg single dose and is contraindicated in pregnant and breastfeeding women and under-
five children. 
c. Albendazole 
Albendazole is a benzimidazole derivative that is used for the treatment of a number of 
helminths infections [39]. It acts by interfering with microtubule assembly and blocking glucose 
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uptake in the parasite. It is usually given in combination with DEC or ivermectin because of its 
microfilaricidal effects and this combination results in a sustained longer lasting effect. 
d. Antibiotics and LF 
Certain antibiotics have been reported to be active against filarial nematodes due to their 
symbiotic relationship with Wolbachia bacteria species that lives within the filarial nematodes 
[40]. These antibiotics include doxycycline and rifampicin. 
e. Doxycycline  
Doxycycline is a member of the tetracycline group of antibiotics. It is used in the treatment of 
many types of bacterial and protozoal infections. Multiple studies have shown that treatment 
of bancroftian filariasis with a 4-, 6- or 8-week course of 200 mg per day dose of doxycycline 
is effective in killing filarial adult worms and reducing circulating antigenaemia and 
microfilaraemia [41-43]. In addition, doxycycline treatment also leads to long-term 
improvements in lymphatic pathological features and decreased severity of lymphoedema and 
hydrocoele [42]. 
f. Rifampicin 
This is a bactericidal drug belonging to the rifamycin group of antibiotics. It is used to treat 
several bacterial infections including tuberculosis and leprosy. Rifampicin has been shown to 
have some macrofilaricidal effects in murine filariasis infected mice where a 14 day treatment 
with rifampicin alone or in combination with doxycycline led to the depletion of Wolbachia 
endobacteria and inhibition of worm development, embryogenesis and adult worm survival 
[44]. Rifampicin has also been shown to have partial macrofilaricidal activity in a pilot study 
that investigated treatment of human LF with doxycycline alone or in combination with 
rifampicin [45]. 
2.3 LF co-infections and co-endemicity 
Multiple infections are constantly present in particular geographical areas or population 
groups. Co-endemic infections are especially widespread in sub-Saharan African countries, 
including Malawi, and may result in co-infection, which is the simultaneous infection of an 
individual host with multiple pathogens [46]. Co-infection is of particular clinical significance 
because pathogens interact with one another within the host in a positive or negative way. 
Positive co-infection interactions involve enhancement of disease transmission and 
progression while negative co-infection interactions involve suppression of virulence or 
colonisation of one pathogen by another [47]. LF is co-endemic in many regions in sub-
Saharan African with other infections and this may lead to potential interactions in co-infected 
31 
 
individuals. This section will focus on two important and overlapping LF co-infections with HIV 
and malaria. 
2.3.1 LF and HIV Co-infection 
Lymphatic filariasis (LF) and HIV are both major public health problems worldwide and where 
they co-exist, have the potential to interact. These interactions may have important 
consequences for annual mass drug administration (MDA), the main strategy for LF 
elimination, particularly whether HIV, through its impact on the immune system interferes with 
the effectiveness of this approach to control and eliminate LF. It has been suggested that co-
infection with HIV and filarial helminths may have bi-directional deleterious interactions by 
affecting susceptibility to HIV, impacting on HIV progression and potentially worsening clinical 
outcomes of filarial infection [48]. Findings from several studies suggest that helminth infection 
may adversely affect HIV-1 progression and that treating helminth infection in HIV-1 co-
infected adults appears to impart beneficial effects on both HIV-1 viral load and CD4 counts 
[15, 17, 49]. In-vitro studies have shown helminth infections to increase susceptibility of 
peripheral blood mononuclear cells to HIV infection, and this susceptibility decreased once 
the individuals were treated for their filarial infection [50]. 
While the consequences of helminth infection on HIV disease have received considerable 
attention, there is limited data on how co-infection with HIV might influence the dynamics of 
filarial infection [51]. It has been hypothesized that immunodeficiency arising from HIV 
infection can alter the clinical course and dynamics of filarial infections but studies that have 
investigated this relationship have found conflicting results. In two small studies of co-infection 
with the filarial infection Onchocerca volvulus, those infected with HIV had more significant 
onchocercal skin disease  and were less likely to have antibodies in response to onchocercal 
antigens , while in another study, Fischer and colleagues found no effect of HIV-1 infection on 
ivermectin efficacy [52].  
A cross-sectional study of 907 adults undertaken in Tanga region of Tanzania reported a 
positive association between HIV and W. bancrofti circulating filarial antigen (CFA) infection 
detected by ICT rapid card test , although a further evaluation of a subgroup of these 
individuals in another cross-sectional study did not support any association between HIV and 
W. bancrofti infection in terms of an association between W. bancrofti co-infection and HIV 
viral load, CD4% and CD4/CD8 ratio and, an association between HIV infection and CFA 
intensity or cytokine levels in response to filarial antigen stimulation [22]. Evaluation of the 
effect of diethylcarbamazine (DEC) treatment, a common drug of choice that kills both the 
microfilaria and some of the adult worms of W. bancrofti infection, found a significant decrease 
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in HIV viral load in Tanzanian individuals co-infected with HIV and LF 12 weeks after treatment 
with DEC, indicating possible benefit of LF treatment in managing HIV progression [23]. 
Similarly, in urban southern India, no quantitative difference in W. bancrofti CFA levels by HIV 
status was found in a study of 432 HIV-positive and 99 HIV-negative patients [24]. A further 
study from the same cohort that compared HIV replication and progression in HIV-positive 
patients with and without W. bancrofti infection found no differences in HIV disease 
progression between the groups after treatment with DEC and albendazole  in contrast to 
previously reported findings from a similar study from Tanzania [23].   
2.4 Public health approaches to LF control 
2.4.1 MDA 
WHO launched the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000 with 
the aim of eliminating LF as a public health problem by the year 2020 [5, 53]. The main strategy 
recommended by WHO that is used is to interrupt LF transmission in endemic areas is mass 
drug administration (MDA), a therapy that uses combinations of two antihelminthic drugs that 
are administered to entire at-risk population in endemic areas [54]. The antihelminthic drugs 
are used to reduce microfilaraemia in infected persons to levels so low that that they can no 
longer sustain transmission by mosquito vectors to new hosts. The target population for MDA 
is all individuals aged 5 years and above living in LF endemic areas. Annual MDA is given for 
at least 5 years in a row, which is generally considered the reproductive life span of the adult 
filarial worms in humans. The number of rounds may vary and depends on the initial 
prevalence of infection, the initial intensity of transmission, the efficacy of medicines, the 
combinations of parasites and vectors, and the density of vectors [54]. MDA aims for coverage 
of at least 65% of the total at-risk population in endemic areas each year as this is considered 
as the minimum level of coverage adequate to achieve LF elimination [55, 56].  
 
Drug selection, dose and frequency 
MDA is delivered using a single annual dose of either ivermectin and albendazole in Africa, 
where onchocerciasis is also endemic because of the contraindications of the use of 
diethylcarbamazine (DEC) in patients with onchocerciasis, or DEC and albendazole in all other 
LF endemic regions of the world, where onchocerciasis is not endemic [54]. Co-endemicity 
with Loa loa in parts of Central and West Africa is a major challenge that places people with 
these infections at risk of serious adverse reactions if they receive ivermectin and the current 
MDA strategy cannot be initiated.    
Community-based distributors 
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MDA is usually administered at community level. This is achieved using one of two drug 
delivery methods. The first method is delivery via regular health services and uses employed 
community health workers as drug distributors [57, 58]. The second method is delivery through 
a system of community-directed treatment in which local health workers train and sensitise 
communities to direct the intervention [57, 58]. The MDA drugs are delivered to the target 
population using door-to-door distribution or fixed posts delivery and uses directly observed 
treatment strategy (DOTS) to ensure compliance. Another strategy used to deliver MDA drugs 
to at-risk populations is through the use of table salt or cooking salt fortified with DEC. DEC-
fortified salt has been used successfully in by China to eliminate LF and is a safe, low-cost 
and effective alternative to MDA of tablet drugs [59]. 
Success of MDA programmes 
Since the launch of the GPELF in 2000, national control programmes in LF endemic countries 
have registered dramatic progress and success in implementing MDA [53]. Between 2000 and 
2015, more than 820 million people received mass treatment in 64 LF endemic countries, 
considerably reducing transmission in many countries and the number of people requiring 
MDA by 25% (351 million) due to successful implementation of the MDA programmes [60]. 
Success of MDA programmes depends both on achievement of high compliance levels among 
individuals and high coverage of populations for 4-5 successive years. Individual compliance 
can be challenging since people have to accept to take the treatment when they have no 
symptoms. Constraints to coverage include fragile health care systems and infrastructures in 
resource-limited countries, difficult to access populations, limited enumeration of households, 
poor supervision of community-based distributors and inadequately funded national 
programmes [61].  
2.4.2 Vector control 
LF is a mosquito-borne parasitic disease and the mosquitoes that transmit the disease are 
night biting. There is an overlap between LF and malaria in many aspects. The two diseases 
occur concurrently in many tropical regions of the world, share common mosquito vectors and 
susceptibility to the same control interventions. Vector control is a major part of malaria control 
and it is likely that this strategy may also significantly impact on LF transmission and 
prevalence.  
The main methods for vector control in malaria are insecticide treated bed nets (ITNs) and 
indoor residual spraying (IRS). An ITN is a bed net that has been treated with safe residual 
insecticide that provides a physical barrier against malaria-transmitting mosquitoes, and kills 
and repels mosquitoes [62]. WHO recommends that ITNs be distributed free of charge or 
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heavily subsidised to all people living in at risk communities and in order to achieve universal 
coverage, one ITN should be distributed for every two persons in a household [63]. ITNs are 
estimated to reduce child mortality by 17% and uncomplicated malaria cases by 50% [64]. 
IRS is the application of a residual insecticide to walls and other surfaces of a house. The 
insecticide kills malaria-infected mosquitoes and other insects that encounter these surfaces 
and prevents disease transmission. The proportion of at risk populations protected from 
malaria by IRS in Africa increased from 5% in 2005 to 11% in 2011 [65]. 
The integration of these vector control interventions with national LF elimination programmes 
has been widely advocated following evidence that ITN use and IRS for malaria significantly 
reduces filarial rates and because of problems with MDA in some areas [66]. Field studies and 
mathematical models have shown that vector control can have an important complementary 
role in the elimination effort resulting in lower coverage levels and fewer annual rounds would 
be needed to achieve elimination. 
2.5 National context in Malawi 
This section gives an introduction of the country of Malawi. It describes the country’s 
geography, population, political, economic and health systems. It also gives details on 
lymphatic filariasis, HIV and the control strategies for these diseases currently underway in 
Malawi. Sources of information used were relevant published literature, unpublished reports 
and national policy documents available in Malawi. Personal communication records in form 
of personal interviews and conversations, letters, memos and emails were also used.  
2.5.1 Population and geography 
2.5.1.1 Geography and climate 
Malawi is a small landlocked country located in south-eastern Africa bordering Tanzania to 
the north and northeast, Mozambique to the east, south and southwest and Zambia to the 
west and northwest (Figure 4). 
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 Figure 4: Map of Malawi Showing Region and District Boundaries 
 (Source: Malawi Demographic and Health Survey 2015-16)  
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It lies south of the equator in the southern end of the Great East African Rift Valley between 
latitudes 090 25’S and 170 08’S and longitudes 320 40’E and 350 55’E. The country is 901 
kilometres long and ranges in width from 80 to 161 kilometres covering a total area of 118,484 
square kilometres of which 94,276 square kilometres is land. The rest of the area is covered 
with water and the major water body in the country is Lake Malawi, which is about 475 
kilometres long and is the third largest lake in Africa and the eighth largest freshwater body in 
the world, and runs down Malawi’s eastern boundary with Tanzania and Mozambique [67].  
The countryside and catchment area of Lake Malawi is characterised by fertile plains, hills, 
and mountain ranges whose peaks range from 1700 to 3000 metres above sea level. There 
are also several river systems in the country and the largest is the Shire River which is the 
outlet of Lake Malawi and drains into Zambezi River in Mozambique [67]. 
The country has a tropical continental climate with two main distinct seasons: the rainy season 
from November to April and the dry season from May to October. The rainy season is hot and 
humid while the rest of the year is mainly dry and cool. There is variability in rainfall and 
temperature depending on altitude and proximity to the lake [67]. It experiences good rainfall 
during the rainy season with an annual mean of 1,037mm and the mean monthly temperatures 
range from 10-16°C in highland areas and 20-29°C along the lakeshore areas [68]. 
The topography of the land together with a good network of rivers and water bodies and the 
tropical climate contribute to extensive mosquito breeding and the epidemiology of mosquito-
borne diseases in the country. In general, a low prevalence of mosquito vectors is found in the 
western side of the country, due to the fact that these areas are dry and of higher altitude and 
thus not ideal for extensive mosquito breeding,  while higher prevalence is found along the 
lakeshore areas and areas bordering major rivers [69]. 
2.5.1.2 Population and demography 
The population of Malawi was estimated at 16.7 million in 2014 with an average annual growth 
rate of 3.1% [70].  There are more females than males (51% vs. 49%), about 59% of the 
population are children under the age of 20 years, and about 17% are children under the age 
of 5 years [67]. Malawi is one of the poorest countries in the world and this is reflected in its 
health indices. The estimated total life expectancy at birth in Malawi is at 63 years, the infant 
mortality rate is 44 deaths per 1,000 live births and under-five mortality rate is 70 deaths per 
1,000 live births. The total fertility rate is 5.7 per woman and maternal mortality ratio is 510 per 
100,000 live births. About 47% of children under-five years of age are chronically 
malnourished and stunted. The adult literacy rate is 61% and most of the population (84%) 
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live in rural areas. There are over 20 tribes in Malawi, however, Chichewa and English are 
regarded as the two official national languages [67, 71]. 
2.5.1.3 Political organisation and socio-economic profile 
Administratively, Malawi is divided into three regions, the northern, central, and southern 
regions, which are further divided into twenty-eight districts, six districts in the Northern 
Region, nine in the Central Region, and thirteen in the Southern Region. The districts are 
subdivided into approximately 250 traditional authorities (TAs), presided over by chiefs. Each 
TA is composed of villages, which are the smallest administrative units and are presided over 
by village headmen. The capital city of Malawi is Lilongwe located in the Central Region and 
is the largest city. Blantyre located in the Southern Region is the commercial centre and the 
second largest city while Mzuzu located in the Northern Region is the third largest city.  
Malawi remains one of the poorest countries in the world with over 60% of Malawians living 
below the poverty line and is among the world’s least developed countries [68]. The backbone 
of Malawi’s economy is agriculture and accounts for 30% of the Gross Domestic Product 
(GDP) [67]. The main occupation of the people is subsistence farming, fishing and livestock 
rearing and agricultural produce is the main contributor to the Gross National Product (GNP).  
Malawi maintains good diplomatic relations with all African countries including its three 
neighbouring countries of Tanzania to the north and northeast, Mozambique to the east, south, 
and southwest and Zambia to the west and northwest. The people of Malawi and its 
neighbouring countries have also maintained relationships across the borders and this 
interrelationship of communities in the region partly forms the historical basis for the existence 
of informal cross-border movements. Informal cross-border movement is facilitated by the 
largely porous borders between Malawi and its neighbouring countries and has the potential 
to undermine disease control activities in border regions.   
2.5.2 The health system in Malawi 
2.5.2.1 Ministry of Health structures  
The Ministry of Health (MOH) is responsible for overall health care provision in the country. It 
is divided into three administrative levels namely ministry headquarters (central level), zonal 
(regional) offices and district health offices.  
At the ministry headquarters, there is the Secretary for Health who heads the ministry and is 
assisted by directors of seven technical directorates that make up the ministry headquarters. 
The seven technical directorates are clinical services, nursing services, reproductive health 
services, preventive health services, planning and policy development, finance and 
administration and central monitoring, evaluation and research development. 
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Five zonal health offices provide technical support to District Health Management Teams 
(DHMTs) in planning, delivery and monitoring of health service delivery at the district level and 
facilitation of central hospitals’ supervision to districts. 
Health service provision is free of charge and is delivered through a three-level system at the 
community, district hospital and central hospital level and these levels are linked through a 
referral system. At the community level, health care provision is delivered by community-based 
cadres such as community health workers (known as health surveillance assistants in Malawi), 
community-based distributors and other health care volunteers. Their official roles include the 
provision of community-based preventive health services conducted through door-to-door 
visitations, village clinics, mobile clinics, and manned or unmanned health posts. In practice, 
however, coverage may be patchy and the performance of health surveillance assistants 
variable.  
Primary health care is delivered through health centres and community hospitals built in the 
communities. These are staffed mostly by medical assistants and nurses/midwives who 
provide both curative and preventive Essential Health Package (EHP) services. 
District hospitals provide secondary level healthcare. There is one hospital for each district in 
Malawi and they serve as referral facilities for health centres and rural hospitals and have an 
admission capacity of 200 to 300 beds. They are staffed by doctors, paramedics and nurses 
and they provide general services, PHC services and technical supervision to lower units. 
They also provide in-service training for health personnel and other support to community-
based health programs in the provision of EHP.  
Tertiary healthcare is provided by central hospitals where specialists are found, and they 
provide specialist referral services for their respective regions. There are currently 4 central 
hospitals namely, Queen Elizabeth Central in Blantyre, Kamuzu Central in Lilongwe, Mzuzu 
Central in Mzimba and Zomba Central in Zomba with admission capacities of 1250, 1200, 300 
and 450 beds, respectively. Queen Elizabeth and Kamuzu Central Hospitals are also teaching 
hospitals because of their proximity to College of Medicine and Kamuzu College of Nursing. 
Central hospitals, however, also provide EHP services which should essentially be delivered 
by district health services [72]. 
The public health care system in Malawi has limited capacity and is chronically under 
resourced and staffed. Malawi has only 3 health workers per 10,000 population and falls way 
too short of the WHO recommended minimum of 23 health workers per 10,000 population 
[73]. The doctor to patient ratio is 2 per 100,000 population and the few doctors that are 
available are mostly concentrated in urban areas or are not working in the areas where they 
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are needed most, and many lack the necessary resources and equipment needed to perform 
effectively. 
2.5.2.2 Other health care providers 
The MOH is the largest provider of public health services in Malawi. Other health care 
providers are also available and complement the MOH in the provision of health care in 
Malawi. Private sector health care providers charge user fees for their services and consist of 
private for profit and private not for profit health care providers. Private for-profit health care 
providers have clinics and hospitals which are mostly located in towns and cities but are 
unaffordable to most Malawians. 
Christian Health Association in Malawi (CHAM) is the largest partner of MOH in the private 
sector and it provides primary level and secondary level not for profit health services through 
its health centres, rural hospitals and mission hospitals which are mostly located in rural areas. 
CHAM also owns 11 health training institutions which train various cadres of health care 
workers. Although the user fees charged by the CHAM health facilities are at more affordable 
rates, they are a major barrier to accessing health care services for most poor Malawians 
hence MOH heavily subsidises CHAM facilities by financing drug and local staffing costs. A 
smaller, but significant other partner in service provision, especially to women, is the Banja La 
Mtsogolo (BLM) a Malawian non-governmental organisation. MOH has signed service level 
agreements (SLAs) with CHAM and BLM facilities to remove user fees for the delivery of 
maternal and neonatal health services and a few facilities have SLAs for all health services 
provided. SLAs involve the transfer of a fee from the District Health Office (DHO) to a CHAM 
facility in exchange for services offered [74]. 
Other health care providers in Malawi include non-governmental organisations, companies 
and firms, private pharmacies and grocery sales of drugs. Traditional health care providers in 
form of traditional healers and traditional birth attendants also play a significant role in health 
service provision in Malawi and many people use the traditional and modern health sectors 
simultaneously or consecutively [75]. 
2.5.2.3 Laboratories and their role in LF and HIV  
Laboratories are an essential part of an effective health delivery service. They provide 
confirmatory diagnosis and improved management of disease, essential public health 
information and disease surveillance and constitute an important part of many disease control 
programmes [76]. 
HIV is mainly diagnosed through rapid diagnostic tests designed to be used in the field, but 
the laboratory is essential to provide quality assurance to ensure accurate results. The 
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laboratory also provides diagnosis of HIV in infants and newly infected individuals. Another 
key role of the laboratory is in the provision and monitoring of antiretroviral therapy through 
measurements of CD4 counts and HIV viral load [76]. 
Rapid diagnostic tests are also available for LF diagnosis. There are simple, finger-prick tests 
that detect infection within minutes and are designed to be used in the field. Again, the 
laboratory is essential to provide quality assurance for these tests to ensure accurate results. 
These tests are also used in mapping of LF endemic areas for inclusion in LF control 
programmes. Laboratory examination of blood for circulating microfilariae is another method 
of LF diagnosis. It is used for monitoring progress of LF treatment and MDA programmes. 
Other laboratory LF diagnostic methods used to monitor treatment and MDA programmes 
include demonstration of specific filarial antibodies and demonstration of parasite DNA in 
mosquito vectors (molecular xenomonitoring) or in human blood samples  [77]. 
2.5.3 Lymphatic filariasis in Malawi 
2.5.3.1 Epidemiology 
Lymphatic filariasis, commonly known as elephantiasis, is a major public health problem in 
Malawi [78]. It is the second most common vector-borne parasitic disease after malaria and is 
the second commonest cause of long-term disability after mental illness [79]. Previously, 
Malawi was known to have two foci of lymphatic filariasis, one in the southern region (Shire 
valley) and the other in the northern region along the Songwe river bordering Tanzania [80]. 
Following a nationwide survey in 2003, it is now known that in Malawi LF infection is more 
widespread than previously appreciated. It is endemic (as defined by WHO guidelines as 
areas with an LF prevalence on ICT of 1% or higher) in all the districts in the country except 
Chitipa [81]. 
Both men and women suffer from lymphatic filariasis but the prevalence of infection and 
disease manifestations are significantly higher in males compared to females [82]. The 
nationwide mapping of LF in Malawi in 2003 also significantly found that males were more LF 
antigenaemic than their female counterparts (11.0% vs. 8.2%) [78]. 
Overall transmission of bancroftian filariasis varies seasonally as well as geographically. This 
variation reflects differences in transmission potential among individual mosquito vectors for 
LF as well as varying climatic and environmental conditions such as rainfall, temperature, solid 
drainage and presence of and/or proximity to permanent or temporal water bodies which 
favour extensive breeding of the mosquito vectors [83]. 
Nearly 90% of the population engages in subsistence farming. Smallholder farmers produce 
a variety of crops, including maize, beans, rice, cassava, tobacco, and groundnuts. Rice-
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growing areas are relatively wet and support more breeding of the mosquito vectors of disease 
and more intense transmission of parasites [80]. 
2.5.3.2 Lymphatic filariasis control programme in Malawi 
In 1997 the World Health Assembly (WHA) passed a resolution to eliminate lymphatic filariasis 
as a public health problem [28]. Following this resolution the Global Programme for Elimination 
of Lymphatic Filariasis (GPELF) with the overall goal of eliminating LF by the year 2020 was 
launched in the year 2000 and the strategy it adopted was to interrupt transmission of the 
parasite by its vectors through mass drug administration (MDA) once yearly for at least 4-6 
years and to manage and prevent LF-related disabilities [25]. 
The stages of any national LF elimination programmes involve an initial assessment and 
mapping of the distribution of infection followed by MDA rounds and disability management 
and prevention [77]. Malawi completed mapping for LF in 2003 in a nationwide survey 
mentioned above [78]. LF is co-endemic in Malawi with onchocerciasis in 8 districts in the 
southern region namely Blantyre, Chikwawa, Chiradzulu, Mulanje, Mwanza, Neno, Phalombe 
and Thyolo [68]. This mapping was followed by the formation of the Malawi National LF 
Elimination Programme in 2008 and Malawi qualified for a free donation of ivermectin and 
albendazole from Merck and Co. and Glaxo Smith Kline respectively for its MDA programme. 
MDA began in 2008 in the 8 LF and onchocerciasis co-endemic districts in the southern region 
[2] where the national onchocerciasis control programme (NOCP) had been operating since 
1997 and had well established structures [79]. 
Scaling up of MDA to all the 27 LF endemic districts in Malawi followed in 2009 and thus far 
two annual country-wide MDA rounds have been completed. Community drug distributors 
(CDDs) and health surveillance assistants (HSAs) (section 3.6.1) under the supervision of 
district LF coordinators deliver MDA in the communities. The CDDs and HSAs are placed at 
health centres and health posts and at other specific places within the communities where the 
drugs are distributed. Training is done by trainers of trainers who are themselves trained at 
central level. These train district trainers responsible for cascading training to health facility 
level staff and health surveillance assistants who in turn train the CDDs at community level.  
The MDA programme and other LF control activities in border districts of Malawi need to take 
into account LF control activities underway in the neighbouring countries as there is extensive 
cross-border movement of people and unless efforts are made to integrate or synchronise LF 
control activities, there is great potential of undermining LF control activities in Malawi and its 
neighbouring countries [78]. 
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The vectors for LF transmission in Malawi are not well known [84]. A study on the role of local 
mosquito species as LF vectors done in 2002 in southern Malawi showed that the potential 
vectors of LF in Malawi are Anopheles funestus, Anopheles gambiae s.s and Anopheles 
arabiensis [85]. These same vectors are also responsible for malaria transmission in the 
country [2]. Currently there are no vector control programmes specific for LF in Malawi but 
malaria vector control interventions such as bed net distribution and indoor residual spraying 
(IRS) (sections 2.5.6.2 and 2.5.6.3) are currently underway through the malaria control 
programme. These are likely going to play a significant role in LF elimination in the country. 
The Malawi National LF Elimination Programme keeps track and monitors progress of the 
MDA programme in the country. MDA is monitored in the country by measuring the 
geographical coverage i.e. proportion of target areas covered by the programme and 
population coverage as well as proportion of the target population that received the drugs 
during each round of MDA. This is achieved by use of special registers and forms that record 
this information during each round of MDA. In the community, the reports are completed by 
the CDDs who submit their reports to district LF coordinators who in turn submit their reports 
to the national LF coordinator. 
Supervisors also make random field visits to monitor coverage and the quality of data 
recording during each round of MDA. After each round of MDA, the supervisors audit the 
reported coverage and identify obvious signs of error [84]. 
The National LF Elimination Programme also states that it will conduct periodic assessment 
of the impact of MDA on the population through review meetings at various levels, independent 
validation of reported coverage through random sampling of household surveys and 
operational research [84]. 
2.5.3.3 Perceptions of lymphatic filariasis in Malawi 
LF is a disfiguring and debilitating disease not well understood in many societies and often 
carries considerable stigma. It is sometimes believed that the condition is the result of 
witchcraft or as a penalty for sins committed and other events that can victimise the affected 
persons [77]. 
Misconceptions about the cause and/or transmission of the disease are also common in 
Malawi. A baseline survey of malaria, LF and other neglected tropical diseases in southern 
Malawi reported various misconceptions in over 75% of the respondents where sexual 
intercourse with a menstruating woman, bad weather and HIV/AIDS were among the common 
perceived causes of the disease [79]. 
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Such kind of misconceptions and local perceptions of the cause and/or transmission of LF are 
key to control interventions of the disease since they are the basis for treatment seeking 
behaviour and community participation in the control strategies such as MDA. These disease 
control interventions are most effective if they take a multidisciplinary approach and 
incorporate these lay knowledge and perceptions [86]. 
2.5.4 HIV and HIV control in Malawi 
The prevalence of HIV among adults aged 15 to 64 years in Malawi was estimated at 9.2% in 
2016 and ranks among the ten countries with the highest rates in the world. An estimated one 
million people were infected with HIV in 2016 and 10% of them were children under the age 
of 15 years [87]. In the same year, there were an estimated 36,000 new HIV infections and 
24,000 AIDS-related deaths in the country [88]. Co-infections with a range of opportunistic 
infections, including tuberculosis, are more common in individuals infected with HIV largely 
because HIV infection compromises the immune system and the individual becomes 
vulnerable to multiple infections [89]. HIV infection may alter the natural history of concurrent 
infections in an unfavourable way, impede diagnosis and response to treatment of concurrent 
infections while concurrent infections may facilitate HIV transmission as well as HIV disease 
progression [90]. 
The Government of Malawi has responded to the HIV/AIDS epidemic by initiating a number of 
policies and intervention strategies on prevention, treatment, care and support such as 
behaviour change intervention for HIV/AIDS and sexual reproductive health, voluntary medical 
male circumcision (VMMC), HIV testing and counselling (HTC), prevention of mother to child 
transmission (PMTCT) and antiretroviral therapy (ART) scaling up [87].  
HTC services are provided through client-initiated testing and counselling (CITC), also known 
as voluntary counselling and testing (VCT), and provider-initiated counselling and testing 
(PITC). These HTC services have increased over the years in Malawi. VCT services started 
in 1985 using ELISA testing and HTC using whole blood rapid testing was initiated by Malawi 
AIDS Counselling and Resource Organization (MACRO) in 2001 and was adopted by MOH 
in 2003 [91]. By 2008, HTC was provided through a combination of PITC services focused on 
ANC, TB patients and STI patients, static, mobile and outreach sites, as well as home-based 
door-to-door testing and HTC national campaign events. 
PMTCT services have also significantly expanded since July 2011 when Malawi became the 
first country to implement the Option B+ programme in which all pregnant women diagnosed 
with HIV are offered antiretroviral treatment for life irrespective of their CD4 count or WHO 
clinical stage [92]. 
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ART was rolled out in Malawi in 2004 and by the end of 2007, 145,000 patients had been 
registered for therapy at 109 ART treatment facilities in the public sector and 45 in the private 
sector countrywide [93]. Malawi’s ART programme has been successful managing to put 68% 
of HIV-infected Malawians on treatment by 2016 [88], with the dual impact of improved health 
of those that are already infected and of prevention of onward transmission through decreased 
onward transmission of HIV [94].  ART clinics also provide diagnosis, treatment and prevention 
service for common opportunistic infections.  
These strategies and plans have assisted the country to achieve a slight decline and 
stabilisation in HIV prevalence from around 16.2% in 1999 to around 10.6% in 2010 and 9.2% 
in 2016. Malawi is also on track to achieve the UNAIDS 90-90-90 targets by 2020, which 
include 90% of people with HIV knowing their status, 90% of these accessing ARVS and 90% 
of those on treatment being virally suppressed [92]. 
ART is delivered by both the public and private sector at ART clinics situated in hospitals 
(central, district, mission, and rural), health centres or other stand-alone sites [93]. By 
December 2014, there were 706 static ART sites in Malawi owned by government, mission, 
NGOs and the private sector [95]. The minimum staff required per ART clinic is one clinician, 
one nurse and one clerk. Medical officers, clinical officers, medical assistants and nurses 
initiate and prescribe ARV drugs in the ART clinics and are required to have attended a pre-
service ART training course recognised by the MOH [93].  
The Malawi Ministry of Health has developed new guidelines for clinical management of HIV 
in children and adults following new WHO recommendations for ART and PMTCT in resource 
limited countries and have been implemented since May 2016 [96]. According to these new 
HIV treatment guidelines, all HIV positive children and adults are started on ART regardless 
of CD4 count or clinical stage (universal coverage). 
There are five different standard ART first line regimens for use in Malawi. The regimens are 
numbered 0 – 6 for ease of reference as below. Fixed dose combinations (FDC) are shown 
with a slash sign (e.g. AZT / 3TC / NVP) while combinations made up of different tablets are 
shown with a plus sign (e.g. AZT/3TC + EFV). There are also five different second line ART 
regimens, numbered 7 – 11, in Malawi and these are used for patients who have confirmed 
treatment failure on a first line regimen. The appropriate second line regimen is determined 
by the 1st line regimen that the patient was taking when failing. A third line regimen is available 
as a last resort for patients failing on the second line in spite of good adherence and can only 
be initiated by a specialised ARV clinician upon authorisation of a review committee [96]. 
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2.5.5 Co-endemicity and shared risk factors for HIV, malaria and LF in 
Malawi   
In Malawi, there is overlap between LF and HIV in the whole country. While HIV prevalence is 
highest in the southern parts of the country it is still high in the adult population in the north of 
the country [97]. As already described in section 2.5.2.1 above LF is most common in low lying 
areas that are close to water bodies including the Songwe river area of Karonga in the north 
and lower Shire valley are of Chikwawa in the south [29]. Malaria is endemic across two thirds 
of Malawi and Karonga is one of the more highly endemic parts of the country for malaria. 
Both malaria and LF are more common in rural areas of the country with HIV being more 
common in the urban areas [97].  
There are actual and theoretical shared risk factors for the three conditions in Malawi. Firstly, 
LF and malaria are other transmitted by night biting vectors so failure to sleep under a bed 
net, proximity to water bodies and poor housing conditions increase night biting risks. Poverty, 
social deprivation and educational levels have all been cited as increased risks for the three 
conditions which area associated with poorer knowledge of transmission and prevention of 
infectious diseases and poor access to prevention and treatment services in Malawi.  
2.5.6 Coverage and uptake of LF, malaria and HIV control measures  
This section will review coverage and uptake of control measures. It focuses on HIV, LF and 
malaria control efforts since HIV LF co-infection is the subject of your enquiry and since 
malaria control is likely to impact LF control through targeting night biting mosquito vectors 
and is therefore an important confounder in this thesis. The section focuses specifically on the 
coverage and update of control measures in Malawi, highlighting factors that have influenced 
coverage and uptake that are of particular relevance to co-infection. 
2.5.6.1 Coverage and uptake of HIV services  
Despite the successful ART programme and scale-up, the scope of the HIV/AIDS epidemic in 
Malawi has placed enormous challenges on the health care system due to its limited capacity 
with more than 50% of the hospital beds in Malawi being occupied by patients with HIV-related 
illnesses. This has increased demands and workload on the already poorly staffed and 
inadequately resourced health care system of Malawi [98]. At the time of the study, only just 
over half of the adults aged 15-49 knew their HIV status with men, young people, people in 
hard to reach areas and key populations being underserved [99]. Inequities in access to 
treatment and significant loss to follow up from ART services were also noted as major 
programmatic challenges. While supply side factors (service delivery) such as limited 
resources have limited the expansion of testing and treatment services, demand side factors 
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(at individual and community level) such as poor access to services, stigma, masculinity and 
cultural norms also play a role in creating these gaps in HIV control efforts.  
2.5.6.2 Scale up of mass drug administration in Malawi 
MDA to eliminate LF in Malawi started in eight districts in the southern region namely Blantyre, 
Chikwawa, Chiradzulu, Mulanje, Mwanza, Neno, Phalombe and Thyolo in 2008 and was 
scaled up in 2009 to all the 27 LF endemic districts in Malawi to reach 100% national 
geographic coverage for the target population of 13 million people at risk [100]. Since then 
until 2014, six consecutive rounds of MDA have been administered and treatment coverage 
remained over 80% for each MDA round. Currently Malawi is conducting transmission 
assessment surveys (TAS) that are required to determine if LF transmission has been 
interrupted. The first TAS was conducted in 2014 in 11 evaluation units (EUs) following WHO 
guidelines and the LF infection rate for each EU was below the critical cut-off level required to 
stop MDA. The NTD Regional Programme Review Group (RPRG) for the WHO African Region 
reviewed and approved the TAS results in 2015 indicating that MDA could be stopped in 
Malawi [100].  
2.5.6.3 Scale-up of insecticide treated nets  
Since 2005 Malawi has scaled up malaria control measures focusing on vector control, case 
management and protection of vulnerable groups including pregnant women and infants. 
Current vector control intervention strategies being implemented by the national malaria 
control programme include distribution and use of ITNs and indoor residual spraying (IRS). 
The ITN policy involves usage and free distribution of ITNs. Free ITNs are distributed 
countrywide to all newborn children born in health facilities, children attending their first 
vaccination (if it was not received at birth) and pregnant women attending their first antenatal 
visit. National free distribution campaigns of ITNs targeting pregnant women and under-five 
children are also conducted every 2-3 years. 
According to the report of the Malawi National Malaria Indicator survey conducted in March 
and April 2010, over 5 million nets have been distributed in Malawi in the two years preceding 
the survey. Nearly 60% of households had at least one ITN while 55.4% of children under the 
age of five years and 49.4% of pregnant women slept under an ITN the night before the survey 
[101]. 
2.5.6.4 Coverage of indoor residual spraying 
IRS is the latest malaria vector control programme to be adopted by the national malaria 
control programme. It involves application of a long-acting insecticide on the walls of all houses 
in order to kill the mosquito vectors that land and rest on these surfaces. The insecticide of 
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choice in Malawi is ICON-CS and is one of the recommended insecticides by WHO. IRS was 
initiated in 2007 as a pilot in the lakeshore district of Nkhotakota in the Central Region and in 
December 2010 MOH expanded IRS to seven high malaria prevalence districts along the 
lakeshore and in the Shire valley, including Karonga district and covering a population of 2.7 
million people. However, the programme was discontinued between 2011 and 2012 due to 
logistical problems including evidence of emerging insecticide resistance until 2013 when it 
was resumed [29]. 
2.5.5.6 Relevance of LF, malaria and HIV disease control programmes to 
coinfection 
The three control programmes for LF, malaria and HIV are of relevance to co-infection 
prevention and clinical management. The overlap of LF and malaria control are of particular 
relevance as vector control can impact on both conditions simultaneously. Stanton et al in 
2014 developed a multiple intervention score map for Malawi that quantified malaria and LF 
control activities and mapped them to areas of the country [29]. The district score maps 
indicated areas that have received high and low coverage of LF-impacting interventions. High 
coverage areas included the LF-onchocerciasis endemic areas in the southern region of the 
country and areas along the shores of Lake Malawi, where malaria vector control had been 
prioritized. This kind of combined mapping allowed the team to prioritize three districts with 
high baseline LF prevalence measures but low coverage of multiple interventions as these 
were most at risk of ongoing transmission or re-emergence. HIV control efforts are also 
relevant as these vertically funded programmes have brought additional resources, health 
systems strengthening and clinical expertise into previously underserved districts. All three 
control programmes are designed as vertical programmes at national level yet work through 
community health workers or community health distribution agents, creating platforms for 
integration at the lowest level of the health system in Malawi [39].   
2.6 Summary and study rationale  
This chapter has reviewed available literature on LF and HIV and other significant co-infections 
putting them into a Malawian context. Available evidence adds further justification to the need 
for a study on LF and HIV co-infection in Malawi, first outlined in section 1.2 of the introductory 
chapter. At the outset of this study there was no clear evidence of an association or 
relationship between HIV and LF (equipoise). The expectation was that HIV might disrupt LF 
control based on the assumption that an individual requires an intact immune system to clear 
LF infection when MDA is given. A poorer response to antihelminthics could therefore be 
expected in immunosuppressed HIV positive individuals. This expected impact would then 
have public health implications for the dose, duration and scheduling of MDA in areas of high 
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HIV prevalence. Before major changes to LF programmes evidence was needed that 
interrogated the association between LF and HIV, including the ability to clear LF over time.  
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 Methodology 
This chapter presents the research methodology that was used to conduct the study. The 
chapter first describes the Karonga Prevention Study (KPS) in Karonga, northern Malawi. It 
then outlines the relevant Karonga Prevention Study studies within which this thesis is nested, 
including their linkage to each other. For the study to make sense, the timelines of the various 
interventions related to LF control in the district are summarised. The chapter then gives a 
detailed description of the methods for each of the filarial research studies that make up this 
thesis. For each the study design, characteristics and selection of the populations studied, 
description of the information collected from the participants, the variables used, and sample 
size considerations are described. Common methods across all the studies are presented 
separately and these include a description of laboratory methods, data handling and 
management, statistical analyses, mapping methods and analyses and ethical considerations. 
3.1 Background to Karonga and the Karonga Prevention Study  
3.1.1 Karonga Prevention Study 
The research programme in Karonga district was started in 1979 with support from the British 
Leprosy Relief Association (LEPRA) to study the incidence and risk factors of leprosy in 
Karonga district [102, 103]. Following a pilot leprosy survey in 1979, a total population leprosy 
survey known as the Lepra Evaluation Project (LEP) was conducted from 1980 to 1984 as a 
large cohort of leprosy covering the entire district of Karonga with a population of 112,000 
people. A second total population leprosy survey was conducted from 1986 to 1989 to 
measure leprosy incidence and to recruit for a large double-blind, randomised, controlled 
vaccine trial comparing the efficacy of a single BCG dose, repeat BCG dose and a WHO-
sponsored combined BCG plus killed M. leprae vaccine in protecting against both leprosy and 
tuberculosis (TB) [104]. The vaccine trial became known as the Karonga Prevention Trial 
(KPT) while the combined epidemiological studies (LEP) and the vaccine trial (KPT) became 
known as the Karonga Prevention Study (KPS). The programme assumed responsibility for 
tuberculosis diagnosis and treatment in the district from 1984 onwards and in 1987 began 
studies of HIV. Annual trial follow ups for leprosy and TB and case control studies of HIV as a 
risk factor for leprosy and TB were conducted from 1990 to 1996.  
The trial follow up results led to two five-year Wellcome Trust supported programmes. The 
first programme from 1996 to 2001 involved case control genetic studies on leprosy and TB, 
controlled trials comparing BCG efficacy in adolescents and young adults between Malawi 
and the UK and a retrospective cohort study of HIV-infected individuals [105, 106]. The second 
Wellcome Trust programme from 2001 to 2006 followed this and had three main themes: 
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immune responses to BCG vaccination, epidemiology of M tuberculosis infection and disease 
and the demographic impact of HIV. In this programme, a cohort of infants was recruited to 
examine responses to BCG, the TB case control study continued to examine the evolving 
relationship between TB and HIV in adults, the TB molecular epidemiology studies were 
extended and a demographic surveillance system of 33,000 individuals was initiated in the 
southern part of the district [103].   
A third Wellcome Trust funded programme from 2006 to 2011 continued the TB epidemiology 
and immunology studies adding pneumococcal and filariasis research studies. HIV became 
the central focus of the programme with studies on HIV epidemiology and its interaction with 
other major infectious diseases and the mitigating effects of antiretroviral therapy. 
Research work on filariasis began in the mid-90s with community prevalence surveys 
identifying Karonga district as one of the high prevalence regions of Malawi. Several KPS 
studies with available data and stored blood samples for nested observational studies on 
filariasis were available and three key on-going studies at KPS were suitable for filariasis 
research since they had robust datasets and available stored blood samples with consent from 
participants and ethical approval for retesting. These were the Karonga Health and 
Demographic Surveillance System (KHDSS) and the Filariasis Elimination Dosage Study (also 
called the Songwe Filariasis Clinical Trial due to its location). These are outlined in sections 
3.1.2, 3.2 and 3.3 respectively.  
3.1.2 The Karonga Health and Demographic Surveillance System and HIV 
sero-surveys 
In 2002, the KHDSS was established to provide cross-sectional estimates of population size 
and structure, and to provide a sampling frame for epidemiological and immunological studies 
[103]. The KHDSS population was 35,730 in 2011 and covers an area of 135km2 in the 
southern part of the district (Figure 1). The surveillance system collects data on vital events 
and migration for individuals and households, cause-specific mortality for all ages, vaccine 
coverage and socio-economic status data. 
Between 2007 and 2011, the KHDSS was combined with annual household HIV sero-surveys 
(HSS). All households including approximately 16,000 individuals over the age of 15, 
underwent an annual census visit following which all consenting adult members aged 15 or 
over underwent a rapid HIV antibody test. Results were provided at their home. This process 
was repeated on an annual basis over a four-year period. Consenting adults provided a 5ml 
blood sample for rapid testing for HIV using the standardised national serial testing algorithm 
(where all reactive results were confirmed by a second rapid test), pre- and post-test 
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counselling protocol [107, 108]. The venous blood sample collected was also used for quality 
control and further laboratory analysis including HIV drug resistance testing Remaining blood 
samples after HIV testing were stored in the KPS laboratory for later testing for other diseases 
related to HIV or of importance in Karonga district.  
As part of the demographic surveillance system, information on socio-economic status of 
individuals and households was collected using a structured questionnaire (See Appendix 1: 
Individual Socio-Economic Survey Form). The questionnaire enquired about education, 
occupation, vaccine, bed net ownership and MDA history. 
The KHDSS is located in the south where the HSS was conducted and the Songwe Filariasis 
Clinical Trial took place in the north of the district (see Figure 1). Thus, these studies were 
geographically separate. Each study collected GPS coordinates and unique identifiers 
meaning that individuals who appear in more than one dataset can be linked. This is 
particularly relevant to the large overlapping KHDSS and HSS datasets where HIV status can 
be linked to behavioural and intervention variables such as MDA and bed net ownership. Not 
all individuals who participated in the KHDSS annual census also consented to participate in 
the HSS. This makes the HSS a subset of the KHDSS.  
3.1.3 Timelines of relevant public health interventions and relationship to 
overall KPS timelines 
Between 2004 and 2012 there have been a number of district wide interventions in an effort 
to control endemic diseases. These include vector borne diseases such as malaria, soil 
transmitted helminths (STH), TB and HIV control among others. Filariasis is a vector borne 
disease treated by the same regiments as soil-transmitted helminths and affected by 
antibiotics and treatment interventions related to malaria, STH and TB control. These are 
described in the text below and summarised in Figure 5. Details of HIV prevention and control 
and other illnesses are not covered in this chapter.  
Since 2007, free insecticide treated bed nets (ITNs) are distributed at health facilities to 
children born in health facilities, children attending their first immunisation visit if not received 
at birth and pregnant women attending their first antenatal care visit through the national 
malaria control programme [109]. 
Indoor residual spraying (IRS) is one of the primary preventive strategies for malaria against 
the vector mosquitoes. It involves application of a long-acting insecticide on inside walls of 
houses and shelters to kill vector mosquitoes when they land and rest on the sprayed surfaces. 
Following a successful pilot of IRS in Nkhotakota district in 2007, the Malawi Ministry of Health 
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scaled up IRS in 2011 to seven highly endemic districts along the lakeshore including Karonga 
and in the Shire valley. 
Six annual MDA rounds as part of the Malawi LF elimination programme have been 
undertaken in Karonga district. The first MDA, using a combination of albendazole and 
ivermectin was done between November and December 2009. The second MDA round was 
conducted between November and December 2010, the third MDA between December 2011 
and January 2012, the fourth in November 2012, the fifth in November 2013 and the sixth in 
August 2014. Access to antihelminthic drugs in Malawi is through STH control activities which 
is part of the national school health and nutrition programme, launched in 2007. In this 
programme, albendazole is given annually to all school age children in all schools in Malawi. 
The first round of HSS fell between September 2007 and September 2008, round two between 
October 2008 and September 2009, round three between October 2009 and October 2010 
while the fourth round fell between November 2010 and December 2011. The Songwe clinical 
trial was conducted from January 2009 to March 2012. 
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Figure 5: Timelines of Interventions and Data Collections 
 
3.2 Filarial Research Study 1: Assessment of Relationship of HIV and 
Markers of Lymphatic Filariasis Infection  
3.2.1 Study design and links to parent studies 
This cross-sectional study used available stored serum and data from the two geographically 
separate studies. It aimed to investigate the relationship between HIV and circulating filarial 
antigenaemia (CFA) and microfilaraemia.  The overall population of Karonga district during 
the study period was 272,789 [110] with the KHDSS population accounting for 33,500. HIV 
prevalence in the KHDSS in the 2007–2008 baseline HIV survey was measured at 7.4% but 
estimated to be 10.4% when adjusted for non-testing by those who already knew they were 
HIV-positive [99]. In the baseline survey, 54.8% of those aged 15 years or more reported 
previous HIV testing.  
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3.2.2 Data and samples from the Songwe Clinical Trial 
The Songwe Filariasis Clinical Trial was conducted in Songwe area in the northern part of 
Karonga district. More details on this study may be found in section 3.3 as the full study also 
forms part of the filariasis research (Filarial Research Study 2) in this thesis. Study participants 
included in this part of the assessment of qualitative CFA and HIV were residents of the 
Songwe area who participated in the screening phase of the Songwe clinical trial. The study 
participants were screened for CFA by the ICT card test and HIV infection. HIV testing 
procedures were done as in the KHDSS HIV sero-survey (section 3.2.3). In addition, all 
individuals with baseline microfilarial counts who had stored plasma samples available for 
retesting were included in the assessment of microfilaraemia and quantitative CFA and HIV 
(see Figure 6). 
 
 
Figure 6: Testing Algorithm for Circulating Filarial Antigen and Microfilarial Counting 
 
Qualitative CFA, HIV and baseline microfilarial counts from Songwe clinical trial participants 
were available from the KPS database and were linked with socio-demographic characteristics 
from a structured questionnaire by unique study identifiers. Stored plasma samples from night 
blood specimens used for microfilarial counting were available from the KPS laboratory 
archive and were reassessed for LF antigen detection and quantification using the Og4C3 
ELISA (see section 3.6.4 below). 
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312 individuals (29 HIV-infected and 283 HIV-uninfected) had stored baseline night blood 
samples. A ratio of 29 HIV-infected and 87 HIV-uninfected individuals was expected to detect 
a 20% difference or greater in mean CFA titre at significance of 1% and power of 88% 
assuming a geometric mean titre of 2000 CFA units (SD 500) in the HIV-uninfected. 
3.2.3 Data and samples from the KHDSS 
Data and samples from a comprehensive population-based HIV sero-survey nested within the 
Karonga Health and Demographic Surveillance Site (KHDSS) were used to further explore 
the relationship between LF and HIV [13]. Since its establishment, the initial population of the 
KHDSS has been under continuous demographic surveillance. In addition, between 
September 2007 and October 2011 four annual HIV sero-surveys were conducted in all 
individuals aged 15 or more years using rapid point-of-care HIV tests on finger-prick whole 
blood samples [14]. Samples from the first surveillance round, which took place between 
September 2007 and October 2008, prior to MDA introduction, were included in this study. 
Community sensitisation meetings to explain the aims and procedures of the study were held 
in each village and were followed by house-to-house visits by counsellors to recruit 
participants. The counsellors were trained and certified by Malawi Ministry of Health staff to 
perform HIV counselling and testing and referral using standard procedures [15]. At each 
home visit, the study was introduced and explained to all eligible participants and written 
informed consent was requested (See Appendix 2 – HIV Sero-survey Consent form). All 
consenting adults were offered HIV pre-test counselling and asked to provide a 5ml blood 
sample for immediate HIV testing at the home, quality control and storage for further laboratory 
analysis including for other diseases of importance in Karonga district. All participants who 
wanted to know their test results were post-test counselled and informed of their results at the 
home, with referral to local clinical services if found to be HIV positive. Plasma samples from 
consenting participants were stored in the project laboratory archive at -20°C and were 
assessed for LF antigen detection and quantification using the Og4C3 ELISA (see section 
3.6.4 below). Viral load, CD4 counts and clinical staging were not measured as a part of the 
survey. 
3.3 Filarial Research Study 2: Songwe Filariasis Clinical Trial 
The filariasis elimination dosage study (FED) also called the Songwe Filariasis Clinical Trial 
was a clinical trial undertaken in the northern part of Karonga district in Songwe area (see 
Figure 1) along the Tanzania border, 110km north of the KHDSS site [111].  
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This was a randomised, controlled, four-arm, open-label, clinical trial.  The study took place 
from January 2009 to March 2012 in all 16 villages in a pre-defined study area close to the 
Songwe River in the north of Karonga District of northern Malawi. This area was known to be 
highly endemic for W. bancrofti infection and no mass treatment intervention had been 
undertaken prior to commencement of this study. The trial was registered with Clinical 
trial.gov, number NCT01213576. 
3.3.1 Study participants 
Eligible participants were all adults aged between 18 and 55 years living within the study area 
who understood and signed the informed consent (Appendix 3 – Consent Form for Lymphatic 
Filariasis Study), were willing to undergo night time blood drawing every 6 months for 2 years, 
had haemoglobin levels ≥9 g/dL and microfilarial levels >80 mf/ml. Exclusion criteria were 
pregnancy, lactation and history of taking albendazole or ivermectin for any reason within the 
previous 6 months or a known allergy to either drug.  
3.3.2 Study procedures 
At the initiation of the study, field study personnel explained procedures at village sensitisation 
meetings. Recruitment was then done through house-to-house visits. Consenting, eligible 
individuals were initially screened for circulating filarial antigenaemia (CFA) using the 
Immunochromatographic (ICT) card test (Binax, Portland, ME) [112]. The ICT card test (Figure 
7) was administered according to the manufacturer’s instructions with measurements read at 
10 minutes and if two lines were visible in the viewing window that individual was recorded 
positive for CFA on the ICT result form (Appendix 4 – ICT Result Sheet). Individuals whose 
samples produced faint lines were recorded as weakly positive and deemed as positive 
individuals for subsequent investigations. Participants were informed of their test results at the 
home and individuals who were CFA positive but declined to participate in the clinical trial or 
did not meet the eligibility criteria for the trial were offered standard dose antifilarial therapy 
with albendazole and ivermectin. 
Individuals who were positive for CFA by the ICT card test and consented to provide a night 
blood sample were evaluated with a brief medical history and physical examination and visited 
at their households between 22:00 and 02:00 hours for collection of two venous ‘night blood’ 
samples. One EDTA sample was used for full blood count and the other, a sodium citrate 
sample, was used for microfilaria measurement by the Nucleopore membrane filtration 
technique [113] expressed as density of microfilariae (mf) per ml of blood.  
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3.3.3 Randomisation  
Participants who fulfilled the eligibility criteria underwent further informed consent and were 
assigned to study treatment groups using a computer-generated randomisation list. An 
independent investigator pre-generated the list which had an allocation ratio of 1:1:1:1 and 
restricted block sizes of 4. Study field personnel enrolled and allocated participants to the 
treatment groups using allocation letters on the randomisation list consecutively for each 
individual recruited into the study. The study field personnel kept the allocation list in a field 
site locker and no blinding was employed since the trial design was open-label. 
3.3.4 Interventions 
Eligible participants were randomly allocated to the four treatment study arms (see Figure 15): 
the standard regimen of single dose albendazole (400 mg) and ivermectin (200 mg/kg) once-
yearly (control group [SDA]), a twice-yearly standard regimen (SDT), a high-dose regimen of 
albendazole (800 mg) and ivermectin (400 mg/kg) given either once-yearly (HDA) and the 
same given twice-yearly for a period of 2 years (HDT).  
Study drugs were taken orally under direct observation by field staff to ensure compliance and 
to record any immediate side effects in the 30 minutes post-ingestion. The study team made 
scheduled visits once a day for 7 days to a pre-defined place within the village to review any 
individual who reported adverse events post-treatment. Adverse events were self-reported 
and assessed according to pre-defined clinical criteria. These were recorded on an adverse 
event form and, if considered severe or life threatening, was referred appropriately to the 
nearest health facility. 
3.3.5 Follow up 
Participants were followed-up every 6 months for 2 years, underwent clinical assessment, 
venepuncture for full blood count and night blood microfilarial counting and received 
subsequent study drug administration as appropriate. In addition to the clinical assessment 
done at each follow up visit, information was collected on filarial related clinical manifestations 
such as fever, lymphoedema, lymphangitis, hydrocoele and skin rash (Appendix 5 – Filariasis 
Dosage Study Follow up Form). Individuals with missed appointments remained in the study 
until 24 months and were actively traced at each follow up appointment. 
3.3.6 Sample size 
The primary study endpoint was a difference in the clearance rate of Wuchereria bancrofti 
microfilaraemia, expressed as microfilariae per ml of blood (mf/ml), at 12 months. Based on 
data comparing single and multi-dose regimens for the treatment of lymphatic filariasis [9, 
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114], the study assumed that the standard annual therapy would clear microfilaraemia in 
approximately 25% of subjects at 1 year whereas multi-dose therapy should give 75% 
clearance. The sample size needed to detect this difference by Fisher’s exact test with two-
sided alpha level of 0.05 and power equal to 80% is 20 per group. Taking 15% attrition at each 
visit into account, the study planned to recruit 30 subjects per each study arm.   
3.3.7 Data management and statistical analyses 
Details of the overall statistical methods can be found in section 3.6. For this study participant 
information was collected onto paper record forms. Forms were transported to the project 
headquarters in Chilumba, Karonga district, where they were checked, coded, double entered 
and verified using Microsoft Access 2007 software. All statistical analyses were done using 
STATA 12.0 (Stata Corporation, USA). The difference in clearance proportions between the 
intervention treatment arms and the comparison group was examined using the Fisher’s exact 
test and the log rank test where appropriate.  
The analysis used the last observation carried forward and intention-to-treat approaches to 
deal with participants who did not take all the intended treatments during the study. 
3.3.8 Ethical Approval 
The study was registered with ClinicalTrials.gov (NCT01213576) and approved by the 
National Health Sciences Research Committee of the Malawi Ministry of Health (protocol 
number 495) and the Ethical Committee of the London School of Hygiene and Tropical 
Medicine (protocol number 5344). Community permission to undertake the study in the area 
was sought from village and community leaders.  
3.4 Filarial Research Study 3: The impact of MDA on circulating filarial 
antigenaemia by HIV status and ITN ownership 
This study set out to investigate the impact of MDA on circulating filarial antigenaemia (CFA) 
by HIV status and bed net ownership using available stored follow up blood samples and data 
collected as part of the whole adult population HIV sero-surveys that were undertaken in the 
Karonga Health and Demographic Surveillance Site (KHDSS). 
3.4.1 Study design and links to parent studies 
This was a longitudinal assessment of the impact of MDA on circulating filarial antigenaemia 
by HIV status and ITN ownership that was nested within a comprehensive population-based 
HIV sero-survey. Repeated rounds of data and sample collection spanned the time periods 
before and after the introduction of MDA. Baseline samples were taken from HSS round 1 
(September 2007 to October 2008) as this pre-dated MDA and follow up samples were taken 
59 
 
from HSS rounds 3 and 4 (November 2009 to October 2011) covering the period 2-3 years 
after MDA had reached all areas. Round 3 samples were preferred but if unavailable then 
round 4 was investigated and if samples on that individual were available these were used 
instead. Individuals HIV profile was obtained from the HSS dataset while baseline 
demographic data, MDA usage, number and timing of doses and household bed net 
ownership were derived from a self-reported questionnaire and were linked with the test 
results via unique study identifiers. 
3.4.2 Study participants and selection of control samples 
Study participants were members of the KHDSS who participated in the annual census and 
HIV sero-survey and provided an EDTA blood sample for storage and further testing in the 
KPS laboratory archive. All individuals with samples from HSS round one were included in the 
baseline assessment.    
Follow up assessments included all individuals who tested positive for CFA in the baseline 
assessment and had stored plasma samples available for retesting. HIV sero-converters were 
excluded from the analysis.  
In addition to this primary cohort, a randomly selected control group of individuals who were 
negative for LF antigen at baseline was established (LF negative group) and these were 
assessed in subsequent samples to investigate natural acquisition of LF antigenaemia during 
a period of MDA administration. To limit the size and cost of the LF negative group, participants 
were selected by frequency matching on age with the LF positive group in a 2:1 ratio. The age 
groups used for frequency matching were 15-40 & >40 years of age. The selection was done 
in a random way by assigning a number to each LF negative participant and listing in a random 
number generator. The selection was made in sequence until the required number of LF 
negatives was achieved.  To avoid selection bias, the identified individuals were included 
whether they were known to have a follow up EDTA sample or not in the same way that LF 
positive individuals were identified.  
3.4.3 Study Procedures 
Plasma samples derived from EDTA blood were selected for assessment of CFA.  Follow up 
samples were selected first from round 3. If no follow up samples were identified in round 3 
then round 4 was checked to see if there was an available sample from the same participant.   
3.4.4 Sample size assumptions 
With an estimated LF prevalence of 10% and HIV prevalence of 10% and assuming low levels 
of ART use in this population, the study expected to have 80 HIV and LF co-infected individuals 
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and 720 HIV-uninfected and LF-positive individuals after screening all individuals who 
participated in the HSS round 1 and with baseline samples stored in the KPS laboratory 
(approximately 8000 individuals). 
Table 1: Estimates of power to show given effects based on available sample size 
 
Assuming post-MDA LF antigenaemia proportion of 0.5 in the HIV-uninfected individuals, the 
study expected to demonstrate a 15% difference in antigenaemia with 69% power (Table 1). 
Primary outcome:  
Difference in CF titre between pre-MDA and post-MDA LF antigenaemia in HIV-infected and 
HIV-uninfected individuals 
Secondary outcomes: 
1. Association of HSS round 1 LF antigenaemia with key predictors: age, gender, HIV, bed 
net usage   and location of residence.  
2. Measurement of the acquisition of LF antigenaemia in LF negative control group. 
3. Cross-sectional prevalence of LF and HIV co-infections and LF antigenaemia by ITN use. 
3.4.5 Data management and statistical analysis 
Details of the overall statistical methods can be found in section 3.6. For this study sub analysis 
adjusted for number of MDA treatments and adjusted for potential confounders such as age, 
gender, location of residence and bed net usage. 
3.5 Laboratory Methods 
These included the ICT card test, microfilarial counting and HIV testing. 
3.5.1 Immunochromatographic (ICT) Card Test  
The ICT card test (Figure 7) is a commercially available assay for detecting filarial antigen 
manufactured by Binax (Maine, USA). It was used as the screening test for LF infection in the 
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Songwe filariasis clinical trial. It is a portable, rapid, point-of-care test suitable for LF screening 
in non-laboratory settings at any time of the day and was used in accordance with 
manufacturer’s instructions. In brief, a 100 μL finger prick blood sample was added to the 
sample application pad and the card was closed. The test result was read after 10 minutes 
and if two lines were visible in the viewing window that individual was recorded positive for 
CFA. Individuals whose samples produced faint lines were recorded as weakly positive and 
deemed as positive individuals for subsequent investigations. The test result was read 
independently by a field worker and was verified by a second field worker who served as a 
field supervisor. 
 
Figure 7: The ICT Card Test for Lymphatic Filariasis 
 
3.5.2 Microfilaria counting 
Microfilaria counting on night blood samples from the Songwe filariasis clinical trial was done 
by the Nucleopore membrane filtration technique. In brief, this involved filtering a measured 
volume of venous blood through a 5µM pore size Nucleopore filter. After filtration, the filter 
was removed, placed on a glass slide and mounted on a light microscope for examination and 
counting of microfilariae. 
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3.5.3 HIV testing 
In all the studies, HIV testing used whole blood rapid diagnostic tests according to Malawian 
national guidelines  with demonstrated high accuracy in community settings in Karonga [107]. 
. The parallel HIV testing algorithm was used for individuals tested until May 2008 and the 
serial testing algorithm for individuals tested after May 2008. The initial screening test was 
with Determine TM HIV-1/2 (Abbott Japan Co Ltd, Japan) and confirmatory testing was done 
with UniGold TM HIV-1/2 (Trinity Biotech PLC, Ireland). Samples with a non-reactive 
screening test were considered negative and those with a reactive screening and confirmatory 
test were considered positive. Where the screening and confirmatory tests were discordant, a 
‘tie breaker’ using a third rapid test, (SD Bioline, Korea) was used. The results of the HIV test 
were recorded on a form by the field personnel (Appendix 6 – Rapid Test Form). After field 
HIV testing, the venous blood sample was transported in a cool-box to the KPS laboratory for 
further laboratory-based HIV testing and quality control. Quality control of the rapid HIV testing 
was done by retesting all positive samples, all inconclusive samples, and a random selection 
of 1 in 10 negative samples. 
3.5.4 Additional filarial research laboratory methods – Og4C3 ELISA 
Sample selection and preparation 
The plasma samples stored in cryotubes to be processed were first pulled from the freezers, 
placed on a rack and left at room temperature until they thawed. 
LF antigenaemia detection and quantification 
LF antigenaemia detection and quantification was done in all the studies using the W. bancrofti 
Og4C3 antigen-capture enzyme-linked immunosorbent assay (TropBio, James Cook 
University, Townsville, Queensland, Australia) following the manufacturer’s instructions as 
described in the Appendix 7 - Trop Bio ELISA kit manual. 
Plate Reading 
The microtitre plate was read using a Dynex revelation plate reader at single wavelength 
(405nm) and dual wavelength (405 and 492nm). The optical density (OD) was determined by 
the ELISA plate reader and in addition to a positive/negative response the TropBio ELISA 
gave a graded response expressed in antigen units or titre group. Using seven control samples 
provided in the ELISA plates, the test samples were allocated into eight titre groups according 
to manufacturer’s instructions. The antigen units present in each titre group were indicated in 
the manufacturer’s instructions and ranged from <10 units to 32,000 units. 
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Quality control  
If the optical density for the high titre control (Standard No 7) was less than 1.1 or the optical 
density for the negative control (Standard No 1) is more than 0.3, the test results were 
regarded as unreliable and the test was repeated. 
3.6 Data Management and Statistical Methods 
All individual data was collected on paper-based questionnaires and returned to the KPS data 
coding office. The questionnaires were checked, coded, double-entered and verified using 
Microsoft Access 2007 software and subsequently exported into STATA statistical software 
version 12 (StataCorp, Texas, USA) for statistical analyses.  
All statistical analyses were done using STATA 12.0 (Stata Corporation, Texas, USA). Basic 
descriptive statistics explored the data and described characteristics of the study population. 
Comparison between categorical data were made using Pearson’s Chi-square, Fisher’s exact 
test and the log rank test where appropriate. Logistic regression was used to calculate odds 
ratios (OR) for risk factors associated with the outcomes of interest. 
For the Songwe clinical trial, the difference in clearance proportions between the intervention 
treatment arms and the comparison group was examined using the Fisher’s exact test and the 
log rank test. The analysis used the last observation carried forward and the intention-to-treat 
approaches to deal with participants who did not take all the intended treatments during the 
study. 
 For the cross-sectional assessment of the relationship of LF and HIV infections, and the follow 
up cohort study, continuous variables were log transformed prior to analysis to achieve an 
approximate normal distribution. Linear regression was used for crude and adjusted analyses 
with results expressed as geometric mean ratios (GMR) and their 95% confidence intervals. 
The association of age, gender and CFA status with HIV positivity was estimated using Chi-
square tests for crude analyses and a logistic regression model for adjusted Odds Ratios. In 
a risk factor analysis for CFA positivity, logistic regression was used to estimate crude and 
adjusted ORs. Variables were retained in the model if significant associations were identified 
in the unadjusted estimates. Geographic identifiers for groups of survey villages were also 
incorporated in the models to adjust for geographic confounding as previous surveys had 
indicated heterogeneity of CFA prevalence across the region. Rather than a binary variable, 
HIV was treated as a categorical variable in the model with the HIV-negative group and two 
HIV-positive groups based on ART use at the time of blood sampling. A sub-group analysis to 
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investigate the effect of cotrimoxazole and duration of ART use on CFA prevalence was 
performed on the HIV-positive group only. 
 Logistic regression models were used to estimate odds ratios. Difference in CFA prevalence 
with increased use of ART was investigated with a Chi-square test for linear trend with odds 
ratios derived from a 2xn table. Adjusted odds ratios were also estimated with logistic 
regression. 
3.7 Ethical considerations  
The National Health Sciences Research Committee of the Malawi Ministry of Health (protocol 
numbers 495 and 419) and the Ethical Committee of the London School of Hygiene and 
Tropical Medicine (application numbers 5344 and 5081) gave ethical clearance for both the 
Songwe filariasis clinical trial and the HIV sero-survey. Study participants in both studies were 
consented for storage and later testing of samples at the time of enrolment. This covered 
testing for HIV and other diseases of local significance. The National Health Sciences 
Research Committee (protocol number 908) and the Ethical Committee of the Liverpool 
School of Tropical Medicine (protocol number 11.77) approved the additional analysis 
conducted on stored samples.   
65 
 
 Results 
This chapter presents the study findings of each of the three filarial research studies that make 
up this thesis. In section 4.1 the cross-sectional analysis is described that underpins the 
findings on the relationship between LF and HIV. The characteristics of the two study 
populations from which samples were drawn are described in detail. Results of the HIV and 
filarial antigen testing are summarised with details of HIV rapid test results, circulating filarial 
antigen, microfilarial testing and LF quantification. Samples sourced from the KHDSS are 
linked to the data from the detailed household survey that included information on bed net 
ownership and ART. Section 4.2 describes the Songwe clinical trial participants and the 
microfilarial clearance in the different treatment arms. In section 4.3 results of samples taken 
before and after a period of mass drug administration are presented. It presents participant 
characteristics at baseline and follow up, CFA clearance rates and an analysis of the impact 
of mass drug administration and bed net ownership. An HIV subgroup analysis is also included 
in this section.  
4.1 Filarial Research Study 1: Cross-sectional Assessment of the 
relationship of HIV and markers of lymphatic filariasis infection  
In this section, the study presents findings from the analysed markers of lymphatic filariasis 
infection, by HIV infection status, among adults in two geographically separate sites in 
Karonga district, northern Malawi. Serum samples for this were drawn from two source studies 
at KPS: 1) screening samples from the Songwe Clinical Trial, results of which are presented 
in section 4.2, and 2) samples from the KHDSS whole population baseline HIV sero-survey 
as described in Chapter 3, section 3.1.2.   
4.1.1 Samples sourced from Songwe Clinical Trial  
4.1.1.1 Characteristics of the study population 
From the estimated total population of 36,643 adults from 44 target villages in the study area, 
1,851 individuals from 16 villages were eligible and consented to participate. The 16 villages 
were chosen because they were historically known to be highly endemic for LF and had easier 
access of recruitment. There were more females (57.8%) than males. Mean age was 32.6 
years (SD 10.4) and the majority were aged between 18 and 30 years old (Table 2). 
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Table 2: Age and sex distribution of the study population 
Age Category Females Males Total 
 N (%) N (%) N (%) 
All 1069 (57.8) 782 (42.2) 1851 (100) 
18-29 years 495 (46.3) 348 (44.5) 843 (45.5) 
30-39 years 302 (28.3) 241 (30.8) 543 (29.3) 
≥ 40 years 272 (25.4) 193 (24.7) 465 (25.2) 
 
4.1.1.2 LF and HIV coinfection 
Of the 1,851 individuals screened for LF antigen by the ICT card test, 447 (24.2%) were CFA 
positive, 1402 (75.7%) were CFA negative while 2 (0.1%) had an invalid ICT test result. A total 
of 1,656 individuals accepted HIV testing and 169 (10.2%) of these were HIV positive (Figure 
8). HIV positive individuals tended to be older but there was no difference in HIV prevalence 
by sex (Table 3). CFA positivity was present in 43 (25.6%) of HIV positive and 351 (23.6%) of 
HIV negative (crude OR 1.11, 95% CI 0.77–1.60) with an LF/HIV co-infection prevalence rate 
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Figure 8: Flow Chart Detailing the Breakdown of Individuals by HIV Status, Circulating 
Filarial Antigen (CFA) Status By Immunochromatographic Card (ICT) Test and 
Microfilarial Counts 
*2 individual had an invalid ICT test. MF—microfilaria.
Total screened 
1851 
HIV+* 
169/1656 
(10.2%) 
HIV-unknown 
195/1851 (10.5%) 
 
HIV-* 
1487/1656 (89.8%) 
 
CFA+ 
43/168 (25.6%) 
CFA- 
125/168 (74.4%) 
CFA+ 
53/195 (27.2%) 
CFA- 
142/195 (72.8%) 
CFA+ 
351/1486 (23.6%) 
CFA- 
1135/1486(76.4%) 
Night sample 
29/43 (67.4%) 
Night sample 
36/53 (67.9%) 
Night sample 
246/351 (70.1%) 
MF+ 12 (41.4%) 
MF- 17 (58.6%) 
MF+ 19 (52.8%) 
MF- 17 (47.2%) 
MF+ 123 (50.0%) 
MF- 123 (50.0%) 
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Table 3: Baseline characteristics of the participants by HIV status 
A 
Characteristic HIV-positive 
(n=169) 
HIV-negative  
(n=1487)  
OR (95% CI†) Adjusted OR (95% CI)# 
Age group 
18 - 29 years 
30 - 39 years 
40 years and above  
 
43 (25.4%) 
68 (40.2%) 
58 (34.3%) 
 
727 (48.9%) 
406 (27.3%) 
354 (23.8%) 
 
- 
2.83 (1.90 – 4.23) 
2.77 (1.83 – 4.19) 
 
- 
2.83 (1.90 – 4.23) 
2.69 (1.77 – 4.08) 
Sex 
Male  
Female 
 
66 (39.0%) 
103 (61.0%) 
 
618 (41.6%) 
869 (58.4%) 
 
- 
1.11 (0.80 – 1.54) 
 
- 
1.14 (0.82 – 1.59) 
CFA status 
Negative 
Positive 
 
125 (74.4%) 
43 (25.4%) 
 
1135 (76.4%) 
351 (23.6%) 
 
- 
1.11 (0.77 – 1.60) 
 
- 
1.13 (0.78 – 1.65) 
MF status 
Positive 
Negative 
 
17 (58.6%) 
12 (41.4%) 
 
123 (50.0%) 
123 (50.0%) 
 
- 
0.71 (0.32 – 1.54) 
 
- 
0.81 (0.35 – 1.85) 
B 
Characteristic  HIV-positive HIV-negative GMR (95% CI) Adjusted GMR (95% CI)# 
CFA GMC Ag/ml (95% CI)  859 (231 – 3193) 1660 (1198 – 2302) 0.85 (0.49 – 1.50) 0.91 (0.55 – 1.51) 
C 
Characteristic HIV-positive HIV-negative P value 
MF count, median (IQR), mf/ml  0 (0 – 22) 1 (0 – 93) 0.13 
A) The association of age group, gender and circulating filarial antigen (CFA) with HIV positivity. Adjusted Odds Ratio (OR) derived from logistic regression 
model. B) Geometric mean concentration (GMC) of CFA in those CFA positive. Geometric mean ratio (GMR) derived from linear regression model. C) 
Microfilaria (MF) count in those CFA positive expressed as median and interquartile range, difference assessed by rank sum testing owing to the skewed nature 
of data. 
#adjusted for age, sex and village location; †CI – confidence interval 
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of 2.6%. The prevalence of LF infection was not affected by HIV infection status and age but 
more males than females were CFA positive (Table 5). There was heterogeneity in the 
prevalence of CFA by village location (Figure 9), median 24.4%, range 15.7–33.3% (Pearson 
χ2 22.7, p<0.01, 9 degrees of freedom). Data on the use of antiretroviral and cotrimoxazole 
was incomplete in the context of this study.  
4.1.1.3 Microfilaria counting 
Microfilaria counting was done in 311 (69.6%) LF antigen positive individuals who were eligible 
and gave consent for night blood sampling. The remainder either refused or left before follow 
up. HIV prevalence in those lost to follow up was broadly similar to those sampled (10.3% vs. 
9.3% respectively, χ2 test p = 0.90). Microfilariae were present in 49.5% of the 311 sampled 
individuals. Twelve (41.4%) of HIV positive individuals and 123 (50.0%) of HIV negative 
individuals had microfilaraemia but this difference was not statistically significant (Figure 8 and 
Table 3). Microfilarial count levels had a trend to lower levels in HIV positive than HIV negative 
individuals did, but similarly without any statistical significance (Table 3).  
4.1.1.4 LF antigen quantification 
Of 311 stored baseline night blood plasma samples that were positive for CFA by the ICT card 
test, 290 (93.2%) were also CFA positive using the Og4C3 antigen-capture ELISA. CFA was 
positive in 26 (89.7%) of HIV positive individuals, 231 (93.9%) of the HIV negative individuals 
and 33 (97.1%) of HIV-unknown individuals respectively (p = 0.47). The geometric mean CFA 
concentration levels by HIV status were 859 and 1660 for HIV positive and HIV negative 
respectively (GMR 0.85, 95% CI 0.49–1.50). CFA and MF counts showed reasonable positive 
correlation (Pearson correlation coefficient r = 0.56, p<0.01) and majority of individuals (53%) 
that were CFA positive by Og4C3 ELISA were also MF positive (Table 4). 
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Table 4: Characteristic features of individuals by Og4C3 ELISA status 
 
     
 
 
 
 
 
 
 
 
 All CFA Negative CFA Positive P Value 
N 309 19 290  
MF status     
MF negative 155 (50.2%) 18 (94.7%) 137 (50.2%) - 
MF positive 154 (49.8%) 1 (5.3%) 153 (49.8%) <0.001 
Gender     
Female 141 (45.6%) 14 (73.7%) 127 (43.8%) - 
Male 168 (54.4%) 5 (26.3%) 163 (56.2%) 0.011 
Age group    
0.715 
18-29 years 137 (44.3%) 7 (73.7%) 130 (44.8%) 
30-39 years 90 (29.1%) 7 (26.3%) 83 (28.6%) 
≥40 years 82 (26.5%) 5 (26.3%) 77 (26.6%) 
HIV status     
HIV negative 246 (79.6%) 15 (78.9%) 231 (79.7%) 
0.474 HIV positive 29 (9.4%) 3 (15.8%) 26 (9.0%) 
HIV unknown 34 (11.0%) 1 (5.3%) 33 (11.4%) 
Village CFA prevalence     
Low 197 (63.8%) 11 (57.9%) 186 (64.1%) - 
High 112 (36.2%) 8 (42.1%) 104 (35.9%) 0.583 
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Table 5: Baseline characteristics of the participants by CFA status 
Characteristic CFA positive 
(N %) 
CFA negative 
(N %) 
OR (95% CI) Adjusted OR (95% CI)* 
Age group     
18-29 years 205 (45.9) 638 (45.5) - - 
30-39 years 129 (28.9) 414 (29.5) 0.97 (0.75-1.25) 0.91 (0.69-1.20) 
40 years and above 113 (25.2) 350 (25.0) 1.00 (0.77-1.31) 0.99 (0.74-1.32) 
     
Sex     
Male 234 (52.3) 547 (39.0) - - 
Female 213 (47.7) 855 (61.0) 0.58 (0.47-0.72) 0.55 (0.44-0.70) 
     
HIV status     
HIV negative 351 (89.1) 1135 (90.1) - - 
HIV positive 43 (10.9) 125 (9.9) 1.11 (0.77-1.60) 1.15 (0.78-1.68) 
     
 
*Adjusted for age, sex, HIV status and village 
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Figure 9: CFA Prevalence by Village Location
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4.1.2 Samples sourced from KHDSS 
4.1.2.1 LF antigen and HIV testing 
The total eligible population of 15-year-olds and older in the KDHSS at the baseline survey 
was 11,756. From this group, 7,863 (66.9%) underwent HIV testing and consented to storage 
of their blood sample. A total of 1,875 (23.9%) individuals were CFA positive by the Og4C3 
ELISA. HIV infection was identified in 411 (5.2%) participants. HIV positive adults tended to 
be older and more likely to be female (Table 6). CFA positivity was present in 86 (20.9%) of 
HIV positive and 1789 (24.0%) of HIV negative (crude OR 0.84, 95% CI 0.66–1.07) with an 
HIV/LF co-infection prevalence rate of 4.6%. In the female participants, CFA positivity was 
present in 17.8% of the HIV-positive and 19.8% of the HIV negative (OR 0.88, 95% CI 0.64–
1.21) and in the male participants, 26.8% of the HIV positive and 29.4% of the HIV negative 
(OR 0.88, 95% CI 0.60–1.28) respectively. CFA concentration levels had a right skewed 
distribution with most values concentrated towards the lower end of the range and 
progressively fewer values towards the top of the range (Figure 10). Overall geometric mean 
CFA concentration was measured at 828 Ag/ml (95% CI 789-869) and was lower in the HIV 
positive individuals by 25% although this association was weakened when adjusted for age 
and sex (Table 6).  
 
Figure 10: Histogram of Geometric Mean CFA Concentration 
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4.1.2.2 HIV, antiretroviral therapy and LF antigenaemia 
Several risk factors were associated with an increased prevalence of CFA (Table 7). These 
included male gender, age between 30 and 39 and lower quality housing, whilst decreased 
CFA prevalence was associated with higher levels of education (p<0.01, χ2 for linear trend) 
the availability of piped tap water or the use of lake water and the use of antiretroviral drugs. 
Bed net ownership was high, however ownership or the number of nets owned in the 
household was not associated with CFA prevalence. Data on actual bed net use was not 
collected for this study. Individuals were found in all 21 reporting groups of the KHDSS, with 
a median of 314 participants (range 129–820). There was considerable heterogeneity in the 
prevalence of CFA by reporting group (Figure 11 and Table 7), median 23.2%, range 5.7–
37.2% (Pearson χ2 354.7, p<0.01, 20 degrees of freedom). The reporting group CFA 
prevalence was lowest in reporting groups 6, 7, 4 and 5, and highest in reporting groups 18, 
12, 19, 3, 1, 15 and 20.        
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Table 6: Baseline Characteristics of the Participants by HIV status 
A 
Characteristic HIV-positive (n= 411)# HIV-negative (n= 7452)# OR (95% CI†) Adjusted OR (95% CI)* 
Age group 
15 - 29 years 
30 - 39 years 
40 years and above 
 
77 (18.7%) 
159 (38.7%) 
175 (42.6%) 
 
3793 (50.9%) 
1480 (19.9%) 
2179 (29.2%) 
 
- 
5.29 (4.00 – 6.99) 
3.96 (3.01 – 5.20) 
 
- 
5.35 (4.04 – 7.07) 
4.02 (3.06 – 5.29) 
Sex 
Female 
Male 
 
269 (65.5%) 
142 (34.5%) 
 
4201 (56.4%) 
3251 (43.6%) 
 
- 
0.68 (0.55 – 0.84) 
 
- 
0.72 (0.58 – 0.89) 
CFA status 
Negative 
Positive 
 
325 (79.1%) 
86 (20.9%) 
 
5663 (75.9%) 
1789 (24.0%) 
 
- 
0.84 (0.66 – 1.07) 
 
- 
0.86 (0.67 – 1.10) 
B 
Characteristic HIV-positive HIV-negative GMR (95% CI) Adjusted GMR (95% CI)* 
CFA GMC, Ag/ml (95% CI) 630 (511 – 778) 839 (799 – 882) 0.75 (0.60 – 0.94) 0.62 (0.38 – 1.02) 
A) The association of age group, gender and circulating filarial antigen (CFA) with HIV positivity. Adjusted Odds Ratio (OR) derived from logistic 
regression model. B) Geometric mean concentration (GMC) of CFA in those CFA positive, Geometric Mean Ratio (GMR) derived from linear 
regression model. 
#2 HIV-positive and 26 HIV-negative with incomplete data; †CI – confidence interval; *Adjusted for age, sex, and reporting group
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Figure 11: Map of KHDSS Showing Distribution of Baseline CFA Positive Individuals 
by Reporting Group  
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Table 7: Reporting Group Population, CFA Positive Individuals and Baseline CFA 
Prevalence 
Reporting 
Group  
Reporting Group 
Population 
CFA Positive 
Individuals 
Baseline CFA 
Prevalence (%) 
95% Confidence 
Interval 
1 624 204 32.7 29.0 - 36.5 
2 672 144 21.4 18.4 - 24.7 
3 820 279 34.0 30.8 – 37.4 
4 313 25 8.0 5.2 – 11.6 
5 365 36 9.9 7.0 – 13.4 
6 314 18 5.7 3.4 – 8.9 
7 386 27 7.0 4.7 – 10.0 
8 252 57 22.6 17.6 – 28.3 
9 624 152 24.4 21.0 – 28.0 
10 470 107 22.8 19.1 – 26.8 
11 360 89 24.7 20.4 – 29.5 
12 391 144 36.8 32.0 – 41.8 
13 279 57 20.4 15.9 – 25.6 
14 311 72 23.2 18.6 – 28.2 
15 278 82 29.5 24.2 – 35.2 
16 301 67 22.3 17.7 – 27.4 
17 260 56 21.5 16.7 – 27.0 
18 129 48 37.2 28.9 – 46.2 
19 318 109 34.3 29.1 – 39.8 
20 189 54 28.6 22.2 – 35.6 
21 207 48 23.2 17.6 – 29.5 
Total 7863 1875 
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Of the 411 HIV positive adults, 142 (34.5%) were taking antiretroviral therapy (ART) and 117 
(28.5%) were using cotrimoxazole prophylaxis (CTX) with only four of the 117 taking CTX 
without ART at the time of sampling (Figure 12). In six of the 411 individuals, information on 
ART and/or CTX use at the time of sampling was unavailable. ART consisted of Lamivudine, 
Stavudine and Nevirapine (Triomune-30) in 94% of cases with Zidovudine or Efavirenz 
substitutions in the remainder. No protease inhibitors were in use. 
 
 
Figure 12: Venn Diagram Showing Use of ART and CPT by the 411 HIV Positive 
Individuals 
In the HIV positive group, ART use was associated with a lower prevalence of CFA when 
compared to those not on ART [12.7% vs. 25.3% (OR 0.43, 95% CI 0.24–0.76)]. Similarly, 
CTX use was associated with lower CFA prevalence [12.8% vs. 24.1% (OR 0.46, 95% CI 
0.25–0.85)]. 
In a multivariable model incorporating ART and CTX use along with age, sex and geographical 
location, the adjusted odds ratio for ART use was 0.47 (95% CI 0.17–1.31) and for CTX use 
0.92 (95% CI 0.31–2.71). When the ART treated group were further sub-divided by year since 
treatment started, there was a significant trend to decreased prevalence of CFA with 
increasing time on treatment, p<0.01 χ2 for linear trend (Figure 13). This relationship persisted 
after adjustment for age, gender and reporting group. In the HIV positive individuals with 
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detectable CFA, the geometric mean concentration of CFA was not significantly different 
between those off and on ART, 647 vs. 512 Ag/ml respectively, GMR 1.27, 95% CI 0.76–2.08 
(Figure 14), nor did the GMC differ by ART duration category 647, 392, 762, 516 & 0 Ag/ml 
for no treatment, year 1, 2, 3 & 4 of treatment respectively.  
 
Figure 13: Relationship of CFA Prevalence and Time on Antiretroviral Therapy 
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Table 8: The association of circulating filarial antigenaemia (CFA) prevalence with HIV 
and antiretroviral therapy (ART) status and major potential confounding socio-
demographic characteristics in the 7,863 KHDSS participants 
Crude and adjusted Odds Ratios (OR) derived from a logistic regression model. Data on reporting group are not shown in the 
table but adjusted models include this as a potential confounder along with the other significant variables in the crude analysis.   
#CI – confidence interval: *Reference category  
Characteristic N (%) CFA prevalence 
(%) 
OR (95% CI#) aOR (95% CI) 
HIV and ART status     
HIV-negative 7452 (94.8) 1789 (24.0) Ref.* Ref. 
HIV-positive – no ART 265 (3.4) 67 (25.3) 1.07 (0.81-1.42) 1.20 (0.90-1.62) 
HIV-positive - ART 142 (1.8) 18 (12.7) 0.46 (0.28-0.76)  0.50 (0.30-0.84) 
Gender  
Male 
Female 
 
3392 (43.1) 
4470 (56.9) 
 
995 (29.3) 
880 (19.7) 
 
1.69 (1.52-1.88) 
Ref. 
 
1.77 (1.59-1.98) 
Ref. 
Age group     
Age 15 – 29 years 3870 (49.2) 896 (23.2) Ref. Ref. 
Age 30 – 39 years 1639 (20.9) 440 (26.7) 1.22 (1.07-1.39) 1.24 (1.08-1.43) 
Age 40 years and above 2354 (29.9) 539 (22.9) 0.99 (0.87-1.11) 0.95 (0.84-1.09) 
Mosquito net 
ownership 
    
0 197 (2.5) 46 (23.4) Ref. - 
1 945 (12.0) 254 (26.9) 1.21 (0.84-1.73) - 
2 1817 (23.1) 461 (25.4) 1.12 (0.79-1.58) - 
3 1835 (23.3) 430 (23.4) 1.00 (0.71-1.42) - 
≥4 2854 (36.3) 640 (22.4) 0.95 (0.67-1.34) - 
Unknown 215 (2.7) - - - 
Educational 
achievement 
    
Nil 277 (3.6) 83 (30.0) Ref. Ref. 
Primary 5493 (71.3) 1379 (25.1) 0.78(0.60-1.02) 0.71 (0.54-0.93) 
Secondary 1886 (24.5) 377 (20.0) 0.58 (0.44-0.77) 0.55 (0.41-0.75) 
Tertiary  45 (0.6) 8 (17.8) 0.51 (0.23-1.13) 0.52 (0.22-1.19) 
Unknown 2 (0.0) - -  
Water supply     
Bore hole 3755 (47.7) 1037 (27.6) Ref. Ref. 
Tap to house 1082 (13.8) 105 (9.7) 0.28 (0.23-0.35) 0.30 (0.24-0.37) 
Shared tap 835 (10.6) 127 (15.2) 0.47 (0.38-0.57) 0.48 (0.39-0.59) 
Covered well 999 (12.7) 303 (30.3) 1.14 (0.98-1.33) 1.16 (0.99-1.35) 
Open well 572 (7.3) 167 (29.2) 1.08 (0.89-1.31) 1.06 (0.87-1.30) 
Lake 456 (5.8) 106 (23.3) 0.79 (0.63-1.00) 0.77 (0.61-0.97) 
Unknown 11 (0.1) - - - 
Housing type     
Burnt brick 5750 (73.1) 1328 (23.1) Ref. Ref.  
Unburnt brick 678 (8.6) 169 (24.9) 1.11 (0.92-1.33) 1.00 (0.83-1.21) 
Mud 1087 (13.8) 299 (27.5) 1.26 (1.09-1.46) 1.03 (0.88-1.20) 
Grass/bamboo 167 (2.1) 49 (29.3) 1.38 (0.98-1.94) 1.14 (0.81-1.62) 
Other 18 (0.2) 2 (11.1) 0.42 (0.10-1.81) 0.43 (0.10-1.91) 
Unknown 163 (2.1) - - - 
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Boxes show the median value and the interquartile range. Whiskers include all values within 1.5 times the 
interquartile range with outliers shown as points.  
Comparison of CFA concentrations by group HIV- vs. HIV +/ART- (p = 0.22): HIV- vs. HIV+/ART+ (p = 0.05): 
HIV+/ART- vs. HIV+/ART+ (p = 0.28), derived from a linear regression model adjusted for age, gender and reporting 
group  
Figure 14: Box plot of CFA Concentration Distribution (on logarithmic scale) by HIV and 
ART Status for the KHDSS Participants 
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4.2 Filarial Research Study 2: Songwe Filariasis Clinical Trial 
In this section, results of the clinical trial that was undertaken in Songwe area in the northern 
part of Karonga district of northern Malawi (Figure 1) are presented. The study took place from 
January 2009 to March 2012 and it was a randomised, controlled, four-arm, open-label clinical 
trial that compared three modified treatment groups with increased dose and/or frequency to 
standard MDA dosage of ivermectin and albendazole in adults with confirmed circulating LF 
antigen and microfilaria. 
4.2.1 ICT card testing, randomisation and follow up  
A total of 1,851 individuals were screened and 70 participants were found to be eligible for 
randomisation into the four treatment arms of the study (Figure 16). Rates of missed 
appointments were similar in all the treatment groups overall. In the twice-yearly arms, this led 
to five missed treatments in SDT and one in HDT in the first year. Recruitment ceased before 
the planned sample size was achieved after the national MDA programme for lymphatic 
filariasis commenced in the study location in October 2009 [17]. Demographic and baseline 
characteristics were similar between the treatment groups except for higher baseline 
microfilarial count levels in the annual standard dose treatment group (Table 7). 
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Figure 15: Flow diagram of Study Participants of the Songwe Filariasis Clinical Trial
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Table 9: Baseline demographic and clinical characteristics for each treatment group in the clinical trial 
Characteristic Annual standard 
dose (n=18) 
Annual high dose 
(n=17) 
Twice-yearly standard 
dose (n=18) 
Twice-yearly high 
dose (n=17) 
Age, median (range), years 32.5 (21 - 50) 31 (20 - 53) 27.5 (18 - 55) 35 (20 - 54) 
Male sex (%) 15 (83.3) 11 (64.7) 11 (61.1) 10 (58.8) 
Microfilarial count, geometric 
mean (95% CI), mf/ml 
464.7 (250.1 - 863.4) 338.7 (198.7 - 
577.4) 
204.5 (145.4 -287.8) 264.7(175.0 -  400.4) 
Eosinophil count, geometric 
mean (95% CI), x 103 cells/uL 
1.3 (1.0 – 1.7) 1.4 (1.0 – 1.9) 1.6 (1.1 – 2.1) 1.1 (0.9 – 1.5) 
Haemoglobin level, geometric 
mean (95% CI), g/dL 
13.7 (13.1 – 14.2) 
 
13.2 (12.7 – 13.6) 
 
13.2 (12.1 – 14.4) 
 
12.4 (11.6 – 13.4) 
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4.2.2 Microfilarial clearance 
In the intention to treat analysis, all the treatment groups achieved significant reduction of 
microfilariae levels after albendazole and ivermectin treatment by 12 months of follow up. 
Microfilarial clearance was 83% (15/18) for SDA, 82% (14/17) for HDA, 72% (13/18) for SDT 
and 100% (17/17) for HDT treatment doses, respectively. There was no statistically significant 
difference between high versus standard dose or between twice-yearly versus once-yearly 
dosing of albendazole and ivermectin (Table 8). In a post-hoc analysis comparing all 
participants with available data at 12 months who had received a single dose (i.e., those in 
the single dose arms plus those in the twice-yearly arms who failed to receive their second 
dose) versus those who received two doses. In total, 35 received one dose, 29 received two 
doses and six did not have 12 months’ data available. Microfilarial clearance was observed in 
31 of 35 (89%) and 28 of 29 (97%), respectively. This was not significantly different, p=0.38 
(Fisher’s exact test). 
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Table 10: Number of participants with complete clearance of microfilaraemia by treatment group and month of follow up 
 
Treatment Group 6 months1 
 
12 months2 
 
18 months 
 
24 months 
 
     
Annual Standard Dose  12/18 (66.7%) 15/18 (83.3%) 15/18 (83.3%) 17/18 (94.4%) 
     
Annual High Dose 13/17 (76.5%) 14/17 (82.4%) 17/17 (100%) 17/17 (100%) 
     
Twice-yearly Standard Dose  13/18 (72.2%) 13/18 (72.2%) 14/18 (77.8%) 14/18 (77.8%) 
     
Twice-yearly High Dose 14/17 (82.4%) 17/17 (100%) 17/17 (100%) 17/17 (100%) 
   
1P = 0.42 – high versus standard dose regimens at 6 months; 2P = 1.00 – twice annual versus single annual dose regimens at 12 months (Fisher’s exact test) 
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While the difference in W. bancrofti microfilarial clearance rate tended towards significance in 
the high dose twice-yearly group at 12 months, this again did not achieve statistical 
significance. The high dose twice-yearly treatment group achieved complete clearance of 
microfilaraemia at 12 months of follow up without any subsequent recurrence of 
microfilaraemia, while the other treatment doses took up to 18 months to achieve complete 
clearance of microfilaraemia (Figure 16). 
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P=0.38 - annual standard versus annual high dose; P=0.40 - annual standard versus twice-yearly standard dose 
 
Figure 16: Kaplan-Meier Plots for the Four Treatment Arms of the Songwe Clinical Trial
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4.2.3 Adverse events 
Twenty-two participants (31%) reported seven different adverse events at various times in all 
treatment groups especially after the first round of treatment. Most of these were mild to 
moderate in intensity and included fever, headache, joint pains and abdominal pains (all 
typically associated with treatment of microfilaraemia). Two cases of malaria, one of 
pneumonia and a case of acute bacterial meningitis, which resulted in the death of the patient, 
were admitted to hospital for treatment, and were not considered treatment related. All other 
symptoms were treated conservatively and did not result in hospital admission.  
4.2.4 LF clinical manifestations 
At baseline, filarial related clinical manifestations were reported in 8 (11%) of the participants 
for lymphoedema, 6 (9%) for lymphangitis, 12 (17%) for fever, 4 (6%) for hydrocoele and none 
for elephantiasis and skin rash, respectively. There was no difference in these clinical 
manifestations between subjects in the four treatment groups of the study. During follow up, 
there were no new cases of lymphoedema, lymphangitis, elephantiasis and skin rash. Four 
individuals (6%) at 6 months and one individual (1%) reported fever at 12 months, while two 
new cases of hydrocoele were reported at 6 and 12 months, respectively. Eosinophilia 
(absolute eosinophil count .500/ml) was present in 68 (97%) patients (see Table 7) at baseline 
and no patient was found with eosinophilia during follow up, indicating a significant reduction 
after treatment.  
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4.3 Filarial Research Study 3: The Impact of Mass Drug Administration 
on Circulating Filarial Antigenaemia by HIV Status and ITN 
Ownership 
This section presents results from a longitudinal cohort study that utilised stored blood 
samples to investigate the impact of MDA on circulating filarial antigenaemia by HIV status 
and bed net ownership. It was nested within comprehensive annual population-based HIV 
sero-surveys that were undertaken at the Karonga Health and Demographic Surveillance Site 
(KHDSS) and used available stored blood samples and data collected as part of the HIV sero-
surveys. Baseline samples were taken between September 2007 and October 2008 before 
introduction of MDA in the study area and follow up samples were taken between October 
2009 and October 2011, 2-3 years after MDA had reached all areas.  
4.3.1 Characteristics of the follow up cohort 
The follow up cohort was derived from the 1875 individuals with a positive baseline CFA and 
5988 with a negative baseline CFA (Figure 17) from filarial research study 1. Of the 1875 
individuals who were CFA positive at baseline, 1722 individuals (91%) had a follow up blood 
sample during the MDA distribution period and were reassessed for CFA. The remainder of 
the individuals who were CFA positive at baseline were not included because they did not 
have a stored blood sample available for retesting in the laboratory archive despite consenting 
to blood drawing and storage on at least one follow up HIV sero-survey round (Figure 17).  
Of the 5988 baseline CFA negative individuals, a random sample of 938 individuals (15.7% or 
1 in 6) was chosen and selected for CFA reassessment during follow up to investigate the 
natural acquisition of LF antigenaemia during a period of MDA administration. Of the 938 
baseline CFA negative individuals selected, 766 individuals had samples available and 
selected from the third annual round of the HIV sero-survey. The remaining 172 individuals 
were not available from the third annual round of the HIV sero-survey and were selected from 
the fourth annual round of the HIV sero-survey. Demographic and baseline characteristics of 
the individuals who were CFA negative at baseline and retested at follow up were broadly 
similar when compared to those not retested at follow up (Table 9).  
Table 10 shows the features of the 1722 and 938 individuals who were CFA positive and CFA 
negative at baseline respectively and were retested for CFA after a period of MDA 
administration. The selected follow up cohort had similar baseline characteristics to the overall 
study population.  
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A total of 1464 (55.0%) individuals were followed up after 1-2 years from the time of baseline 
sample collection, 869 (32.7%) after 2-3 years and 327 (12.3%) after 3-4 years. Follow up 
time ranged from 414 days to 1391 days (mean 787 days, SD 150 days, IQR 709-751 days).   
 
 
Figure 17: Flow diagram of CFA Assessment of the Follow up Cohort 
 
4.3.2 Circulating filarial antigenaemia at follow up 
Of the 1722 individuals who were CFA positive at baseline and were reassessed for CFA 
during follow up, 524 (30.4%) remained CFA positive (Figure 18) translating to a calculated 
CFA clearance of 69.6% and clearance rate of 324 cases per 1000 person-years at risk. Of 
the 938 individuals who were CFA negative at baseline, all but 2 (0.2%) remained CFA 
negative at follow up translating to a calculated CFA gain of 0.2% and rate of CFA acquisition 
of one case per 1000 person-years at risk (Figure 17). At baseline, geometric mean CFA 
concentration was measured at 828 Ag/ml (95% CI 789-869). At follow up in those that were 
positive, geometric mean CFA concentration was 1124 Ag/ml (95% CI 998-1265). Similar to 
the baseline CFA concentration distribution, follow up CFA concentration had a right skewed 
distribution with most values concentrated towards the lower end of the range and 
CFA + 
N=1875 
CFA - 
N=5988 
Selected for retest 
 N=938 Follow -up 
Baseline 
Rate of CFA loss 
324/1000pyar 
Rate of CFA gain 
1/1000pyar 
Available for retest 
 N=1722 
CFA + 
 N=524 
CFA + 
 N=2 
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progressively fewer values towards the top of the range (Figure 18). Figure 19 shows the 
distribution of baseline and follow up level of CFA prevalence in the KHDSS by reporting 
group. CFA prevalence was lowest in reporting groups 6, 7, 4 and 5 respectively, and highest 
in reporting groups 18, 12, 19, 3, 1 and 15. These reporting groups are adjacent areas for both 
the highest and lowest CFA prevalence categories. 
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Figure 18: Histograms of Geometric Mean CFA Concentration of the 1722 individuals 
who were CFA positive at baseline  
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In the two individuals who were CFA negative at baseline and became CFA positive at follow 
up, CFA concentration was measured at 141 and 318 Ag/ml respectively at follow up. They 
were both males from reporting groups 2 and 3 and aged 26 and 29 years respectively, HIV 
negative and both had received only one MDA dose. The first individual had follow up time of 
714 days between collection of the baseline and follow up samples, and according to the 
timing of MDA administration in the study area, this individual could have received a maximum 
of one MDA dose during this period. The second individual had follow up time of 1106 days 
between collections of the baseline and follow up samples and could have received a 
maximum of one MDA dose during this period. It is hard to interpret if any of these 
characteristics could be linked to CFA acquisition because of the small numbers.  
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Figure 19: Maps of KHDSS Showing Distribution of Baseline (A) and Follow up (B) CFA 
Prevalence by Reporting Group  
A 
B 
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Table 11: Baseline characteristic features of LF negative individuals retested and those 
not retested 
Characteristic LF-negative not 
retested 
(n=4542) 
LF-negative 
retested 
(n=939) 
OR (95% CI) 
Age group    
15-29 years 2271 (50.0%) 459 (48.9%) Ref. 
30-39 years 887 (19.5%) 202 (21.5%) 1.13 (0.94-1.35) 
40 years and above 1384 (30.5%) 278 (29.6%) 0.99 (0.84-1.17) 
    
Sex    
Female 2735 (60.2%) 574 (61.1%) Ref. 
Male 1807 (39.8%) 365 (38.9%) 0.96 (0.83-1.11) 
    
HIV and ART status‡    
HIV negative 4302 (94.8%) 878 (93.5%) Ref. 
HIV positive - no ART 146 (3.2%) 34 (3.6%) 1.14 (0.78-1.67) 
HIV positive - ART 91 (2.0%) 27 (2.9%) 1.45 (0.94-2.25) 
    
Mosquito net use    
None  116 (2.6%) 20 (2.1%) Ref. 
Any bed net use 4334 (95.4%) 895 (95.3%) 1.20 (0.74-1.94) 
Unknown 92 (2.0%) 24 (2.6%) - 
    
Mosquito net number    
0 116 (2.6%) 20 (2.1%) Ref. 
1 538 (11.8%) 98 (10.4%) 1.06 (0.63-1.78) 
2 1002 (22.1%) 234 (24.9%) 1.35 (0.83-2.22) 
3 1063 (23.4%) 229 (24.4%) 1.25 (0.76-2.05) 
≥4 1708 (37.6%) 327 (34.8%) 1.11 (0.68-1.81) 
Unknown 115 (2.5%) 31 (3.3%) - 
    
CPT use in those HIV 
positive† 
   
None  166 (69.2%) 35 (57.4%) Ref. 
Any CPT use 72 (30.0%) 26 (42.6%) 1.69 (0.97-2.95) 
    
MDA use    
None 687 (15.1%) 144 (15.3%) Ref. 
Any MDA use 3283 (72.3%) 701 (74.7%) 1.02 (0.84-1.24) 
Unknown 572 (12.6%) 94 (10.0%) - 
    
MDA doses    
0 687 (15.1%) 144 (15.3%) Ref. 
1 1133 (24.9%) 228 (24.3%) 0.96 (0.76-1.20) 
2 2150 (47.3%) 473 (50.4%) 1.05 (0.85-1.29) 
Unknown 572 (12.6%) 94 (10.0%) - 
    
‡3 LF-negative not retested individuals have missing HIV and ART status 
†2 LF-negative not retested individuals have missing CPT status 
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Table 12: Characteristic features of the follow up cohort 
Characteristic CFA positive 
(n=1722) 
CFA negative 
(n=938) 
OR (95% CI) Adjusted OR 
(95% CI)* 
Age group     
15-29 years 668 (38.8%) 393 (41.9%) Ref. Ref. 
30-39 years 477 (27.7%) 216 (23.0%) 1.30 (1.06-1.59) 1.57 (0.52-4.74) 
40 years and above 577 (33.5%) 329 (35.1%) 1.03 (0.86-1.24) 1.69 (0.55-5.26) 
     
Sex     
Male 915 (53.1%) 364 (38.8%) Ref. Ref. 
Female 807 (46.9%) 574 (61.2%) 0.56 (0.48-0.66) 0.62 (0.31-1.27) 
     
HIV and ART status     
HIV negative 1643 (95.4%) 877 (93.5%) Ref. Ref. 
HIV positive - no ART 61 (3.5%) 34 (3.6%) 0.96 (0.62-1.47) 0.89 (0.23-3.42) 
HIV positive - ART 18 (1.1%) 27 (2.9%) 0.36 (0.19-0.65) 0.46 (0.11-1.87) 
     
Mosquito net 
ownership 
    
None  60 (3.5%) 23 (2.4%) Ref.  
Any bed net use 1642 (95.3%) 906 (96.6%) 0.69 (0.43-1.13) - 
Unknown 20 (1.2%) 9 (1.0%) - - 
     
Mosquito net 
number 
    
0 60 (3.5%) 23 (2.4%) Ref. - 
1 171 (9.9%) 100 (10.7%) 0.66 (0.38-1.13) - 
2 427 (24.8%) 206 (22.0%) 0.79 (0.48-1.32) - 
3 470 (27.3%) 251 (26.8%) 0.72 (0.43-1.19) - 
≥4 561 (32.6%) 341 (36.3%) 0.63 (0.38-1.04) - 
Unknown 33 (1.9%) 17 (1.8%) - - 
     
CPT use in those 
HIV positive 
    
None  64 (81.0%) 35 (57.4%) Ref. Ref. 
Any CPT use 15 (19.0%) 26 (42.6%) 0.38 (0.19-0.77) 0.60 (0.18-1.95) 
     
MDA use     
None 278 (16.1%) 144 (15.4%) Ref. - 
Any MDA use 1265 (73.5%) 699 (74.5%) 0.94 (0.75-1.17) - 
Unknown 179 (10.4%) 95 (10.1%) - - 
     
MDA doses     
0 278 (16.1%) 144 (15.4%) Ref. - 
1 448 (26.0%) 227 (24.2%) 1.02 (0.79-1.32) - 
2 817 (47.4%) 472 (50.3%) 0.90 (0.71-1.13) - 
Unknown 179 (10.4%) 95 (10.1%) - - 
     
*Adjusted for age group, sex, ART use, CPT use and reporting group 
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4.3.3 MDA use and CFA clearance 
Participants were interviewed during two consecutive annual survey rounds if they had 
previously received MDA drugs during the annual MDA treatment campaigns for LF in the 
area. Of the 2660 individuals that were followed up, 1964 (73.8%) had received at least one 
MDA dose during the follow up period, 422 (15.9%) did not receive any MDA drugs while 274 
(10.3%) had unknown MDA use. Of the 1964 individuals who received at least one MDA dose, 
1289 (65.6%) received two MDA doses while 675 (34.4%) received one MDA dose.  
The characteristics of the1722 individuals who were CFA positive at baseline are shown in 
Table 11 broken down into those who became negative and those who persisted with 
detectable CFA. In a univariable analysis, the clearance of CFA was not associated with age, 
HIV and ART status, educational achievement, water supply and housing type. Any MDA use 
did not appear to associate with CFA clearance, however, when MDA was categorised into 
number of doses, two doses of MDA were associated with a 34% reduction in CFA positivity 
compared to no doses (Table 11). However, a single dose of MDA was associated with no 
evidence of clearance and a borderline association with increased CFA positivity at follow up, 
but this association disappeared in the multivariable analysis. CFA concentration in individuals 
with persisting CFA at follow up also showed a similar relationship when analysed by MDA 
treatment (Figure 20), with no apparent impact by any MDA use and slightly reduced CFA 
concentration in those who had two doses of MDA. 
Among the other characteristics that were associated with CFA clearance, clearance 
increased with increasing duration of follow up, females were more likely to clear CFA than 
males while individuals from high CFA prevalence areas were more likely to clear CFA than 
individuals from low CFA prevalence areas. 
The characteristics of the1722 individuals who were CFA positive at baseline by number of 
MDA doses is shown in Table 12. All the characteristics except HIV status, and educational 
achievement, were significantly associated with MDA dosing. 
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Figure 20: Box Plots of CFA Concentration in Individuals Who Persisting CFA Positivity 
by MDA Treatment 
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4.3.4 Bed net ownership per household 
Of the 2,660 individuals aged 15 years and above reassessed for CFA at follow up, 2,548 
(95.8%) reported possessing at least one mosquito net in the household; 83 (3.1%) indicated 
that they did not possess a mosquito net while the remaining 29 (1.1%) had an unknown bed 
net ownership status. The number of mosquito nets per household ranged from 0 to 9 nets 
(median 3, IQR 2-4). When bed net ownership per household was categorised into number of 
mosquito nets per household, 83 (3.1%) had no mosquito net in the household, 271 (10.2%) 
had one, 633 (23.8%) had two, 721 (27.1%) had three while 902 (33.9%) had four or more 
mosquito nets per household. The remaining 50 (1.9%) individuals had an unknown mosquito 
net number per household. Data on actual bed net use and bed use among children were not 
collected as part of this study. 
Table 15 shows the characteristics of the 2,660 individuals aged 15 years and above who had 
follow up samples available for CFA testing and were reassessed for CFA at follow up. There 
was no clear association between mosquito net ownership and CFA clearance. The only 
characteristics that were associated with bed net ownership among the individuals aged 15 
years and over were the level of education which showed strong evidence that bed net 
ownership increased with increasing level of educational achievement and reporting group 
CFA prevalence at baseline which showed that individuals from medium reporting group CFA 
prevalence areas were more likely to own a mosquito net than that individuals from low 
reporting group CFA prevalence areas. This was also the case when comparing individuals 
from high reporting group CFA prevalence areas and low reporting group CFA prevalence 
areas although this was not statistically significant.  
4.3.5 HIV subgroup analysis 
In a subgroup analysis of follow up CFA status of 79 individuals who were CFA positive and 
HIV positive at baseline (Table 16), 54 (68.3%) cleared CFA while 25 (31.7%) remained CFA 
positive at follow up. In a univariate analysis, all the characteristics examined did not yield any 
statistical significance. This may suggest that there is loss of statistical power because of very 
small numbers in this subgroup. However, the tendency of the relationship of the 
characteristics with CFA clearance was similar to that of the overall group except MDA use 
which had odds ratios in the opposite direction to that of the overall group and suggesting 
increased CFA clearance in individuals who had no MDA than individuals who had any MDA 
use.    
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Table 13: Comparison of the characteristics of the 1722 CFA positive follow up cohort and 
association with CFA clearance 
Characteristic CFA negative CFA 
positive 
OR 95%CI Adjusted OR 
(95%CI) 
 n=1198 n=524   
MDA use     
None 190 (68.3%) 88 (31.7%) Ref. - 
Any MDA use 895 (70.8%) 370 (29.2%) 0.89 (0.67-1.18) - 
Unknown  113 (63.1%) 66 (36.9%) - - 
MDA doses     
0 190 (68.3%) 88 (31.7%) Ref. Ref. 
1 270 (60.3%) 178 (39.7%) 1.42 (1.04-1.95) 1.37 (0.98-1.93) 
2 625 (76.5%) 192 (23.5%) 0.66 (0.49-0.90) 0.72 (0.52-0.99) 
Unknown 113 (63.1%) 66 (36.9%) - - 
Duration of follow up     
1-2 years 626 (62.8%) 371 (37.2%) Ref. Ref. 
2-3 years 395 (76.6%) 121 (23.4%) 0.52 (0.41-0.66) 0.52 (0.39-0.69) 
3-4 years 177 (84.7%) 32 (15.3%) 0.31 (0.20-0.45) 0.23 (0.15-0.35) 
Age group     
15-29 years 454 (68.0%) 214 (32.0%) Ref. - 
30-39 years 327 (68.6%) 150 (31.4%) 0.97 (0.76-1.25) - 
40 years and above 417 (72.3%) 160 (27.7%) 0.81 (0.64-1.04) - 
Sex     
Male 607 (66.3%) 308 (33.7%) Ref. Ref. 
Female 591 (73.2%) 216 (26.8%) 0.72 (0.59-0.89) 0.66 (0.52-0.83) 
HIV  and ART status     
HIV negative 1144 (69.6%) 499 (30.4%) Ref. - 
HIV positive - no ART 41 67.2%) 20 (32.8%) 1.12 (0.65-1.93) - 
HIV positive - ART 13 (72.2%) 5 (27.8%) 0.88 (0.31-2.49) - 
Mosquito net use     
None  40 (66.7%) 20 (33.3%) Ref. - 
Any bed net use 1143 (69.6%) 499 (30.4%) 0.87 (0.51-1.51) - 
Unknown 15 (75.0%) 5 (25.0%) - - 
Mosquito net number     
0 40 (66.7%) 20 (33.3%) Ref. - 
1 116 (67.8%) 55 (32.2%) 0.95 (0.51-1.77) - 
2 311 (72.8%) 116 (27.2%) 0.75 (0.42-1.33) - 
3 330 (70.2%) 140 (29.8%) 0.85 (0.48-1.50) - 
≥4 378 (67.4%) 183 (32.6%) 0.97 (0.55-1.70) - 
Unknown 23 (69.7%) 10 (30.3%) - - 
CPT use in those HIV 
positive 
    
None 47 (70.1%) 20 (29.9%) Ref. - 
Any CPT use 10 (66.7%) 5 (33.3%) 1.18 (0.36-3.88) - 
Unknown 3 (75.0%) 1 (25.0%) - - 
Reporting group CFA 
prevalence 
    
Low 145 (60.7%) 94 (39.3%) Ref. Ref. 
Medium 486 (61.1%) 310 (38.9%) 0.98 (0.73-1.32) 0.97 (0.68-1.38) 
High 567 (82.5%) 120 (17.5%) 0.33 (0.24-0.45) 0.37 (0.25-0.54) 
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Separate regression models used for mosquito net use and mosquito net number 
*Adjusted for MDA dose, duration of follow up, sex, water source, and reporting group CFA prevalence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Educational 
achievement 
    
Nil 51 (68.0%) 24 (32.0%) Ref. - 
Primary 893 (70.4%) 376 (29.6%) 0.89 (0.54-1.48) - 
Secondary 227 (66.2%) 116 (33.8%) 1.09 (0.64-1.85) - 
Tertiary 6 (75.0%) 2 (25.0%) 0.71 (0.13-3.77) - 
Unknown 21 77.8%) 6 (22.2%) - - 
Water supply     
Bore hole 674 (70.3%) 284 (29.7%) Ref. Ref. 
Tap to house 62 (62.0%) 38 (38.0%) 1.45 (0.95-2.23) 1.05 (0.64-1.73) 
Shared tap 64 (56.1%) 50 (43.9%) 1.85 (1.25-2.75) 1.37 (0.86-2.17) 
Covered well 223 (79.1%) 59 (20.9%) 0.63 (0.46-0.86) 0.73 (0.51-1.05) 
Open well 94 (67.6%) 45 (32.4%) 1.14 (0.78-1.66) 1.24 (0.79-1.96) 
Lake 61 (59.8%) 41 (40.2%) 1.60 (1.05-2.43) 1.18 (0.74-1.90) 
Unknown 20 (74.1%) 7 (25.9%) - - 
Housing type     
Burnt brick 857 (70.0%) 367 (30.0%) Ref. - 
Unburnt brick 105 (67.7%) 50 (32.3%) 1.11 (0.78-1.59) - 
Mud 186 (68.9%) 84 (31.1%) 1.05 (0.79-1.40) - 
Grass/bamboo 29 (63.0%) 17 (37.0%) 1.37 (0.74-2.52) - 
Other 2 (100.0%) 0 - - 
Unknown 19 (76.0%) 6 (24.0%) - - 
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Table 14: Characteristics of individuals by number of MDA doses 
 
 
 
 
 
 
 
 
 
 
 
Characteristic No MDA 
dose 
One MDA 
dose 
Two MDA 
dose 
Unknown 
MDA dose 
 n=278 n=443 n=823 n=178 
Duration of follow 
up  
   
≤2 years 162 (16.3%) 256 (25.6%) 480 (48.1%) 99 (9.9%) 
2-3 years 79 (15.3%) 111 (21.5%) 265 (51.4%) 61 (11.8%) 
3-4 years 37 (11.7%) 76 (36.4%) 78 (37.3%) 18 (8.6%) 
Age group     
15-29 years 110 (13.4%) 203 (24.7%) 407 (49.6%) 101 (12.3%) 
30-39 years 56 (13.9%) 116 (28.9%) 192 (47.8%) 38 (9.4%) 
40 years and 
above 
112 (22.4%) 124 (24.8%) 
224 (44.9%) 39 (7.8%) 
Sex     
Female 103 (12.8%) 225 (27.9%) 405 (50.2%) 74 (9.2%) 
Male 175 (19.1%) 218 (23.8%) 418 (45.7%) 104 (11.4%) 
HIV status     
HIV negative 262 (94.2%) 419 (94.6%) 792 (96.2%) 170 (95.5%) 
HIV positive 16 (20.2%) 24 (30.4%) 31 (39.2%) 8 (10.1%) 
Mosquito net use     
None  14 (23.0%) 15 (24.6%) 15 (24.6%) 17 (27.9%) 
Any bed net use 262 (16.0%) 419 (25.5%) 807 (49.2%) 153 (9.3%) 
Unknown 2 (0.7%) 9 (2.0%) 1 (0.1%) 8 (4.5%) 
Reporting group 
CFA prevalence 
    
Low 63 (18.0%) 125 (35.7%) 115 (32.9.0%) 47 (13.4%) 
Medium 81 (14.5%) 183 (32.7%) 229 (41.0%) 66 (11.8%) 
High 134 (16.5%) 135 (16.6%) 479 (58.9%) 65 (8.0%) 
Educational 
achievement 
    
Nil 231 (17.2%) 342 (25.4%) 629 (46.8%) 142 (10.6%) 
Primary/Secondary 42 (12.0%) 98 (27.9%) 177 (50.4%) 34 (9.7%) 
Unknown 5 (18.5%) 3 (11.1%) 17 (63.0%) 2 (7.4%) 
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Table 15: Characteristics of the follow up cohort and association with bed net 
ownership 
*Adjusted for sex, age group, reporting group CFA prevalence and educational achievement 
 
Characteristic No bed 
net 
Bed net Unknown  Crude OR (95% CI) Adjusted OR 
(95% CI) 
 n=83 n=2548 n=29   
Age group      
15-29 years 33 (3.1%) 1015 (95.7%) 13 (1.2%) Ref. Ref. 
30-39 years 18 (2.6%) 669 (96.5%) 6 (0.9%) 1.21 (0.67-2.16) 1.37 (0.74-2.52) 
40 years and 
above 
32 (3.5%) 864 (95.4%) 20 (1.1%) 0.88 (0.54-1.44) 1.06 (0.63-1.78) 
Sex      
Female 44 (3.2%) 1321 (95.7%) 16 (1.2%) Ref. Ref. 
Male 39 (3.1%) 1227 (95.9%) 13 (1.0%) 0.95 (0.62-1.48) 1.19 (0.75-1.89) 
HIV status      
HIV negative 80 (3.2%) 2403 (95.8%) 26 (1.0%) Ref. - 
HIV positive 3 (2.0%) 145 (96.0%) 3 (2.0%) 1.61 (0.50-5.16) - 
CFA status      
CFA negative 63 (3.0%) 2047 (95.9%) 24 (1.1%) Ref. - 
CFA positive 20 (3.8%) 501 (95.2%) 5 (1.0%) 0.77 (0.46-1.29) - 
Reporting group 
CFA prevalence 
     
Low 22 (4.5%) 466 (94.7%) 4 (0.8%) Ref. Ref. 
Medium 33 (2.6%) 1207 (96.1%) 16 (1.3%) 1.73 (1.00-2.99) 1.83 (1.04-3.21) 
High 28 (3.1%) 875 (95.9%) 9 (1.0%) 1.48 (0.83-2.61) 1.62 (0.91-2.89) 
Educational 
achievement 
     
Nil 9 (8.3%) 98 (90.7%) 1 (0.9%) Ref. Ref. 
Primary 59 (3.1%) 1823 (95.8%) 21 (1.1%) 2.84 (1.37-5.89) 2.90 (1.35-6.23) 
Secondary/Tertiary 12 (2.0%) 580 (96.8%) 7 (1.2%) 4.44 (1.82-10.81) 4.67 (1.81-12.07) 
Unknown 3 (6.0%) 47 (94.0%) 0 (0.0%) -  
Water supply      
Bore hole 43 (3.1%) 1328 (95.8%) 15 (1.1%) Ref. - 
Tap to house 8 (3.1%) 240 (93.8%) 8 (3.1%) 0.97 (0.45-2.09) - 
Shared tap 8 (3.4%) 226 (96.2%) 1 (0.4%) 0.91 (0.42-1.97) - 
Covered well 9 (2.4%) 367 (96.6%) 4 (1.0%) 1.32 (0.64-2.73) - 
Open well 10 (5.0%) 189 (94.5%) 1 (0.5%) 0.61 (0.30-1.24) - 
Lake 2 (1.3%) 148 (98.7%) 0 (0.0%) 2.40 (0.57-9.99) - 
Unknown 3 (5.7%) 50 (94.3%) 0 (0.0%) - - 
Housing type      
Burnt brick 53 (2.8%) 1831 (96.2%) 19 (1.0%) Ref. - 
Unburnt brick 9 (3.7%) 230 (95.0%) 3 (1.2%)  0.74 (0.36-1.52) - 
Mud 17 (4.3%) 375 (94.0%) 7 (1.7%) 0.64 (0.37-1.12) - 
Grass/bamboo 1 (1.5%) 64 (98.5%) 0 (0.0%) 1.85 (0.25-13.6) - 
Other 0 (0.0%) 3 (100.0%) 0 (0.0%) 1 - 
Unknown 3 (6.2%) 45 (93.8%) 0 (0.0%)  - - 
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Table 16: Characteristics of the 79 individuals who were CFA positive and HIV positive 
at baseline and association with CFA clearance 
Characteristic CFA negative 
(n=54) 
CFA positive 
(n=25) 
OR (95% CI) 
MDA use    
None 12 (75.0%) 4 (25.0%) Ref. 
Any MDA use 36 (65.4%) 19 (34.6%) 1.58 (0.45-5.59) 
Unknown 6 (75.0%) 2 (25.0%) - 
    
MDA doses    
0 12 (75.0%) 4 (25.0%) Ref. 
1 12 (48.0%) 13 (52.0%) 3.25 (0.82-12.88) 
2 24 (80.0%) 6 (20.0%) 0.75 (0.18-3.17) 
Unknown 6 (75.0%) 2 (25.0%) - 
    
Duration of follow up    
≤2 years 30 (60.0%) 20 (40.0%) Ref. 
2-3 years 13 (81.2%) 3 (18.8%) 0.35 (0.09-1.37) 
3-4 years 11 (84.6%) 2 (15.4%) 0.27 (0.05-1.36) 
    
Age group    
15-29 years 4 (57.1%) 3 (42.9%) Ref. 
30-39 years 26 (68.4%) 12 (31.6%) 0.62 (0.12-3.19) 
40 years and above 24 (70.6%) 10 (29.4%) 0.56 (0.10-2.95) 
    
Sex    
Male 22 (61.1%) 14 (38.9%) Ref. 
Female 32 (74.4%) 11 (25.6%) 0.54 (0.21-1.41) 
    
ART status    
HIV positive - no ART 41 (67.2%) 20 (32.8%) Ref. 
HIV positive - ART 13 (72.2%) 5 (27.8%) 0.79 (0.25-2.52) 
    
Reporting group 
CFA prevalence 
   
Low 9 (69.2%) 4 (30.8%) Ref. 
Medium 21 (52.5%) 19 (47.5%) 2.03 (0.54-7.71) 
High 24 (92.3%) 2 (7.7%) 0.19 (0.03-1.21) 
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 Discussion  
This chapter reiterates the overall study objective and presents a short summary of the main 
findings of the study. It examines and gives details of these findings and discusses these in 
the light of the existing evidence from elsewhere. It also provides alternative explanations of 
the findings and summarises and acknowledges the main limitations of the study. Finally, it 
draws generalisations from the important findings and implications for public health, makes 
recommendations for LF control programmes and outlines areas for further research.  
5.1 Introduction  
This study set out to investigate the relationship between HIV and LF in the context of on-
going MDA treatment for LF elimination and presents data from two geographically separate 
studies undertaken in Karonga district, rural northern Malawi. In both studies a high LF and 
HIV prevalence was measured with HIV co-infection rates of 2.6% and 4.6% among those 
who were CFA positive and 15 years and older. There was no evidence that HIV is associated 
with an increased risk of LF infection but there was a tendency to lower CFA prevalence in the 
HIV positive group, attributable to significantly lower CFA prevalence in the ART treated sub-
group. This persisted following adjustment for key potential confounders and showed a 
significant trend to lower CFA prevalence with duration of ART use.  
In an associated randomised controlled open-label clinical trial comparing double dose vs. 
standard dose and once-yearly vs. twice-yearly dosing, all four treatment groups achieved a 
significant reduction of microfilaraemia by 12 months, with additional clearance in all arms at 
24 months. Doubling the standard dose and giving it twice yearly showed a non-significant 
tendency towards faster and more complete clearance of microfilaraemia compared to the 
WHO-recommended annual standard dose albendazole 400 mg single dose and ivermectin 
200 mg/kg treatment regimen, without serious adverse reactions.  
At follow up, two doses of MDA treatment effectively reduced CFA prevalence and worm 
burden and its effectiveness was unaffected by HIV co-infection and ART status. During follow 
up a very low rate of new infections was measured, and this could not be directly linked to an 
MDA effect. 
5.2 LF, HIV and antiretroviral therapy 
This study did not find any evidence that HIV has any impact on the prevalence of LF 
antigenaemia but found evidence to support significantly lower CFA prevalence in ART treated 
HIV positive individuals.  
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5.2.1 No interaction between LF and HIV infection 
Previous studies on the association between LF and HIV infections have been few with small 
samples from selected populations and have reported divergent findings. A positive 
association of LF and HIV infections, with increased LF infection levels in HIV positive 
individuals, was reported in a cross-sectional study of 907 adults undertaken in Tanga coastal 
region, north-eastern Tanzania [21]. A further evaluation of the same study population in a 
subgroup comprising of 59 individuals infected with HIV and/or W. bancrofti did not support 
any association between HIV and W. bancrofti infection [22]. No association between HIV and 
LF infections in terms of quantitative difference in W. bancrofti CFA levels by HIV status was 
also reported in another cross-sectional study of 432 HIV positive and 99 HIV negative patients 
in urban southern India [24]. A recent study from the same cohort in India found no differences 
in HIV replication and disease progression in HIV positive patients after treatment with DEC 
and albendazole [115].   
In contrast to these studies, this study had a larger sample taken from a whole population 
survey, including a high proportion of the at-risk population in an area with high prevalence 
rates of LF and HIV infections. Findings in this thesis are supported by a recently published 
study that was undertaken in Kyela and Mbeya districts, southwestern Tanzania, a 
neighbouring country to Malawi and about 200km to the north of the KHDSS  [116]. In a cross-
sectional analysis of LF antigenaemia and HIV infection, the study reported no difference in 
the prevalence of LF infection in HIV positive and HIV negative adults. Similar to the study in 
this thesis, this study had a larger sample taken from a whole population survey that was 
conducted in an area with high prevalence rates of LF and HIV infection and with no previous 
LF treatment campaigns with MDA or other antifilarial drugs. However, their sample was 
smaller than the study sample in this thesis and did not include ART use data in HIV positive 
patients but included children below 18 years of age.  
Both source studies in this thesis had some degree of selection bias, but it is unlikely that this 
has fundamentally altered the findings in this thesis. In filarial research study 1 component 
sourced from the Songwe Clinical Trial, villages known historically to have a high prevalence 
of LF infection were targeted [117, 118]. If participation by HIV positive individuals was 
reduced because of perceived stigma associated with an HIV test, this study may have had 
reduced power to identify an association between LF and HIV. However, a similar finding in 
the much larger filarial research study 1 component sourced from the KHDSS provides 
consistency. In this study, it is known that HIV positive adults were under-represented. Adults 
who knew their status from earlier HIV testing studies or through routine service provision in 
the district, declined participation [99]. However, it is difficult to see a mechanism whereby LF 
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co-infection would disproportionately lead to non-participation by HIV positive adults and, ART 
treated HIV positive adults, thereby obscuring the true association. As with all observational 
studies, it is possible that unaccounted for confounding has limited our ability to observe a true 
difference. We may be partially reassured by the follow up component of this study which did 
not demonstrate any impact of HIV modifying the effects of MDA treatment, which may have 
been expected if HIV modifies the control of the host response to filarial. 
5.2.2 Antiretroviral therapy associated with reduced LF prevalence  
The findings in relation to ART use are novel and only one other study that investigated 
whether ART is associated with reduced prevalence of helminth infections among HIV positive 
adults attending a primary HIV clinic in a semi-rural area in Gabon reported similar findings 
[119]. However, in contrast to the study findings in this thesis in relation to ART use, the Gabon 
study reported no association between ART use and helminths infections. However, the 
helminths related outcomes of interest that were investigated in this study were positive stool 
for intestinal helminths (T. trichiura, A. lumbricoides, N. americanus, S. stercoralis), and 
presence of Loa loa microfilaraemia on microscopy. In addition, the study was clinic based 
and reported very low numbers of infections, which may have masked a more discrete effect 
of ART which the study also acknowledges among its major limitations. Another explanation 
of the contrasting results to these findings may be that because this study measured W. 
bancrofti CFA and therefore investigated the macrofilaricidal effects of ART while the Gabon 
study measured Loa loa microfilaraemia and investigated the microfilaricidal effects of ART. 
In this study, individuals receiving ART may represent a select group of the HIV positive 
population who have better health seeking behaviour, may be more educated, live in better 
accommodation and/or may live near health providers. However, as this work was undertaken 
in the context of an ongoing demographic surveillance survey and annual HIV cross-sectional 
surveys  [103, 107], it was able to investigate these potential confounders by adjusting for 
reported educational status, housing quality, access to clean water and geographic location. 
ART treated individuals may survive longer but at the expensive of increased use of non-ART 
medications and therapies with the potential for antihelminthic effects. More detailed 
information on antibiotic usage and other “over the counter” treatments was unavailable and 
would represent an area for further study going forward.   
Residual confounding or an unrecognised selection bias remains possible but seems unlikely 
given the highly significant trend to lower CFA prevalence with duration of ART therapy i.e a 
strong dose response relationship. If LF infection adversely impacts on the success of ART 
therapy, then over time the prevalence of CFA positivity in this group will reduce as the LF/HIV 
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co-infected die. There is no evidence from the Malawi national HIV programme that outcomes 
from ART treatment are worse in regions of the country endemic for LF compared to those 
with low LF prevalence. Helminth infections have been linked to increased viral load in non-
ART treated individuals [23] but not to evidence of faster HIV progression [120]. Similarly, LF 
infection had no significant effect on HIV disease progression in a study of W. bancrofti and 
HIV coinfections in southern India [115]. Altered diagnostic accuracy of the Og4C3 ELISA in 
the presence of ART has not been reported. ART has been rarely linked to false negative HIV 
results in children and adults, but this is more likely to be due to low levels of virus and/or 
antibody than a direct inhibitory effect. The reduction in CFA prevalence by ART treatment 
duration and the antigen capture nature of the Og4C3 ELISA would be difficult to explain by 
ART inhibition of the assay. Immune reconstitution as a result of ART does not adequately 
explain the findings in this thesis either as there is a similar prevalence of CFA in the HIV 
negative and the HIV positive untreated. There is no precedent for immune recovery following 
ART leaving the immune system in a more competent state than that of an HIV negative 
person. ART treatment is an imprecise proxy marker of duration of HIV infection. If the natural 
history of LF in the HIV positive is a steady fall in antigenaemia, could this explain the 
association? The study did not have accurate HIV sero-conversion dates for the majority of 
this population so it was not possible to fully consider this possibility. However, with ART use, 
the “natural history” of HIV is dramatically altered and it might be expected that any tendency 
to lower antigenaemia with time would also be altered and this would be inconsistent with the 
findings in this thesis.  
The most plausible explanation for the finding of lower CFA prevalence in ART treated HIV 
positive individuals is a direct filaricidal activity of the major ART agents. Further evaluation of 
these molecules or their metabolites as antihelminthics would be appropriate as the underlying 
mechanism of the antifilarial effects of ARTs remains less clear.  The Anti-Wolbachia (AWOL) 
Consortium based at Liverpool School of Tropical Medicine (LSTM) aims to develop new drugs 
against onchocerciasis and lymphatic filariasis and has developed assays to screen various 
drugs for antifilarial activity [121]. The ART drugs, Lamivudine, Stavudine and Nevirapine, 
were included in the AWOL drug screening process and the results have shown that these 
drugs have no direct effect on microfilariae, adult female worms or Wolbachia levels as single 
drugs. Nevirapine had some modest activity against male worms, with a slow decline in motility 
over a 14-day period, but this was not interpreted as displaying typical direct anti-filarial 
activity. It remains possible that these drugs may show some synergism in combination but 
not as single drugs (Professor Mark Taylor, personal communication).  
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One possible explanation is through mitochondrial toxicity of the ART on the worms which is 
a well-known adverse effect of many ART drugs [119]. Few other previous studies that have 
investigated the effects of ART drugs on intestinal parasites and found significant reductions 
of helminths infections in ART treated HIV positive individuals, also speculate on the antifilarial 
effects of the ART drugs [122-124]. Another possible way in which the ART drugs can work 
against filarial infections is by a process of activation of autophagy in the adult filarial worms 
and this action has been shown to produce bactericidal activity against the Wolbachia 
endobacteria and consequent death of the adult filarial worm [125]. This has not been tested 
in laboratory conditions and may be interesting to see ongoing research in this area. ART 
drugs may also produce antifilarial effects through their metabolites and screening of these as 
part of existing drug screening strategies currently investigating possibilities for repurposing 
approved drugs for use in may provide further insight to their antifilarial effects. 
5.2.3 Co-trimoxazole preventive therapy in HIV patients and LF 
Cotrimoxazole preventive therapy (CPT) is part of the standard package of preventive services 
that are provided to all HIV positive patients to help reduce and prevent serious HIV-related 
diseases according to the Malawi clinical guidelines for the management of HIV/AIDS [93]. 
CPT is provided to all HIV positive adults for life as a daily dose of one 960 mg cotrimoxazole 
tablet. In this study, 28.5% of HIV positive patients were on CPT. A crude association of CTX 
therapy with lower CFA prevalence was observed but no significant effect of CTX therapy on 
CFA prevalence when analysed in a multivariable model. The crude association of CTX with 
lower CFA prevalence seems adequately explained by concomitant use of ART, and data to 
support either sulphonamides or trimethoprim, the components of CTX, as effective antifilarial 
agents is limited and less clear. A recently published study from Gabon reported a significant 
reduction of Loa loa microfilaraemia with CTX therapy in HIV-positive adults and suggested a 
direct antihelminthic effect of CTX through interference with folic acid biosynthesis and 
metabolism in the worms [119]. This is in contrast to the study findings in this thesis which 
reported no significant effect of CTX therapy on CFA prevalence after controlling for known 
potential confounders. Nevertheless, given the strong collinearity between ART use and CTX 
use, from a purely epidemiological and mathematical perspective we are not able to firmly 
conclude that CTX has no effect. Thus further experimental investigation of this agent may be 
merited.    
5.3 Factors associated with LF positivity in cross-sectional analysis  
Of the factors associated with CFA positivity in this study, which included gender, age, quality 
of housing, level of education and source of water, all except ART use have been reported 
111 
 
previously, providing reassurance that the epidemiology of LF disease in Karonga is not 
unique and results are generalizable to other similar regions.  
One surprise was the lack of association with bed net ownership. However, most households 
possessed bed nets limiting the power of any comparison as a consequence of major 
imbalances in group sizes. Moreover, this survey did not specifically ask about usage, or 
condition of the nets, thus limiting the value of this finding. More detailed evaluation of this will 
be needed in future work with careful attention to reliable methods for determining true bed 
net usage and protection. 
There were more females than males amongst the study participants in both source studies. 
This may represent the easier access to females at the time of recruitment since females are 
more likely to be at home and males are often out in the field for work and recreation activities. 
In most communities including the study area, significantly more males than females are 
infected with LF and more females than males are infected with HIV. Although it is known that 
men are more likely to be infected with LF in this population, this under-representation may 
not have meaningfully affected the LF/HIV association. Sub-group analyses showed similar 
odds ratios for the LF/HIV association by gender in filarial research study 1 component 
sourced from the KHDSS, suggesting no major effect modification. 
5.4 MDA dosing regimens and frequency 
This study found high levels of microfilarial clearance from both the standard MDA treatment 
and experimental arms after 12 months, with additional clearance in all arms at 24 months. 
The twice-yearly high dose albendazole (800 mg dose) and ivermectin (400 mg/kg) treatment 
regimen had a non-significant tendency to faster clearance of microfilaraemia compared to 
the WHO-recommended annual standard dose albendazole 400 mg single dose and 
ivermectin 200 mg/kg treatment regimen, without any increase in adverse events. 
These findings are consistent with available historic and contemporary trials of anti-filarial 
agents in other settings [10-12, 126].  A randomised controlled clinical trial conducted in Mali 
just prior to this study also reported that the higher dose twice-yearly treatment regimen was 
more effective than the standard dose annual regimen [12]. Another randomised controlled 
trial of anti-filarial agents recently reported from India showed that higher and more frequent 
doses of albendazole were more effective than the standard regimen in producing clearance 
of microfilaria and reductions in antigenemia [126]. The Mali trial was conducted in an area 
where there had been considerable previous exposure to ivermectin for onchocerciasis as 
well as a number of rounds of MDA for LF elimination and infected subjects with adequate 
microfilarial levels were difficult to find. Similarly, the study area in the India trial had seen 
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intermittent MDA activity initially using DEC alone and later DEC and albendazole [126]. This 
study endorses, and adds to, the findings in Mali and India since it had three intervention 
groups compared with the standard regimen and was conducted in a setting of high LF-
endemicity with no known previous exposure to LF treatment or MDA for LF elimination. 
The response to standard treatment was much better than the expected 25% and 75% at 12 
and 24 months, respectively and this was a contributory reason for failure to achieve a 
definitive outcome in this study. The sample size calculations were based on findings 
emerging from data comparing single and multi-dose regimens for the treatment of LF [9, 114]. 
The reduced response to standard treatment in the Mali study may be due to the selection of 
less sensitive strains as a consequence of previous exposure to LF treatment. With the 
excellent response to standard treatment in this study, a much larger cohort will be needed to 
investigate these dosing schedules further. However, future studies like this are likely to prove 
increasingly difficult to undertake with the introduction and increased coverage of MDA.  
The principal limitation of this study was the failure to recruit adequate numbers of participants. 
Recruitment did not reach the protocol target due to lower numbers of potential subjects with 
the target microfilaraemia of .80 microfilariae/ml and only 70 were randomised into the study. 
Recruitment was also discontinued following the rollout of the albendazole/ivermectin national 
MDA programme in the study area in October 2009. Thus the study was under powered to 
confirm a true positive effect of the non-standard interventions. Other limitations of the study 
were a relatively high rate of missed follow up appointments compounded by a series of 
earthquakes in late 2009 that affected the ability of field workers to reach potential subjects. 
The study was non blinded in the field. This should not have affected the outcome assessment 
as this was undertaken blind in the laboratory. However, there is the potential for participants 
to seek additional therapies if they believed they were being under treated. Although this was 
felt to be unlikely and questioning was done to seek evidence of additional anti filarial 
medications, it is not possible to fully exclude this possibility as an explanation for the better 
than expected performance in the standard arm. 
5.5 Test sensitivity and specificity  
The measurement of exposure (HIV) and outcome endpoints (LF status) in this study were 
based on accurate and well described tests and these are not believed to have introduced 
significant bias into the study. Both parallel and serial rapid HIV testing strategies were used 
during the period of data collection for the annual HIV surveys that were used as source 
studies for this study. Under both testing strategies, Determine HIV-1/2 (Abbott Japan Co Ltd, 
Tokyo, Japan) was combined with Uni-Gold HIV (Trinity Biotech PLC, Bray, Ireland) as the 
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first and second rapid tests respectively, while SD Bioline HIV 1/2 3.0 (Standard Diagnostics 
Inc, Kyonggi-do, Korea) was used as a third tie-breaker. All three rapid tests used in Malawi  
have been reported to have sensitivities and specificities of, respectively, 100% and 99.4% 
(Determine™), 100% and 100% (Uni-Gold™), and 100% and 99.3% (SD Bioline) when 
evaluated under standard operational conditions [107]. Laboratory-based quality control at 
KPS was conducted by systematically re-testing plasma from all samples that were positive, 
inconclusive or for which the initial two rapid tests were discordant using the parallel testing 
strategy, and from every tenth negative sample collected [107].   
The study used different tests for assessment of circulating filarial antigen in the two studies 
with different sensitivities and specificities, the ICT card test with sensitivity and specificity 
reportedly close to 100% and the Og4C3 ELISA test with 100% sensitivity and specificity of at 
least 94% [127-129]. There was some disparity between these two tests identified in filarial 
research study 1 component sourced from the Songwe Clinical Trial. This is consistent with 
previous studies that have reported overall agreement between the ICT and Og3C4 tests but 
different sensitivities and specificities [127, 128]. MF counts were not assessed in the filarial 
research study 1 component sourced from the KHDSS due to the use of a stored sample 
collection. Whilst this study cannot categorically rule out an association between MF density 
and HIV, data from study 1 showed a positive correlation between CFA levels and MF density. 
Previous studies have also shown a positive correlation between CFA levels and MF density 
[129, 130]. This implies that the CFA relationship will broadly apply to MF counts. 
5.6 Declining LF incidence and rise of malaria vector control 
programmes 
This study found very low rates of CFA incidence in individuals who were CFA negative and 
demonstrated a natural background loss of CFA in individuals who were CFA positive and 
reported no MDA use. This demonstrates that there are other drivers of the decline in 
lymphatic filariasis infection in the study area besides annual MDA treatment campaigns and 
demonstrates a declining problem of LF generally in the population.  
A reduction in LF incidence was observed in the study area for the Songwe clinical trial. Prior 
work in the area had shown a high prevalence of LF antigenaemia (46%) and microfilaraemia 
(30.8%) some 10 years previously in 2000-2001[80]. During the screening process for the 
clinical trial, the prevalence of LF antigenaemia was 24%, 22% lower than previously observed 
in earlier LF studies in the same area [80], suggesting a reduction in the incidence of new 
infections during this period. A similar trend was observed in Zambia, a neighbouring country 
to Malawi, where LF prevalence decreased from 33.3 to 14.8% between 2003 and 2011 [131]. 
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This was attributed to a decrease in LF transmission following the scaling up of malaria vector 
control activities since the anopheline mosquito vector that transmits malaria in these areas 
also transmits LF and these control activities could also be contributing to the decline in LF 
incidence. 
Bed net distribution is one such malaria vector control activity that has been scaled up in 
Malawi, including this study’s area, with 55% of households in rural areas reported owning at 
least one insecticide-treated mosquito net [132]. In contrast to this study, several studies have 
reported a significant effect of use of insecticide-treated nets in lowering the prevalence and 
transmission of LF. Some studies have shown how ITN use alone without the need for 
combination with MDA can reduce LF infection and transmission; a prospective study 
conducted in south-eastern Nigeria which reported a significant decrease in LF infection and 
infectivity in mosquitoes from areas which had full coverage of LLIN distribution ;  a study of 
three filariasis surveys in The Gambia conducted over a period of 17 years which attributed a 
significant decline in LF endemicity and transmission to widespread use of ITNs [133];  and a 
longitudinal study in coastal regions of Kenya which reported significant reductions in LF 
infection prevalence and intensity  despite the fact that the study villages missed MDA in some 
of the years [134]. A cross-sectional study from south-eastern Tanzania which reported a 
marked reduction in W. bancrofti CFA in young school children is one of the studies which 
have provide evidence on how ITN use for malaria control complements MDA in achieving an 
accelerated and increased reduction of LF infection and transmission is [135].  
Thus, long term use of bed nets may be the most likely explanation for the long term downward 
trend in filarial infection and the downward trend noted in the follow up study.  Contrary to the 
expectations of this study and findings from previous studies, bed net results from this thesis 
did not demonstrate a significant association with CFA clearance. As noted in section 5.3 
above, this study was not able to measure bed net use directly and did not ask about frequency 
of use or condition of the nets and whether all household members slept under nets. Bed net 
ownership was used as a proxy of bed net use. To ensure efficiency of field work, a time 
limitation was placed on the length of any household interview and detailed questions on this 
topic were avoided. This was in hindsight a limitation of the study and further, more detailed 
evaluation of this is needed to understand ownership and use. 
Several studies have reported changes in mosquito biting patterns including shifts from 
outdoor to outdoor feeding with malaria transmission occurring both indoors and outdoors 
[136-138]. Since the same mosquito vectors transmit both malaria and LF in Malawi, this could 
also apply to LF transmission additionally occurring outdoors and therefore reducing the 
impact of bed nets on LF transmission. A change in the principal mosquito vector and 
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consequently biting patterns may explain a change in epidemiology. However, if this was away 
from the night biting anopheline vector to a daytime biting species an increase in infections 
might be expected and would not be in keeping with the findings from this study.  
Another malaria vector control strategy that may account for the LF decline observed in the 
area of this study is IRS. In Malawi, IRS was initiated in 2007 as a pilot in the lakeshore district 
of Nkhotakota in the Central Region and scaled up to a further six districts in 2010 including 
Karonga district. However, the programme was discontinued between 2011 and 2012 due to 
logistical problems including evidence of emerging insecticide resistance until 2013 when it 
was resumed [29]. This means that the study area had only one IRS round during the study 
duration and the IRS intervention is less likely to have been as effective as anticipated 
because of this and the reports of emerging insecticide resistance. The contribution of MDA 
over the period of follow up for this study is less easy to establish, but the recorded low rate 
of new infections suggests that MDA superimposed on effective vector control is highly 
effective at limiting new infections and leading to filarial elimination. 
Several factors were considered as possible explanations for failure to see a lack of bed net 
effect on CFA clearance. Leading amongst these was the evidence of minimal LF transmission 
and acquisition and a natural background loss of CFA occurring in the study area. An already 
much reduced transmission limits the power of this study to identify an impact, 2 per 1000 
person-years at risk would need a very large study to show even a 50% effect size of bed 
nets. Moreover, most households possessed bed nets and the almost universal ownership 
limits further the statistical power of any comparison by virtue of the small group sizes in those 
without nets. Misclassification of bed net ownership, particularly if bidirectional would reduce 
the effect of the study towards the null. Although over-reporting of bed nets might be possible 
or ownership without use, under-reporting of ownership seems unlikely and given that the vast 
majority of households reported ownership this is most unlikely. Bed nets in households have 
also been reported to be mainly used by children and pregnant women [139]. The study 
sample did not include children, and this might also have affected the examination of the 
association between bed net use and CFA clearance.  
 
5.7 MDA treatment in routine use 
Two doses of MDA were shown to significantly increase the reduction in CFA prevalence when 
compared to those who received no doses. This would be expected from previous studies 
confirming the impact of MDA. A single dose of MDA was associated with a borderline slower 
decrease in CFA prevalence when compared to those who were not treated. This is a difficult 
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finding to explain and although the effect size lost significance in the adjusted analysis, the 
point estimate remained very similar. The individuals who recorded receiving only a single 
dose of MDA showed a greater proportion of individuals who had been followed up for 3 or 
more years, which might associate with a more mobile or chaotic life style, greater propensity 
to be put at risk of biting and a lower likelihood of being sampled in consecutive years. 
Adjusting for length of follow up in the overall analysis did not significantly adjust the MDA 
effect sizes and longer follow up was associated with a reduction in CFA. Thus, it is not clear 
that heterogeneity in follow up explains these findings. Individuals who received a single dose 
of MDA were more likely to reside in a medium prevalence CFA reporting group, unlike the no 
dose and two dose groups who resided predominantly in high prevalence areas. Residence 
in a high prevalence area may be associated with greater use of mosquito nets if biting 
intensity is higher, and its questioning in this study would not be sensitive to this finding. This 
could explain the relatively higher prevalence in the individuals receiving just a single dose if 
the benefits of bed net usage are greater than the impact of MDA. In the overall adjusted 
clearance analysis, residence in the highest prevalence areas was associated with the 
greatest CFA reduction lending some support to this idea. Alternatively, a by chance finding 
is a possible explanation for this unexpected association. 
5.8 Implications for LF control programme and community health 
A primary research question of this work was whether HIV would impact on the effect of MDA 
on LF control. No effect of HIV infection was noted in the overall clearance analysis and in the 
analysis of the HIV-infected subset alone and these findings were similar to the follow up 
cohort as a whole. This is the first investigation of this magnitude into HIV and LF co-infection 
in Malawi and it adds significantly to existing knowledge in the field. MDA effectively reduces 
CFA prevalence and worm burden and the effectiveness of MDA treatment is unaffected by 
HIV co-infection and ART status. Thus, the study concludes that there is no interaction 
between HIV infection status and success of MDA treatment, an important conclusion for 
filarial control programmes in regions of high HIV prevalence. This provides assurance to the 
Malawi national LF programme and countries with high prevalence rates of both infections that 
HIV coinfection will not interfere with the current LF control and elimination strategies. 
In addition, the findings from the clinical trial indicate that standard treatment may be adequate 
for national LF programmes in settings with similar epidemiology and treatment history to 
Malawi. Doubling the standard MDA dose and giving it twice yearly have the potential to 
achieve a successful and accelerated outcome of mass treatment programmes which could 
be at a lower overall cost to national programmes by achieving critical programmatic 
milestones much earlier. 
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5.9 Recommendations for future research  
A significant association of ART use with decreased CFA prevalence merits further 
investigation to understand the potential of antiretrovirals as molecules with antihelminthic 
properties and to exclude any adverse impact of LF on HIV. Although the AWOL Consortium 
initial screening of these drugs as single antifilarial agents has shown that these drugs have 
no direct effect on microfilariae, adult female worms or Wolbachia levels, it remains possible 
that these drugs may show some synergism in combination. A significant association of ART 
use with lower CFA prevalence merits further investigation to understand this apparent 
beneficial impact of ART.  
This study confirms that there is no evidence that HIV infection has an impact on LF 
epidemiology that will interfere with LF control measures and that MDA effectively reduces 
CFA prevalence and worm burden and the effectiveness of MDA treatment is unaffected by 
HIV co-infection and ART status. However further studies with a longer duration of follow up 
time of MDA coverage are also needed to validate the effectiveness of MDA treatment in HIV 
endemic settings.  
With the excellent response to standard treatment in this study and the finding of a non-
significant tendency to faster clearance of microfilaraemia in the twice-yearly high dose 
albendazole (800 mg dose) and ivermectin (400 mg/kg) treatment regimen compared to the 
WHO-recommended annual standard dose albendazole 400 mg single dose and ivermectin 
200 mg/kg treatment regimen, much larger cohorts will be needed to further investigate the 
benefit of higher and more frequent regimens definitively. Higher annual doses or more 
frequent dosing regimens might have the potential to achieve a successful and accelerated 
outcome of mass treatment programmes. This could be at a lower overall cost to national 
programmes in countries with limited resources by achieving critical programmatic milestones 
much earlier. However, future studies like this are likely to be increasingly challenging and 
expensive to undertake at the required scale with the introduction and increased coverage of 
MDA.  
More detailed evaluation of malaria vector control interventions that impacts on LF 
transmission are also needed. This can include trials investigating impact of bed net use rather 
than ownership.  
5.10 Conclusion  
This PhD thesis described the relationship between HIV and LF in Karonga district, rural 
northern Malawi, both before and after introduction of MDA treatment for LF elimination in the 
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area. There was a high prevalence of LF and HIV infections among the study participants, but 
no evidence was observed of a negative impact of HIV coinfection on LF epidemiology. A 
significant reduction of LF prevalence and worm burden was observed after a period of MDA 
treatment and its effectiveness appeared to be unaffected by HIV coinfection and ART status. 
In addition, all regimens were effective in clearing microfilaraemia with a tendency to faster 
and more complete clearance when the standard dose was doubled and given twice yearly. 
In conclusion, the findings from this PhD thesis confirms that there is no negative interaction 
between LF and HIV infections in co-infected individuals that can impair the effectiveness of 
MDA treatment for LF elimination. The current treatment regimen for MDA may be adequate 
and doubling the standard dose and giving it twice yearly has the potential to achieve 
successful and accelerated outcomes for LF control and elimination programmes.  
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KARONGA PREVENTION STUDY CONSENT FORM FOR LYMPHATIC 
FILARIASIS STUDY (SCREENING) 
 
EFFECT OF ALBENDAZOLE AND IVERMECTIN DOSE ON WUCHERERIA 
BANCROFTI MICROFILARIAL CLEARANCE IN MALAWI: A RANDOMIZED, 
OPEN LABEL STUDY 
 
 
Consent to Participate in Screening for Filariasis 
 
Investigators: _______________________________________________________ 
 
Site:_______________ 
 
Volunteer’s Name_____________________________________________________ 
   First     Middle    Last 
 
Identification Number  __ __ __-__ __ __ __ Age ______ years 
 
We invite you to take part in a research study being undertaken by Karonga Prevention 
Study/LEPRA on behalf of the Global Programme for the Elimination of Lymphatic Filariasis.  
It is important that you understand several general principles that apply to all that take part in this 
study: 
 
1.  Participation in the study is entirely voluntary. 
2.  Personal benefit to you may not result from taking part in the study, but knowledge may be 
gained that will benefit others. 
3.  You may withdraw from the study at any time. 
 
 
Lymphatic filariasis (LF) is a disease caused by infection of the blood with very small worms 
called Wuchereria bancrofti. These worms are spread by Mosquitoes.  LF can cause swellings in 
the arms, legs, breast and genitals. It can also progress to a permanent swelling of the legs or 
arms called elephantiasis.  Usually, infection with the worms causes no illness at all.  When a 
person with LF is treated with the right medicines, the risk of developing elephantiasis is lower.  
If an entire community could be treated at one time, the risk of getting infected in that area 
would be reduced because the mosquitoes that spread the infection could no longer become 
infected.  Doctors hope to eliminate this infection in your community soon by treating everyone 
with medicines but research is required to find out the right quantity and type of medicine to 
give. At present medicines must be given yearly for 4-6 years.  If the medicines were better at 
lowering the numbers of worms in the blood of infected people, less time might be needed to 
eliminate the infection.  This could make it easier for countries like Malawi to succeed in 
eliminating this disease. 
 
Study Design 
 
We would like to see if treatments given once or twice a year with either the usual dose of 
albendazole and ivermectin (the two drugs used to treat LF in Africa) or with a higher dose of 
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albendazole are better at getting rid of the worms from the blood than the current standard 
treatment.  In order to do this, we plan to treat some people with filarial worms in the blood with 
the medicines at the normal dose once a year.  A second group of people with filarial worms in 
the blood will receive the higher dose of albendazole once a year, a third group will receive the 
normal dose twice a year and a fourth group will receive the higher albendazole dose twice a 
year.    The treatments will be given either every 6 months (total of 4 treatments) or yearly (total 
of two treatments) and the study will last for 2 years.   
 
Before we give any treatment we need to see if a person is infected. To do this we will take a 
sample of blood from a finger prick (like a malaria test). If this test shows the presence of the 
filarial worm we would then wish to take a sample of blood (10ml or a tablespoon in quantity) at 
nighttime. The blood needs to be taken at nighttime as this is when the worms appear. If this test 
confirms there are a large number of worms we will ask you to participate in the study of 
different treatments, however we will ask for your consent again before going any further. If you 
have a small infection of worms and are not suitable for the treatment study we will give you the 
current standard treatment if you wish to be treated. In all, we plan to screen 1000 people and 
expect to find 120 people to take part in the treatment part of the study. 
 
We are looking for healthy people, ages 18 to 55, who are not pregnant to be in the study. We 
will ask you some questions about your health, including whether or not you have been treated 
for filariasis .You will be told whether or not you are infected with filarial worms and you may 
choose, based on this or any other information, not to take part in the study. All study visits and 
blood drawing will take place at home. 
 
Risks/benefits 
 
The risks associated with this screening study are few. Drawing blood may cause discomfort and 
occasional bruising at the site. 
 
The benefit from this study is that you will be tested for filarial infection.  Filarial infections can 
cause swelling of arms, legs, scrotum or breasts and this may be prevented or lessened by 
treatment.  If you are infected, you will be offered and provided the medicines to treat filarial 
infection even if you do not wish to participate in our treatment study.   
 
Alternatives to Participation and Exclusion from the Study  
 
You do not have to take part in this study and may refuse to take part at any time.  If you are 
infected with the worm that causes lymphatic filariasis but do not wish to take part in our 
treatment study, you will still be treated for this infection if you wish.   
 
Reporting of Findings and Confidentiality 
 
Although your study records and medical information will be kept confidential, personnel from 
GPELF, Ministry of Health or other supervisory body may need to review information.   All 
unanticipated uses of your medical information will be reported to the Institutional Review 
Board in Malawi. 
 
Do you have any questions about participation in this study? 
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If you have questions or concerns at a later date, you may speak with one of our staff or you can 
call The Karonga Prevention Study Office on 01364256 or 09971860 and speak with Dr Bagrey 
Ngwira    
 
If you agree to participate in this study, please put your signature or thumb or fingerprint where 
indicated below.  
 
 
 
____________________________  ____________ _____________________ 
Signature, Finger or Thumb Print   Date    Name 
 
 
___________________   ____________          ______________________ 
Witness Signature    Date    Name 
 
 
___________________   ____________          ______________________ 
Physician Signature      Date     Name 
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KARONGA PREVENTION STUDY CONSENT FORM FOR LYMPHATIC 
FILARIASIS STUDY (TREATMENT) 
 
EFFECT OF ALBENDAZOLE AND IVERMECTIN DOSE ON WUCHERERIA 
BANCROFTI MICROFILARIAL CLEARANCE IN MALAWI: A RANDOMIZED, 
OPEN LABEL STUDY 
 
Consent to Participate in a Filariasis Treatment Study  
 
Investigators: _______________________________________________________ 
 
Site:_______________ 
 
Volunteer’s Name_____________________________________________________ 
   First     Middle    Last 
 
Identification Number  __ __ __-__ __ __ __  Age ______ years 
 
You have already kindly participated in a study to see if you are infected with the lymphatic 
filariais worm. We would now like to invite you to take part in a further research study being 
undertaken by Karonga Prevention Study/LEPRA on behalf of the Global Programme for the 
Elimination of Lymphatic Filariasis.  It is important that you understand several general 
principles that apply to all that take part in this study: 
 
1. Participation in the study is entirely voluntary. 
2. Personal benefit to you may not result from taking part in the study, but knowledge may 
be gained that will benefit others. 
3. You may withdraw from the study at any time. 
 
Introduction 
 
Lymphatic filariasis (LF) is a disease caused by infection with very small worms called 
Wuchereria bancrofti. Mosquitoes spread these worms.  LF can cause swellings in the arms, 
legs, breast and genitals. It can also progress to a permanent swelling of the legs or arms called 
elephantiasis.  Usually, infection with the worms causes no illness at all.  When a person with LF 
is treated with the right medicines, the risk of developing elephantiasis is lower.  Treatment also 
eliminates the parasites from the blood.  If an entire community could be treated at one time, the 
risk of getting infected in that area would be reduced because the mosquitoes that spread the 
infection could no longer become infected.  Doctors hope to eliminate this infection in your 
community soon by treating everyone with medicines. 
 
One of the problems with eliminating lymphatic filariasis is the cost of the treatment program. 
Medicines must be given yearly for 4-6 years.  If the medicines were better at lowering the 
numbers of worms in the blood of infected people, less time might be needed to eliminate the 
infection.  This could lower the cost of the program and make it easier for countries like Malawi 
to succeed in eliminating this disease. 
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Study Population/Study Design 
 
Our study is designed primarily to see whether higher or more frequent doses of albendazole and 
ivermectin is better at lowering the numbers of Wuchereria bancrofti worms in the blood than 
the standard dose of albendazole given yearly with ivermectin.  We would also like to study the 
effects of these two treatments on the adult worms, which live in the lymphatics.  The reason you 
have been invited to participate in this study is because you were identified by our screening 
study as being in good health, and it is known that you have filarial worms in your blood.  You 
should have already been informed that you are infected, and you may decide, based on this or 
any other information, not to participate further. In all, up to 120 people will be selected to 
participate in the treatment study.  
 
In order to participate in the treatment part of this study, you must: 
 
1) be between the ages of 18 and 55 
2) be in good health 
3) not be pregnant  
4) not be allergic to the drugs being used (albendazole, mebendazole) or ivermectin 
5) not drink alcohol to excess (more than 1 beer or other alcohol-containing drink/day) 
6) have no laboratory evidence of low red blood cells (Haemoglobin) 
7) sign informed consent 
8) have a minimum number of worms in your blood (80mf/ml) 
9) be willing to have an HIV test performed 
 
For the treatment portion of the study you will be assigned to one of four groups:  
1. albendazole (400 mg) and ivermectin (150 mcg/kg) given once a year 
2. albendazole (400 mg) and ivermectin (150 mcg/kg) given twice a year 
3. albendazole (800 mg) and ivermectin (150 mcg/kg) given once a year   
4. albendazole (800 mg) and ivermectin (150 mcg/kg) given twice a year   
 
During the study, you may not take albendazole or ivermectin except when it is given to you by 
or discussed with the study team.  Other medicines are allowed. 
 
You will be assigned to a treatment group using a method similar to flipping a coin.  The 
morning that you receive the treatment, we will measure your temperature and ask you some 
questions about how you feel.  If you are a woman of child-bearing age, we will also check your 
urine to make sure that you are not pregnant.  Then, if you are not pregnant, you will be given 
the medicines.  The visit will take approximately 30 minutes.  If you develop symptoms at any 
time during the treatment part of the study, you are encouraged to let the study doctors know. 
Additional medicines (including paracetamol, antihistamines and antibiotics) will be available 
from the study physicians at no charge to you to treat symptoms due to the study medicines or 
procedures.  
 
If you agree to participate, an ultrasound test will be performed to look for filarial worms in your 
body.  This test involves putting some gel on your groin or chest and using a small machine to 
look inside your body with sound waves.  The test takes about 15 minutes.  It does not hurt and is 
not harmful in any way.   
 
Six months after the beginning of the treatment part of the study, you will be asked to come to 
the clinic for a short history and physical examination.  We will also draw one tube of blood (less 
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than10 cc or 2 tablespoons) at nighttime to check for worms and to repeat the testing done at the 
start of the study.  If you are a woman of childbearing age, we will also check your urine to make 
sure that you are not pregnant. If you are not pregnant and in the group that is receiving medicine 
every 6 months, you will be given a second dose of medicine at this time. The morning that you 
receive the treatment, we will measure your temperature and ask you some questions about how 
you feel.   
 
One year after the beginning of the study, you will be asked to come to the clinic again for a 
short history and physical examination.  We will also draw one tube of blood (less than10 cc or 2 
tablespoons) at nighttime to check for worms and to repeat the testing done at the start of the 
study.   If you are a woman of childbearing age, we will also check your urine to make sure that 
you are not pregnant. Then if you are not pregnant, you will be given a second (or third) dose of 
medicine at this time. The morning that you receive the treatment, we will measure your 
temperature and ask you some questions about how you feel. If you had adult worms detected by 
ultrasound at the beginning of the study, the ultrasound test will be repeated to see if the worms 
are still alive. 
 
Eighteen months after the beginning of the treatment part of the study, you will be asked to come 
again to the clinic for a short history and physical examination.  We will also draw one tube of 
blood (less than10 cc or 2 tablespoons) at nighttime to check for worms and to repeat the testing 
done at the start of the study.  If you are a woman of childbearing age, we will also check your 
urine to make sure that you are not pregnant. If you are not pregnant and in the group that is 
receiving medicine every 6 months, you will be given a fourth dose of medicine at this time. The 
morning that you receive the treatment, we will measure your temperature and ask you some 
questions about how you feel.   
 
Two years after the beginning of the study, we will ask you to return to the clinic a final time for 
a short history and physical examination. , We will also draw one tube of blood (less than10 cc 
or 2 tablespoons) at nighttime to check for worms and to repeat the testing done at the start of the 
study.  If you had adult worms detected by ultrasound at the beginning of the study, the 
ultrasound test will be repeated to see if the worms are still alive.   
 
 
Risks  
 
The risks associated with this study are few. Drawing blood may cause discomfort and 
occasional bruising at the site.  Rarely, fainting or infection occurs as a result of drawing blood. 
We will clean your arm with alcohol before taking blood and will use new, sterile needles every 
time.   
  
We expect some of those who are treated with albendazole and ivermectin to develop symptoms 
from the body reacting to dying worms (fever, headache, soreness in muscles or joints, tiredness, 
weakness, itching, diarrhea or nausea).  We do not expect any serious reactions, and we expect 
all of them to resolve after a few days. Both of the medicines (albendazole and ivermectin) also 
kill many types of gut worms.  You may pass some worms in your stool or develop small lumps 
from dead worms under your skin during the days after treatment.   
 
Other than the reactions to dying worms, side effects from these medicines in the doses we are 
using are very rare.  People who take albendazole every day occasionally develop abdominal 
pain, diarrhea, nausea, vomiting, dizziness, hair loss, fever and headaches.  Albendazole may 
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damage babies in the mother if taken whilst pregnant.  Laboratory tests for pregnancy will be 
carried out before each dose of albendazole is given. In addition, women of childbearing age are 
advised not to have sex or to use a contraceptive method of their choice for one month after 
taking albendazole. Pregnant women will not be given albendazole, but will continue to be 
followed until the end of the study. 
 
Benefits 
 
Albendazole and ivermectin are medicines that kill a variety of intestinal and tissue parasites.  
Although everyone in the community will eventually be eligible for treatment with albendazole 
and ivermectin as part of the campaign to eliminate lymphatic filariasis, if you have a parasite 
infection, including but not restricted to lymphatic filariasis, you will benefit from earlier 
treatment of these infections.  If taking part in this study causes you any medical problems or 
makes you feel bad in any way, you will receive appropriate medical treatment at no cost to you.  
 
Alternatives to Participating in the Study.    
 
If you were found to be infected with the filarial parasite that causes lymphatic filariasis by the 
screening blood test but do not wish to participate in the treatment study, you will be offered 
treatment with albendazole and ivermectin. These are the same two medicines that will 
eventually be distributed by the government as part of a program to eliminate lymphatic filariasis 
in Malawi that is planned to start sometime in the next several years.  
 
Early Withdrawal 
 
You may withdraw from the study at any time.  In addition, if you become pregnant, develop a 
serious medical illness, or if the study physician feels that it is not in your best interest to remain 
in the study, you may be withdrawn.   
 
Reporting of Findings and Confidentiality 
 
The findings of this study may be reported at scientific meetings or in medical journals, but your 
name will not be used in the report. Although your study records and medical information will be 
kept confidential, personnel from the Task Force for Child Survival or the GPELF or their 
representatives may review the study records. All unanticipated uses of your medical information 
will be reported to the Institutional Review Board in Malawi. 
 
Do you have any questions about participation in this study? 
If you have questions or concerns at a later date, you may speak with one of our staff or you can 
call The Karonga Prevention Study Office on 01364256 or 09971860 and speak with Dr Bagrey 
Ngwira    
 
If you agree to participate in this study, please put your signature or thumb or fingerprint where 
indicated below.  
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____________________________  ____________            _____________________ 
Signature, Finger or Thumb Print   Date    Name  
 
 
___________________   ____________            _____________________ 
Witness Signature    Date    Name 
 
 
___________________   ____________           ______________________ 
Physician Signature      Date     Name 
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FEDE –ELIGIBILITY CRITERIA FOR FILARIA DOSAGE STUDY 
1 Fed subject ID: 
 
|__|__|__|-|__|__|__| 
 
fedid 
 Subject’s  initials: |___|___|  
2 Interview date: |___|____|______| intdat 
3 Spectset number  specset 
    
 Inclusion Criteria  (All answers must be “YES”)   
3 Is the subject 18 to 55 years of age?  Y N inage 
4 Is the Wb count above ≥80mf/mL?  Y N wbcnt 
    
 Exclusion criteria  (All answers must be “NO”)   
7 
Is the subject less than 18 years of age or more than 55 
years of age? 
Y N Excage 
8 Is the subject a pregnant female? Y N preg 
9 Does the subject have Hgb less than 9g/dL? Y N hgb 
10 
Does the subject use alcohol heavily (more than seven beers 
or other alcohol containing drink per week)? 
Y N alcoh 
11 
Does the subject have a temperature ≥ 37.5 C or other 
serious medical condition?  
Y N temp 
12 Does the subject have a history of benzimidazole allergy? Y N alballgy 
13 Does the subject have a history of ivermectin allergy? Y N Iverallgy 
14 
Has the subject used albendazole or ivermectin within the 
past six months? 
Y N Iver/alb 
     
 ENROLLMENT INFORMATION    
15 Is the subject eligible for enrolment? Y N Enrol 
16 Did the subject sign the treatment informed consent? Y N Icf 
17 Date subject signed  |___|____|_______| consdat 
     
 Assignment of study group    
18 Annual standard Dose Y N annsd 
19 Annual High Dose Y N annhd 
20 standard Dose Semiannual Y N Semsd 
21 High Dose Semiannual Y N semhd 
    
 
Staff code ……...   Signature……………….     Date……………       coder………..    
Checker………….      
Rcdr 
Cdr 
chkr 
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FEDF – FILARIASIS DOSAGE STUDY FOLLOW-UP FORM 
1 Fed subject ID:  |__|__|__|-|__|__|__| fedid 
 Subject’s  initials: |___|___|  
2 Interview date: |___|____|______| intdat 
3 Month of follow-up (0, 06, 12, 18, 24) |____| mnthf 
4 Specset number  specset 
 Medical History (please tick that applies)   
 Symptom Now ≤ 1 month  >1 month   Never comments  
4 Lymphedema      lymphe 
 If yes, where?  (LLE  RLE  LUE  RUE  other) whlym 
5 Lymphangitis      lympha 
6 Cellulitis      cellu 
7 Elephantiasis      eleph 
 If yes, where?  (LLE  RLE  LUE  RUE  other) whelep 
8 Hydrocele       hydro 
9 Hematuria       hematu 
10 Chyluria       chylur 
11 Pruritus      prurit 
12 Fever/chills      fever 
13 Headaches      heada 
14 Vomiting       vomit 
 If now, # of episodes in last 24 hrs  episod 
15 Diarrhoea      diarr 
 If now, blood?  Y N blood 
16 Abdominal pain       abdpai 
17 Weight loss >5kg        wtloss 
18 Jaundice      jaund 
19 Respiratory symptoms      Resp 
20 If now, cough? Y N cough 
21 Other………………………      other 
22 Heavy alcohol use       alcohol 
   
 VITAL SIGNS  
23 Weight |__|__|__|.|__| wt 
24 Axillary temperature |__|__|.|__| temp 
25 Pulse/min |__|__|__| pulse 
26 Respiration rate/min |__|__| resp 
   
 PHYSICAL  EXAM  
 Physical Sign Yes No Comments  
27 Dehydration     dehyd 
28 Icterus/jaundice    jaund 
29 
Lung Exam Abnormal 
If yes add comments 
   
lungs 
30 
Cardiac Exam Abrnomal 
If yes add comments 
   
cardiac 
31 Hepatomegaly    hepato 
33 Hydrocele    hydro 
34 
Skin rash 
If yes add comments 
   
skin 
  Version 1  19/02/2009 
11  
  White 
35 Pitting edema    edema 
36 Lymphedema 
  Grade: 1  2  3  4   5  
Site:  LLE  RLE  LUE  RUE  other 
lymphe 
37 Lymphadenitis   Site:  LLE  RLE  LUE  RUE  other adenitis 
38 Elephantiasis   Site:  LLE  RLE  LUE  RUE  other elepha 
39 
Other symptoms and signs  
If yes, add comments 
   
 
   
 LABORATORY TESTS  
40 At what time was venipuncture performed? |__|__|: |__|__| venitm 
41 Pregnancy Test Y N NA: reason……………………………………………….. preg 
42 White Blood cell count ….……….cells/mm3 wbc 
43 Eosinophil Count ……………………..% eosin 
44 Heamoglobin ……………………g/dl hb 
   
 CALIBRATED THICK SMEAR (NIGHTTIME)  
45 W . bancrofti Y N If yes   …………………………mf/mL wban 
46 M. perstans Y N If yes   …………………………mf/mL mpers 
   
 SPECIMEN COLLECTION  
47 Was serum stored for other research tests? Y N If no, reason…………………………… plasma 
48 Was whole blood for other research tests? Y N If no, reason…………………………… wbloo 
   
 DRUG ADMINISTRATION  
49 Was drug administered? Y N drug 
 If yes, select the assigned study group and dosages given     
 
Annual standard dose (albendazole (400mg)+ Ivermectin (200µg/kg) x wt(………….kg)= 
… 
 
 ……..µg/1000= ………..mg    
 
 Ivermectin tablets administered ………………. 
Y N 
Annsd 
 
iver 
 
Annual high dose (albendazole (800mg)+ Ivermectin (400µg/kg) x wt(……………..kg)= 
 
 …………µg/1000 =   ………..mg    
 
 Ivermectin tablets administered ………………. 
Y N 
Annhd 
 
iver 
 
semiannual standard dose (albendazole (400mg)+ Ivermectin (200µg/kg) x  
 
wt(………….kg)= … ………..µg/1000=  ………..mg    
 
 Ivermectin tablets administered ………………. 
Y N 
Semsd 
 
iver 
 
semiannual high dose (albendazole (800mg)+ Ivermectin (400µg/kg) x wt(…………..kg)= 
…  
 
…………..µg/1000= …………...mg    
 
 Ivermectin tablets administered ………………… 
Y N 
Semhd 
 
iver 
54 Lot Number: Albendazole  lotalb 
55 Lot Number: Ivermectin  lotivr 
 
Staff code ……...   Signature………………..     Date……………       coder………..    Checker………….      
Rcdr 
Cdr 
chkr 
Version 1 21/11/08 
 
 
FEDR- ICT RESULT SHEET 
 
1 
 
FED- ID 
 
 
 
fedid 
    
2 Initials   
    
3 Specset number  specset 
4 Lab number  labno 
 
5 
 
ICT test 
 
Date 
 
…………………………dd/mm/yyyy 
 
datetest 
   
Time set 
 
………………:…………Hrs 
 
timeset 
   
Time read 
 
………………:………….Hrs 
 
timeread 
  
 
      
 
6 
 
ICT 
result 
 
Test 1 
 
Positive 
 
Negative  
 
Faint 
 
Invalid 
 
ictresult1 
   
Test 2 
(If test 1 =  invalid) 
 
Positive 
 
Negative  
 
Faint 
 
Invalid 
 
ictresult2 
     
 
7 
 
Field staff code……….  
 
Coder…………  
 
Checker……… 
Rcdr 
Codr 
       Chkr 
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  FEDI –FILARIASIS DOSAGE STUDY-  IDENTIFIER   
1. FED – ID   fedid 
 Identity    
2. Name   name 
ident 
3. Sex M male F female  
sex 
4. 
Date of birth 
Birth decade estimate 
<1910 1910-19 1920-29 1930-39 1940-49 1950-59 1960-69 1970-79 1980-89 1990-99 
 
birthest 
birthmm 
birthyear 
B C D E F G H I J K 
5. Name of mother   
idmoth 
 
if alive elsewhere, name head of 
HH and village 
HH: vge.: Alive  Died 
in year: 
mothvita 
mothdyr  
6. Name of father   
idfath 
 
if alive elsewhere, name head of 
HH and village 
HH: vge.: Alive  Died 
in year: 
fathvita 
fathdyr  
7. Village of birth   
bvil 
        
 Household and Residence  
 
8. Current Household   Namehdhse 
 
10. Current Village   
currvll 
11. GPS South                       S  GPS East                       E   gpssdeg 
gpsedeg 
 Additional identifiers 
 
12 
Have you been known by any other names in the past? 
  
13 Specify previous contact: LEP1 LEP2 HC Control HH year:  
 
14 Name HH & village or HC where last seen:  
 
15 If not seen before, why? born after LEP’s unknown    
 
 came from:   in year:  
 
16 
List siblings alive in Karonga 
If no siblings are known alive in Kga.: List other members of the HH where last seen 
tick if 
same: mother father 
 (1)    
 (2)    
 (3)    
 Field staff code…………… Coder…………….. Checker……………………. Date…………… 
Rcdr 
Codr 
Chkr 
recdate 
 
 
Version 11d  30/10/2008                                        form entry   a  _____      b  _____      ident entry    a  _____     b  _____. 
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Fill in the non-marked sections 
for non-study samples only 
 
GSP - SPECIMEN FORM – KPS (One form per specimen)  
  
1a. Name   name ident 
1b. Initials only     
2. Sex M male F female  sex 
3. 
Date of birth     or 
Birth decade estimate 
<1910 1910-19 1920-29 1930-39 1940-49 1950-59 1960-69 1970-79 1980-89 1990-99 
  B C D E F G H I J K 
4. Name of mother    
5. Head of household    
6. Village    
7. Study number   
studyno 
8. Set (first) number + Specimen number   
specset 
specno 
9. Where collected    hccode 
10. Accompanying form  the form that this specimen form belongs to – this might not be the form that it is returned to the lab with  accform 
11. TB SPECIMENS ONLY if sputum is collected for both TB work and bacteriology then fill 2 specimen forms, one for each test   
11a. C   CSF  P   pleural fluid W   needle aspirate (Washing)  
F    fresh/frozen lymph node biopsy  S   sputum Z   needle aspirate (Z-N slide) 
H    formalin lymph node biopsy  U   pus                  other (specify) ………………… 
N   needle aspirate (unspecified)  
 
 
 
 
spectype 
11b. Reason  1  suspect      2  TB admission  3   scheduled review  2  4  6  mo  4  Other ………………….   reascoll 
monthsrev 
11c. 
      TB lab no.  
 
tblabno 
12.. OTHER SPECIMENS ONLY   
12a. Collection Reason: HSS HIV Sero-survey                     THI    TB HIV Immunlogy (incl control fup) 
ART    ART cohort LEP Leprosy Suspect                     TBX  TB Case only 
BIB BCG Immunology Baby PSU Paediatric Cohort                    TXI TB case &  immunology 
BIM BCG Immunology Mother  PVC Pneumo carriage study           TBO TB Control only 
EUI      EU Immunology                             ROP Regular Outpatient                  TOI TB control &  immunology 
ESC     EU sick control                              GSC     Gates sick control                 THP Gates follow-up (TB case) 
GBS     Group B strep study                      FED     Filariasis study                       LIS Long term infection                                                                                                                                  
 
 
 
Baseline 
Followup  
reascoll 
 
 
 
 
basefoll 
 
 Is this a repeat sample? Y  N 
 
Rptsample 
12b. Specimen type: Refrigerate 
C  Fresh Stool M  Cheek cell swab V  Saliva 
D Naso-pharyngeal aspirate N  Serum  W  Per nasal swab 
E  EDTA blood P  Paxgene U   Fresh Urine 
G  Sputum  (bacteriology)                R  Fluid (including CSF)           Other __________ 
T Throat swab 
Specimen type: Ambient 
A    Finger prick 
I     EDTA immunology 
H    Heparin blood  
L     Blood culture 
J     Skin smear 
 
 
spectype 
 
12c. 
12d 
12e. 
 Volume  
 Cord blood 
 Finger-prick taken 
 
ml 
Y N 
Y N 
vene 
cordblood 
fpind 
12f.   Lab no.  labno 
12g. 
Tests required; if not specified by study______________________________________________________  testreq1/2/3 
13. Post counselling required Y N postcoun 
14. If female, pregnant? (relevant for prescribing) Y N preg 
15. Date collected   Time produced   Time refrigerated/preserved       Staffcode     
dt/timecol 
timepres 
staff 
16. Date received    Time received in lab       Staffcode receiver     Checker     
dateinlab  
labstaffco 
checker 
 
Version 1 (27/01/2009) 
LF HIV consent form (english) 
Page 2 of 2 
KARONGA PREVENTION STUDY 
 
WELLCOME TRUST LEPRA 
PO Box 46, Chilumba (tel:08 263001) 
 
 
Consent Form for HIV testing in the Filariasis study:  
 
The Karonga Prevention Study is carrying out a study to determine the best dosage and 
schedule for the control of lymphatic filariasis. From research studies done on Malaria there 
is evidence that suggests impairment in clearance of malaria parasites following efficacious 
treatment in HIV infected individuals. It is plausible that this may also happen with LF. The 
KPS is therefore planning to investigate this in the current study   
 
1. WHY ME?  
You are being asked to give consent to have an HIV test as you have accepted to participate in the 
LF dosage study being undertaken by the KPS.  
2. WHAT IS KPS TRYING TO LEARN?  
As mentioned above KPS would like to find out how HIV affects clearance of microfilaria following 
treatment. Our current scientific knowledge suggests that HIV interfers with clearance of malaria 
parasites following therapy. It is possible that this might also happen in filariasis. This has not been 
tested before anywhere in the world. The results of this study will help the Malawi Government and 
others (with high HIV prevalence and endemic for filariasis) in deciding the best approach for the 
control filariasis. 
3. WHAT WILL IT MEAN TO TAKE PART?  
If you agree to have an HIV test, we will take a blood sample at the same time as we test for LF.  Your 
HIV as well as LF result will be given to you on the spot. If you are HIV positive you will be referred to 
Kaporo ART clinic for staging and further management 
6. WHAT ARE THE BENEFITS OF THIS PART OF THE STUDY?  
You will know your HIV status. If you have HIV we will counsel you on how to look after yourself 
and keep strong, as well as how to prevent passing HIV on to other people. We will also refer you 
to Kaporo ART clinic where you can find out whether you need treatment.  
 
7. IS THERE ANY RISK TO BEING IN THE STUDY?  
Taking a blood sample may cause a little pain but this will soon go away. You may be worried about 
knowing you HIV status, but our trained counselors can help with this.  
8. WHAT IF I DO NOT WANT TO TAKE PART?  
You participation is voluntary. You are free to choose to be tested for LF only, or choose not to 
participate at all. 
9. WHO WILL SEE THE INFORMATION THAT WE COLLECT?  
Information about your HIV and treatment status is confidential. We will conduct interviews in 
private, we will not record your name on confidential information, and we will keep your records 
secure. KPS will tell the Government and local health services what they find, and will also publish 
these findings as scientific papers, but they will never let people know your name. 
Version 1 (27/01/2009) 
LF HIV consent form (english) 
Page 2 of 2 
We would like you to answer the following to see if you will participate: 
 The information has been read to me; I have had the opportunity to ask questions, and 
my questions have been answered satisfactorily. I understand that the information about 
HIV and access to care services is confidential and I understand that I can withdraw from 
the study at any time.  
 
1 I AGREE voluntarily to take part in this study.                      (Yes, No) Y  N 
consent 
 
I understand that I will have blood taken for HIV and LF testing by KPS. The results of 
the test will be confidential.  
 
 
 
3 I AGREE to have blood taken for HIV testing.    (Yes, No) Y  N 
consbl 
4 I WANT to know the result.                                                  (Yes, No) Y  N 
wantres 
 
 
 
 
 
 
 
(Signature/thumbprint of participant)  
counsellor signature 
 
 
 
 
 
   rcdr.........      .......codr                   chckr 
 
Version 1 (27/01/2009) 
I:\forms\general forms\rtr_ rapid test result form version 5  
 yellow 
    Fill in only the marked sections 
for laboratory testing 
RTF - RAPID TEST FORM – KPS 
Version 5a 
10/10/2008 
9. Date of interview  (DD/MM/YYYY)  
intdate 
10. Reason for form 
BIM    BCG Imm Mother      TBX    TB Case Only         FED   Filariasis 
HSS   HIV Serosurvey        TXI      TB Case & Imm      LIS     Latent TB 
EUI    EU Imm / ESC          TBO    TB Control only       PSU  Under 5s 
THI    TB HIV Imm.              TOI     TB Control &  Imm  PVC Pneumo vaccine 
TBR   TB Review sputum    TBF    TB Annual F’up        
 
Reasrt 
 
 
 
 
 
sex 
3a. Study number  
studyno 
3b. Specimen set number  
 specset 
    
 
 ARV and PROPHYLAXIS   
 
4a. Have you ever had an HIV test? Yes No Unknown 
Refuse                           
to answer 
Y N U R evertest 
4b. If yes, what was the result? Positive Negative Unknown 
Refuse                           
to answer 
P N U R testout0 
5. 
Have you ever been referred for ARV 
therapy? 
Yes No Unknown 
Refuse                            
to answer 
Y N U R Refever 
6a. 
Have you ever taken anti-retrovirals?  
(ARV, e.g. Triommune, Duovir, Nevirapine) 
Yes 
 
No 
 
Yes, Only during 
pregnancy 
Refuse                            
to answer 
Y N O R Arvever 
 If Yes 6b. When did you start taking ARVs?  (DD/MM/YYYY)  
Arvstart 
  6c. Do you still take ARVs? Y N  
Arvcurr 
  6d. If No,  when did you stop taking ARVs?  (DD/MM/YYYY)  
arvstop 
7a. Have you ever taken co-trimoxazole prophylaxis? Y N  Unknown  
cotriever 
 If Yes 7b. When did you start taking co-trimoxazole prophylaxis? (DD/MM/YYYY)  
cotristart 
  7c. Do you still take co-trimoxazole prophylaxis? Y N  
cotricurr 
  7d. If No,  when did you stop taking co-trimoxazole prophylaxis?           (DD/MM/YYYY)  
cotristop 
8a. Have you ever taken isoniazid prophylaxis?  Y N Unknown 
INHever 
 If Yes 8b. When did you start taking isoniazid prophylaxis? (DD/MM/YYYY)  
INHstart 
9. Informant Self / Other Relationship   relinform 
   
     
. RAPID TEST RESULTS      
10. Has the participant accepted testing?  (Z when Not Applicable) Y N  Z acceptrtr 
11. TEST 1 (Determine) Reactive Non-reactive Invalid R N I  testout1 
12. TEST 2 (Unigold)  
all R, al I, and only N where check digit is ) 
Reactive Non-reactive Invalid    (not done if test 1 is N) R N I  testout2 
13. RAPID TEST RESULT 
Positive  
(Both tests 
reactive) 
Negative  
(First test non-
reactive) 
Invalid  
(Both tests 
invalid) 
Discrepant  
(Any other combination, 
go to test 3: tie-breaker) 
P N I D Rtr1 
14. TEST 3 (Bioline)                Tie-breaker only for Discrepant results  
 
  Reactive Non-reactive Invalid R N I  testout3 
15. TIE-BREAK RESULT: 
Positive  
(2 out of 3 tests 
reactive) 
Negative  
(2 out of 3 tests 
non-reactive) 
Invalid  
(2 out of 3 tests 
invalid) 
Discrepant  
(Any other  
combination) 
P N I D Rtr2 
16. Date of testing  (DD/MM/YYYY)   
Rtrdate 
17a. 
17b. 
Was participant given result? 
Was participant referred to HIV clinical services? 
Y 
Y 
N 
N 
 
Rtrgiven 
refserv 
 Staff code  Lab staff code  Coder/Checker   
Rcdr labsc 
chkr  codr 
SEX 
 HSS & ABS consent form (english) 
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KARONGA PREVENTION STUDY 
 
WELLCOME TRUST LEPRA 
PO Box 46, Chilumba (te:08 263001) 
 
 
HIV SEROSURVEY & ADULT BEHAVIOUR SURVEY:  
KPS CONSENT FORM 
 
1. WHY ME?  
We are asking you to take part in a study being done by the Karonga Prevention Study (“LEPRA") to help 
improve the health of your community. The study is about HIV. 
 
2. WHAT IS HIV?  
HIV causes AIDS, but now there is free treatment called “antiretroviral (ARV) therapy”. The treatment helps 
people stay healthy for longer. 
 
3. WHAT IS KPS TRYING TO LEARN?  
Firstly, we would like to find out how many people are affected by HIV and whether this number is changing. 
Secondly, we want to find out more about the sexual behaviours that may put people at risk, and about whether 
and when people want to have children. Finally, we want to find out who needs treatment. This will help improve 
services for your community. 
 
4. WHAT WILL IT MEAN TO TAKE PART IN THE STUDY?  
If you are 15 years or older and agree to take part in our study, we will first ask you a few questions about 
marriage, other sexual relationship, your use of condoms, and your plans for children. Then we will discuss the 
HIV test with you, and what it means to know your result. If you agree to a test we will take a little blood 
from your arm. If you prefer we can do this with a finger-prick. If you want to know the result we will tell you 
immediately.  
Version 03b (01/07/2008) 
Date of interview __/ __ / ____ 
intdate 
Was subject present?    Y      N 
present 
hssstudyno 
(pink): 
 
 
specset 
(white) 
 
 
 Round 
rd 
 HSS & ABS consent form (english) 
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5. WHAT WILL HAPPEN TO MY BLOOD?  
We will take the blood sample to the laboratory so we can do further HIV-related tests at KPS to confirm 
your test result, and tell us more about the HIV virus, and another infection called HSV-2 that may be 
important in the spread of HIV in the community. If we understand HIV better then we can help stop the 
infection spreading, so even if you do not want to know the result of your HIV test we would still like a blood 
sample.  
We would also like to store your blood for possible later testing for other diseases related to HIV or of 
importance in Karonga District. Further testing will only be done if approved by the Malawi Ministry of Health. 
We will let you know if you could benefit from the results of these tests. You can choose at any time to have 
your stored blood destroyed. 
 
6. WHAT ARE THE BENEFITS TO BEING IN THE STUDY?  
There are many advantages to knowing whether or not you have HIV (your HIV status). If your test shows us 
you have HIV we will counsel you on how to look after yourself and keep strong, as well as how to prevent 
passing HIV on to other people. We will also refer you to the hospital where you can find out whether you need 
treatment – a trained clinician will help you there. Not everyone needs treatment immediately; but for pregnant 
women this is especially important, as there is also treatment to help prevent their babies from getting HIV. 
If you do not have HIV you will have more reason to take care and remain negative.  
 
7. IS THERE ANY RISK TO BEING IN THE STUDY?  
Taking a blood sample may cause a little pain but this will soon go away. You may be worried, but our trained 
counselors can help. We strongly encourage everyone to be tested, since knowing the results can help them 
protect themselves and their partners from infection, and also help them plan for their own and their families’ 
future.  
 
8. WHAT IF I DO NOT WANT TO TAKE PART?  
The choice is yours  
 
9. WHO WILL SEE THE INFORMATION THAT WE COLLECT?  
Information about your HIV and treatment status is confidential. We will conduct interviews in private, we 
will not record your name on confidential information, and we will keep your records secure. KPS will use the 
information to find out more about HIV and tell the health services what they find, but they will never let 
people know your name. 
 
10. SUPPORT AVAILABLE FOR PEOPLE AFFECTED BY HIV/AIDS  
We will talk to you about support available for you and your family regardless of what your results show. Your 
KPS counsellor can also tell you about local HIV/AIDS prevention, care and support activities and where you 
can find help locally. If you want an HIV test but not as part of our study you can go to Chilumba Rural Hospital 
VCT Centre; people who are HIV positive will also be seen there by a trained medical professional at Mwabi 
Clinic who will ensure you have the necessary care. Staff at the VCT centre and at Mwabi will tell you what to 
do next. Ask your counsellor or telephone us if you want to find out more. 
 
 
 
 
 HSS & ABS consent form (english) 
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We would like you to answer the following to see if you will participate: 
 The information has been read to me; I have had the opportunity to ask questions, 
and my questions have been answered satisfactorily. I understand that the 
information you collect is confidential and I understand that I can withdraw from 
the study at any time without it affecting my right to appropriate medical care.  
 
1 I AGREE voluntarily to take part in this study.                        (Yes, No) Y  N 
consent 
 I understand that, I will be asked about marriage, other types of sexual 
relationship, my use of condoms, and my plans for children so that KPS can find out 
more about the behaviours that put people at risk of becoming infected. The 
answers are confidential. 
 
2 I AGREE to take part in the KPS behavioural study.                 (Yes, No,  Ineligible) Y  N  I 
consbeh 
 I understand that I will have blood taken for HIV and related testing by KPS. The 
results of the test will be confidential.  I understand that I can choose whether I 
am told the result. If I am found to be HIV positive I understand that I will be 
helped further and will receive treatment if necessary.  
 
 
 
3 I AGREE to have blood taken for HIV and related testing.      (Yes, No) Y  N 
consbl 
4 I WANT to know the result.                                                     (Yes, No) Y  N 
wantres 
 
I understand that my blood will be stored for possible later testing for other 
diseases related to HIV or of importance in Karonga District. I understand that 
further testing will only be done if approved by the Malawi Ministry of Health, and 
that I can choose at any time to have my stored blood destroyed.  
 
5 I AGREE to my blood being stored for later testing                        (Yes, No) Y  N 
consblstore 
 
Crsno: 
 
repgp cluster hhlistno member visitor 
Name: 
 
Sex: 
 
ident 
 
 
 
 
 
 
 
(Signature/thumbprint of participant)  
counsellor signature 
 
 
 
 
 
   rcdr.........      .......codr                   chckr 
 
If consent to give blood is refused ask the subject the main reason for refusal  
 
01 no reason    06  already tested & knows status 
02 family/community decision   07  thinks knows status 
03 confused/incapable of consenting 08 prefers clinis 
04 afraid of needles/fingerprick  09 does not think he/she is at risk 
05 afraid for other reasons  10 other 
 
Rsnbloo
d  
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 SEI – INDIVIDUAL SOCIO-ECONOMIC SURVEY – KPS              22/09/2010 Version 5 
1.1. Round  4 Interview Date     (DD/MM/YYYY)                                                                                                    
rd 
intdate 
1.2.  RG Sess: 
repgp 
sess 
 Identity 
 
1.3. GHHID      ghhid 
1.4. CRS number       crsnum 
1.5. Name:     name ident 
1.6. Sex M              F  Birth date  
sex 
birthdat 
birthyr 
1.7. Informant type Self Parent 1 spouse, sibling, child 2 
grandparent, grandchild,  
other relative Non-relative S P 1 2 N 
infmtype 
1.8. 
Name of informant 
(If Self, write Self) 
  informtid 
 
Current household 
 
1.9. 
Relationship to household 
head 
1 self   2 spouse 3 child   4 grand-child     5 niece/nephew     6 sibling     7 cousin    8 parent 
9 aunt/uncle       13 step-child           14 step grand-child    15 parent-in-law    16 grandparent 
10  family friend    11  other relative  12   other non-relative 
 relhh 
1.10. Was subject seen?  Y      N seen 
1.11. When was (s)he last here? 0 today 1 yesterday 2  in last 7 days 3 in last 4 wks 4 more than 4 wks ago  when 
 Parents survival status and education (ask only of individuals aged ≤30 years old)  
1.12. 
Is your father alive? 
If no, when did he die? 
Y        N        DK 
Is your mother alive? 
If no, when did she die? 
Y        N        DK 
fathvita 
mothvita 
1.13. Year died Year died 
fathdyr 
mothdyr 
1.14. 
Did your father go to school? If yes, 
highest level attended  by father 
None  Prim  Sec   Tert   
Unknown 
Did your mother go to school? If yes, 
highest level attended by mother 
None  Prim  Sec   Tert   
Unknown 
fschltype 
mschltype 
 
 IF SUBJECT IS AGED UNDER 5 YEARS THEN SKIP → Q39,   IF SUBJECT IS AGED 5-11 THEN SKIP → Q22 
 
 
 
 Marital Status (ask only if aged 12+ years old)  
1.15. N never married   M married  D  divorced/septd   W widowed      If never married skip→ Q22 marital 
1.16. How many spouses do you have now?   spousenum 
 Spouses 
For individuals who are currently married, use Columns 1-4 to contain information on current spouses. 
For individuals who are divorced/separated, use Column 1 for the most recently divorced/separated spouse. 
For individuals who are widow(er)s, use Column 1 for the spouse who died most recently. 
For individuals who are divorced/separated, or widowed, fill Q17 (name), Q18 (NA if widowed), and Q20. Fill Q19 (the spouse CRS number) only 
if the spouse was previously seen in the CRS in this household. 
 
  Column 1 Column 2 Column 3 Column 4  
1.17. Name     spname1-4 
1.18. Residency in CRS 
area 
Y      N      DK      NA Y      N      DK Y      N      DK Y      N      DK sparea1-4 
1.19. crsno     spcrsno1-4 
1.20. 
Year marriage 
start and end 
Start End Start Start Start spmarstrt1-4 
spmarend1-4 
1.21. ident      spident1-4 
 
 Fill spouse ident in office - use GP form for current spouse if  not co-resident and not in CRS area, and attach  (tick)   
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 Education and Occupation and Economic activities  
1.22. Have you ever been to school?                                                            Never        Ever     Current  schlever 
1.23. What is the highest level of education attended?  Prim          Sec      Tertiary form/standard  
schltype 
schlstd 
1.24. What is your main occupation? 
(Specify occupation with a salary or if unsalaried the occupation with most income) 
Emp Occ emp 
occ 
 Ask Q25-26 only of individuals aged 5-20 years old  
1.25. 
During the last 4 weeks, did you participate in any economic activities?  
For example farming, fishing, gathering natural products, piece work, preparing and selling food or beverages, selling goods manufactured 
by this household, providing a service? 
Y    N hhecyn 
1.26. If yes, which ones? (record the two most important activities, in order of importance) 
ec1 ec2 ecactivity1 
ecactivity2 
 
For individuals >30 years old, skip → Q46.           For individuals who have never been to school (Never), skip →Q46 
For individuals who have been to school, but are not currently enrolled in school (Ever), skip →Q27 
For individuals who are currently enrolled in school, skip → Q28 and then continue with Q29-38 
 
1.27. 
What is the reason that you left school?   (record the two most important reasons, in order of importance) 
Do not read out possible answers. Record the reasons given, without "prompting".   
Now continue with Q28-Q30  
rsn1 rsn2 
rsnleft1 
rsnleft2 
1.28. What is the highest educational qualification you have acquired?   edqual 
1.29. Age, or year, first started primary school  (age) (year) don’t know 
aschstart 
yschstart 
1.30. Age, or year, left school (Z if still in  school) (age) (year) don’t know Z 
aschleft 
yschleft 
 Now ask Q31-38 if individual is currently enrolled in school.   If not currently enrolled in school,  skip → Q37  
1.31. Name of school     schlname 
1.32. Who are the fees primarily paid by? 
1 parent/step-parent   2 aunt/uncle   3 Sibling   4 Grandparent    5 Other relative     
6  Non-relative   7  Organisation    8    Not applic     9   DK   10  Self   11 Government 
 feespaid 
1.33. 
Have you attended school during the last 4 weeks that your school was in session? Y     N schlattd 
schlday 
schlwk 
If yes: During the last 4 weeks that your school was in session, how many school days / weeks did you miss? 
(now skip   →  Q35 if 0 days missed. If has not attended school in last 4 weeks must still ask Q34) 
days wks 
1.34. 
What were the 2 most important reasons that you missed school,  
during the last 4 weeks that your school was in session? 
rsn1 rsn2 rsnattd1 
rsnattd2 
1.35. At any time in the last 12 months, did you ever miss >2 weeks of school at one time (consecutive)? Y      N schlbrk 
1.36. Have you attended your current standard/form before? If yes, how many times (including this year)? Y     N  
cstdrep 
cstdnum 
1.37. Did you ever leave school for at least 12 months, and later return? Y      N schleave 
1.38. 
If yes  
(to Q37): 
Age first left  
Form / Standard when first left: 
Number of years absent: 
P  S   T    _______ Reason  
first left 
 
leftage 
lefttype 
leftstd lftyrs 
;eftrsn (years) 
1.39. Vaccine history for children <5 years old.   If 5+ years old,  skip →Q46 Health passport available? Y      N cardseen 
 Vaccines recvd. Vacc. date Vacc. HC   Vacc. date Vacc. HC  
1.40. BCG Y    N   Polio0 Y    N   
bcgdate 
p0date 
1.41. Penta1 Y    N   Polio1 Y    N   dpthh1date p1date 
1.42. Penta2 Y    N   Polio2 Y    N   dpthh2date p2date 
1.43. Penta3 Y    N   Polio3 Y    N   dpthh3date p3date 
1.44. Measles Y    N   No of doses Vit A  Measdate vitados 
1.45. Record dates of the first two doses vit A  1st 2nd Vitadat1 Vitadat2 
 Health and Caring (ask of individuals aged  > = 10   years old)  
1.46. 
During the last 3 months, for how many days/weeks have you cared for a sick adult (aged 15 or above) at home or at a health facility? 
(record in EITHER days or weeks, but not both) 
(days) (weeks) 
sdaycare3 
sweekcare3 
1.47. 
During the last 3 months, for how many days/weeks have you been unable to work and/or attend school due to your own illness?  
(record in EITHER days or weeks, but not both) 
(days) (weeks) 
illdays 
illweeks 
 Clothing expenditure (money spent by this household on clothes and shoes, including school uniform. Gifts not included)  
1.48. 
Over the last 12 months, how much money has been spent on 
clothing for you? 
0   K 0          1   K 1-500          2   K 501-1000       3   K 1001-2000 
4   K 2001-5000       5   K 5001-10000      6   K >10000        7   DK 
 clothexp 
1.49. 
Over the last 12 months, how much money has been spent on 
footwear for you? (incl. slippers) 
0   K 0          1   K 1-250          2   K 251-500         3   K 501-1000 
4   K 1001-2000       5   K 2001-5000        6   K   >5000        7   DK 
 shoesexp 
1.50. Mass drug treatment for worms: Did you receive tablets for filariasis during the mass treatment campaign in Oct/Nov2009? 
 
Y  N  U massfila 
1.51. Measles – ask if >8months &<15 years old: Did you receive measles vaccine during the mass vaccine campaign in 2010? Y  N  U massmeas 
1.52. TB case finding, if individual is seen:  do you have a cough? Y      N Duration of cough (weeks)  cough couweeks 
1.53. Haemoptysis? Y    N If cough >3 weeks / haemoptysis / TB suspect on other grounds fill GP form and collect sputum 
tbsuspect 
Y      N 
haemopt 
tbsuspect 
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END Field-Staffcode             Coder /L1 Checker   
rcdr 
codr,chkr 
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Abstract
Background
Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health
problems. Individuals may be co-infected, raising the possibility of important interactions be-
tween these two pathogens with consequences for LF elimination through annual mass
drug administration (MDA).
Methodology and Principal Findings
We analysed circulating filarial antigenaemia (CFA) by HIV infection status among adults in
two sites in northern Malawi, a region endemic for both LF and HIV. Stored blood samples
and data from two geographically separate studies were used: one a recruitment phase of a
clinical trial of anti-filarial agent dosing regimens, and the other a whole population annual
HIV sero-survey. In study one, 1,851 consecutive adult volunteers were screened for HIV
and LF infection. CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% (351/
1487) in HIV-negative participants (p=0.57). Geometric mean CFA concentrations were
859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean ratio
(GMR) 0.85, 95%CI 0.49-1.50. In 7,863 adults in study two, CFA prevalence was 20.9%
(86/411) in HIV-positive and 24.0% (1789/7452) in HIV–negative participants (p=0.15).
Geometric mean CFA concentrations were 630 and 839 Ag/ml respectively (GMR 0.75,
95%CI 0.60-0.94). In the HIV-positive group, antiretroviral therapy (ART) use was associat-
ed with a lower CFA prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95%CI
0.24-0.76). Prevalence of CFA decreased with duration of ART use, 15.2% 0-1 year (n=59),
13.6% >1-2 years (n=44), 10.0% >2-3 years (n=30) and 0% >3-4 years treatment (n=9),
p<0.01 χ2 for linear trend.
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Conclusions/Significance
In this large cross-sectional study of two distinct LF-exposed populations, there is no evi-
dence that HIV infection has an impact on LF epidemiology that will interfere with LF control
measures. A significant association of ART use with lower CFA prevalence merits further in-
vestigation to understand this apparent beneficial impact of ART.
Author Summary
Lymphatic filariasis (LF) and HIV are both major public health problems worldwide and
where they co-exist have the potential to interact. The main strategy for LF elimination is
annual mass drug administration (MDA). A particular concern is whether HIV, through
its impact on the immune system, will interfere with the effectiveness of this approach to
control and eliminate LF. We report findings from cross-sectional studies in two separate
populations in northern Malawi where both HIV and LF are common. One group (1,851
individuals) were studied at enrolment into a trial of anti-LF treatments, whilst the other
study used samples stored from adult participants in a whole population HIV survey
(7,863 individuals). Between 5–10% of the study participants were HIV-positive and 24%
were LF-infected. We found no evidence that LF infection was more or less common in
HIV-positive adults in either population. However, we identified robust evidence that an-
tiretroviral therapy use was associated with lower LF prevalence rates. We have no evi-
dence to suggest HIV will have a detrimental effect on LF control. On the contrary, the
evidence suggests that antiretroviral therapy may have beneficial effects and merits further
careful evaluation of the anti-filarial properties of these compounds.
Introduction
Human immunodeficiency virus (HIV) and parasitic infections affect widely overlapping pop-
ulations in sub-Saharan Africa. Of the estimated 35 million people infected with HIV world-
wide at the end of 2013, about 70% were from sub-Saharan Africa [1]. Parasitic infections,
including lymphatic filariasis (LF) are also widespread in sub-Saharan Africa, raising the possi-
bility of clinically significant interactions between the two pathogens. It has been suggested
that HIV and parasitic co-infections may have bidirectional deleterious interactions by affect-
ing susceptibility to HIV, impacting on HIV progression and potentially worsening clinical
outcomes of filarial infection [2]. Previous in-vitro studies have shown helminth infections to
increase susceptibility of peripheral blood mononuclear cells to HIV infection [3]. In addition
deworming can result in increases in CD4+ cells and reduction in plasma HIV-1 RNA concen-
trations [4]. Derangements in the immune response associated with HIV-infection might also
be expected to alter susceptibility to, or complications from, filarial infection or other hel-
minths such as Strongyloides [5]. To date, there are few studies that have investigated LF and
HIV co-infection and to our knowledge, none have been on a large population scale. A cross-
sectional study of 907 adults undertaken in Tanga region of Tanzania reported increased circu-
lating filarial antigen (CFA) concentration in HIV-positive persons [6], although a further eval-
uation of this group of individuals did not support any association between HIV and
Wuchereria bancrofti infection [7]. Similarly, in urban southern India, no quantitative differ-
ence inW. bancrofti CFA levels by HIV status was found in a study of 432 HIV-positive and 99
HIV-negative patients [8].
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Malawi embarked on a programme of mass drug administration (MDA) for LF control and
elimination in 2009 [9]. Concerns that the programme may be less effective in areas of high
HIV and LF prevalence prompted this study in Karonga, a district in the northern region of Ma-
lawi which was known to be highly endemic for LF infection [10]. Karonga is bordered by Lake
Malawi to the east, the Songwe river to the north (which also forms the boundary with Tanza-
nia), and by the Nyika plateau and escarpment to the west and south. The population is rural
and dependent on subsistence agriculture including rice growing and fishing from the lake.
Two previous studies had been undertaken by co-authors in the district and both had serum
samples stored with approval for later testing. The first was the recruitment phase of a rando-
mised controlled clinical trial that investigated alternative schedules and dosing regimens of
ivermectin and albendazole use in MDA programmes (study 1). Findings from this clinical
trial are reported elsewhere [11]. The second study was nested within a comprehensive
population-based HIV survey which enabled a longitudinal assessment of CFA in a whole
adult population (study 2). In this paper we report the prevalence and relationship of LF and
HIV infections from these two studies.
Methods
Study 1 used samples and data collected as part of the screening phase of a clinical trial of the
effectiveness of increasing the dose and frequency of albendazole and ivermectin as antifilarial
agents for clearing LF microfilaraemia (clinical trials registration number NCT01213576) [11].
It was undertaken between January 2009 to March 2012 in the northern portion of Karonga
district along the Tanzanian border and Songwe river delta. Villages in this area had previously
been shown to have a high prevalence of filarial antigenaemia and chronic manifestations of LF
[10]. No mass treatment interventions had been undertaken in the area at the time the study
was started.
Enrolment to the clinical trial required individuals to have a microfilarial count of>80
microfilariae per ml of blood. Consequently a population-based screening process was under-
taken to identify suitable participants for enrolment in the therapeutic trial. The estimated total
adult population of the target villages was 36,643 [12]. Sensitization meetings were held with
community members, the Traditional Authority (TA) and all the village headmen and their
aides who are administratively responsible for the study area. At these meetings the aims and
procedures of the study were explained. Following verbal approval by the community leaders, a
team of field workers went house-to-house seeking written consent and recruiting individual
participants. All households in selected villages were visited in sequence before moving on to
the next village. This screening phase was planned to continue until 120 eligible individuals
with appropriate microfilarial levels were recruited into the trial. However, screening and re-
cruitment into this study was discontinued following the rollout of the albendazole/ivermectin
national MDA programme in the study area as further recruitment into the clinical trial be-
came impractical. At the end of the recruitment phase individuals from 16 villages were includ-
ed. For analysis purposes smaller villages were combined in a geographically appropriate way
to produce 10 village location categories with suitable numbers of participants.
Individuals were eligible if they provided written informed consent, were residents of the
area and aged between 18 and 55. At each home visit, the study was introduced and explained
to all members and individual participants were asked to provide written informed consent by
signing (or thumb printing if they were illiterate) the informed consent forms that were translat-
ed in the local language (Tumbuka). A questionnaire was administered to capture personal de-
tails. Eligible individuals were screened for CFA by the immunochromatographic (ICT) card
test and for HIV by trained counsellors following the national HIV rapid testing algorithm.
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CFA positive individuals were asked to provide a night blood sample between 22:00 and 02:00
hours when a 5ml sodium citrate sample was collected for microfilaria counting and later stored
in the project laboratory archive at -20°C. All individuals who were CFA positive but declined to
participate in the clinical trial or did not meet the eligibility criteria for the trial were offered
standard dose antifilarial therapy with albendazole and ivermectin. Individuals who were HIV
positive were referred for HIV treatment and care. Assessment of HIV clinical stage, CD4 count
and viral load were not performed on these individuals as a part of the study protocol.
Study 2 used samples and data from an annual whole adult population survey. Repeated
rounds of data and sample collection spanned the time periods before and after the introduc-
tion of MDA. It was undertaken in the Karonga Health and Demographic Surveillance Site
(KHDSS) and nested within a comprehensive population-based HIV sero-survey [13]. The
KHDSS area is mapped and divided into geographically defined clusters of 20–30 households
which are further aggregated into 21 geographically distinct reporting groups. The KHDSS was
established between August 2002 and August 2004 to serve as a sampling frame for on-going
epidemiological and clinical studies. Unlike study 1, data from study 2 included detailed socio-
demographic information allowing for inclusion of these factors in statistical analysis. Since its
establishment, the initial population of the KHDSS has been under continuous demographic
surveillance. In addition, between September 2007 and October 2011 four annual HIV serolog-
ical surveys have been conducted in all individuals aged 15 or more years using rapid point-of-
care HIV tests on finger-prick whole blood samples [14]. Community sensitisation meetings to
explain the aims and procedures of the study were held in each village and were followed by
house-to-house visits by counsellors to recruit participants. The counsellors were trained and
certified by Malawi Ministry of Health staff to perform HIV counselling and testing and refer-
ral using standard procedures [15]. Written informed consent was obtained as in study 1. In
addition, all consenting adults were asked to provide a 5ml blood sample for quality control
and storage for further laboratory analysis including for other diseases of importance in Kar-
onga district. Plasma samples from consenting participants were stored in the project laborato-
ry archive at -20°C. Samples from the first surveillance round, which took place between
September 2007 and October 2008, prior to MDA introduction, were included in our study.
Viral load, CD4 counts and clinical staging were not measured as a part of the survey.
Common laboratory methods for both studies
The ICT card test (Binax, Portland, ME) [16] was only used as the screening test for LF infection
in study 1. This is a portable rapid point-of-care test suitable for screening in non-laboratory
settings and was used in accordance with manufacturer’s instructions. Microfilaria counting
was done on ICT card test positive individuals in study 1 by the nucleopore membrane filtration
technique [17]. This involves filtering a measured volume of venous blood through a 5μM pore
size nucleopore filter. After filtration, the filter is removed, placed on a glass slide and mounted
on a light microscope for examination and counting of microfilariae. Filarial antigenaemia was
quantified in all plasma samples in both study 1 and study 2 by means of the Og4C3 antigen-
capture ELISA (TropBio, Australia) [18]. Samples were analysed in accordance with the manu-
facturer’s instructions and expressed as antigen units per ml of blood (Ag/ml) based on control
samples supplied with the ELISA kits. Samples with CFA concentration more than 128Ag/ml
were considered clear positives for CFA. Samples with CFA concentration of 32Ag/ml and
below were considered negatives. Samples with a titre between 32 and 128Ag/ml were consid-
ered indeterminate.
In both studies HIV testing used whole blood rapid diagnostic tests according to Malawian
national guidelines [15] with demonstrated high accuracy in community settings in Karonga
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[14]. The initial screening test was with Determine TMHIV-1/2 (Abbott Japan Co Ltd, Japan)
and confirmatory testing was done with UniGold TM HIV-1/2 (Trinity Biotech PLC, Ireland).
Samples with a non-reactive screening test were considered negative and those with a reactive
screening and confirmatory test were considered positive. Where the screening and confirma-
tory tests were discordant, a tie breaker using a third rapid test, (SD Bioline, Korea) was used.
Common data management and statistical methods for both studies
Study forms were checked, coded, double entered and verified using Microsoft Access software.
Statistical analysis was done in Stata 12 software (StataCorp, Texas, USA). Continuous vari-
ables were log transformed prior to analysis to achieve an approximate normal distribution.
Linear regression was used for crude and adjusted analyses with results expressed as geometric
mean ratios (GMR) and their 95% confidence intervals. The association of age, gender and
CFA status with HIV positivity was estimated using χ2 tests for crude analyses and a logistic re-
gression model for adjusted Odds Ratios (OR). In a risk factor analysis for CFA positivity, lo-
gistic regression was used to estimate crude and adjusted ORs. Variables were retained in the
model if significant associations were identified in the unadjusted estimates. Geographic identi-
fiers for groups of survey villages were also incorporated in the models to adjust for geographic
confounding as previous surveys had indicated heterogeneity of CFA prevalence across the re-
gion [19]. Rather than a binary variable, HIV was treated as a categorical variable in the model
with the HIV—negative group and two HIV-positive groups based on ART use at the time of
blood sampling. A sub-group analysis to investigate the effect of cotrimoxazole and duration of
ART use on CFA prevalence was performed on the HIV-positive group only. Logistic regres-
sion models were used to estimate odds ratios. Difference in CFA prevalence with increased
use of ART was investigated with a χ2 test for linear trend with odds ratios derived from a 2xn
table. Adjusted odds ratios were estimated with logistic regression.
Ethics
The National Health Sciences Research Committee of the Malawi Ministry of Health (protocol
numbers 495 and 419) and the Ethical Committee of the London School of Hygiene and Tropi-
cal Medicine (protocol numbers 5344 and 5081) gave ethical clearance for both studies 1 and 2.
Study participants in both studies were consented for storage and later testing of samples at the
time of enrolment. This covered testing for HIV and other diseases of local significance. The
National Health Sciences Research Committee (protocol number 908) and the Ethical Com-
mittee of the Liverpool School of Tropical Medicine (protocol number 11.77) approved the ad-
ditional analysis conducted on stored samples.
Results
The overall population of Karonga district during the study period was 272,789 [12] with the
KHDSS population accounting for 33,500. HIV prevalence in the KHDSS in the 2007–2008
survey year was measured at 7.4% but estimated to be 10.4% when adjusted for non-testing by
those who already knew they were HIV-positive [20]. At baseline 54.8% of those aged 15 years
or more reported previous HIV testing.
Study 1
From the estimated total of 36,643 adults of the target villages, 1,851 individuals were eligible
and consented to participate. Of these 1,851 individuals screened for LF antigen by the ICT
card test, 447 (24.2%) were CFA positive (Fig 1). A total of 1,656 individuals accepted HIV
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testing and 169 (10.2%) of these were HIV-positive. HIV-positive individuals tended to be
older (Table 1). CFA positivity was present in 43 (25.6%) of HIV-positive and 351 (23.6%) of
HIV-negative (crude OR 1.11, 95% CI 0.77–1.60) with an LF/HIV co-infection prevalence rate
of 2.6%. CFA positivity did not differ by HIV infection status (Table 1). There was heterogene-
ity in the prevalence of CFA by village location, median 24.4%, range 15.7–33.3% (Pearson χ2
22.7, p<0.01, 9 degrees of freedom). Data on the use of antiretroviral and cotrimoxazole was
incomplete in the context of this study.
Microfilaria counting was done in the 311 (69.6%) LF antigen positive individuals who were
eligible and gave consent for night blood sampling. The remainder either refused or left before
follow up. HIV prevalence in those lost to follow up was broadly similar to those sampled
(10.3% vs. 9.3% respectively, χ2 test p = 0.90). Microfilariae were present in 49.5% of the 311
sampled individuals. Microfilarial detection and levels did not differ by HIV infection status
(Fig 1 and Table 1).
Of 311 stored baseline night blood plasma samples, 290 (93.2%) were CFA positive using
the Og4C3 antigen-capture ELISA. CFA was positive in 26 (89.7%) of HIV-positive individu-
als, 231 (93.9%) of the HIV-negative individuals and 33 (97.1%) of HIV-unknown individuals
respectively (p = 0.47). The geometric mean CFA concentration levels by HIV status were 859
and 1660 for HIV-positive and HIV-negative respectively (GMR 0.85, 95% CI 0.49–1.50). CFA
and MF counts showed reasonable positive correlation (Pearson correlation coefficient
r = 0.56, p<0.01).
Fig 1. Study 1 flow chart detailing the breakdown of individuals by HIV status, circulating filarial antigen (CFA) status by immunochromatographic
card (ICT) test andmicrofilarial counts. *2 individual had an invalid ICT test. MF—microfilaria.
doi:10.1371/journal.pntd.0003825.g001
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Study 2
The total eligible population of 15 year olds and older in the KDHSS at the baseline survey was
11,756. From this group, 7,863 (66.9%) underwent HIV testing and consented to storage of
their blood sample. Of these, 1,875 (23.9%) individuals were CFA positive by the Og4C3
ELISA. HIV infection was identified in 411 (5.2%) participants. HIV-positive adults tended to
be older and more likely to be female (Table 2). CFA positivity was present in 86 (20.9%) of
HIV-positive and 1789 (24.0%) of HIV-negative (crude OR 0.84, 95% CI 0.66–1.07) with an
HIV/LF co-infection prevalence rate of 4.6%. In the female participants, CFA positivity was
present in 17.8% of the HIV-positive and 19.8% of the HIV-negative (OR 0.88, 95% CI 0.64–
1.21) and in the male participants, 26.8% of the HIV-positive and 29.4% of the HIV-negative
(OR 0.88, 95% CI 0.60–1.28) respectively. Geometric mean CFA concentration was lower in
the HIV-positive individuals by 25% although this association was weakened when adjusted
for age and sex (Table 2).
Several risk factors were associated with an increased prevalence of CFA (Table 3). These in-
cluded male gender, age between 30 and 39 and lower quality housing, whilst decreased CFA
prevalence was associated with higher levels of education (p<0.01, χ2 for linear trend) the
availability of piped tap water or the use of lake water and the use of antiretrovirals. Bed net
ownership was high, however ownership or the number of nets owned in the household was
Table 1. Baseline characteristics of Study 1 participants by HIV status.
A
Characteristic HIV-positive (n = 169) HIV-negative (n = 1487) OR (95% CI†) Adjusted OR (95% CI)#
Age group
18–29 years 43 (25.4%) 727 (48.9%) - -
30–39 years 68 (40.2%) 406 (27.3%) 2.83 (1.90–4.23) 2.83 (1.90–4.23)
40 years and above 58 (34.3%) 354 (23.8%) 2.77 (1.83–4.19) 2.69 (1.77–4.08)
Sex
Male 66 (39.0%) 618 (41.6%) - -
Female 103 (61.0%) 869 (58.4%) 1.11 (0.80–1.54) 1.14 (0.82–1.59)
CFA status
Negative 125 (74.4%) 1135 (76.4%) - -
Positive 43 (25.4%) 351 (23.6%) 1.11 (0.77–1.60) 1.13 (0.78–1.65)
MF status
Positive 17 (58.6%) 123 (50.0%) - -
Negative 12 (41.4%) 123 (50.0%) 0.71 (0.32–1.54) 0.81 (0.35–1.85)
B
Characteristic HIV-positive HIV-negative GMR (95% CI) Adjusted GMR (95% CI)#
CFA GMC Ag/ml (95% CI) 859 (231–3193) 1660 (1198–2302) 0.85 (0.49–1.50) 0.91 (0.55–1.51)
C
Characteristic HIV-positive HIV-negative P value
MF count, median (IQR), mf/ml 0 (0–22) 1 (0–93) 0.13
A) The association of age group, gender and circulating ﬁlarial antigen (CFA) with HIV positivity. Adjusted Odds Ratio (OR) derived from logistic
regression model. B) Geometric mean concentration (GMC) of CFA in those CFA positive. Geometric mean ratio (GMR) derived from linear regression
model. C) Microﬁlaria (MF) count in those CFA positive expressed as median and interquartile range, difference assessed by rank sum testing owing to
the skewed nature of data.
†CI—conﬁdence interval;
# adjusted for age, sex and village location
doi:10.1371/journal.pntd.0003825.t001
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not associated with CFA prevalence. Individuals were found in all 21 reporting groups, with a
median of 314 participants (range 129–820). There was considerable heterogeneity in the prev-
alence of CFA by reporting group, median 23.2% range 5.7–37.2% (Pearson χ2 354.7, p<0.01,
20 degrees of freedom).
Of the 411 HIV-positive adults, 142 (34.5%) were taking antiretroviral therapy (ART) and
117 (28.5%) were using cotrimoxazole prophylaxis (CTX) with only 4 of the 117 taking CTX
without ART at the time of sampling. In 6 of the 411 individuals, information on ART and/or
CTX use at the time of sampling was unavailable. ART consisted of Lamivudine, Stavudine and
Nevirapine (Triomune-30) in 94% of cases with Zidovudine or Efavirenz substitutions in the
remainder. No protease inhibitors were in use. In the HIV-positive group, ART use was associ-
ated with a lower prevalence of CFA when compared to those not on ART [12.7% vs. 25.3%
(OR 0.43, 95% CI 0.24–0.76)]. Similarly, CTX use was associated with lower CFA prevalence
[12.8% vs. 24.1% (OR 0.46, 95% CI 0.25–0.85)]. In a multivariable model incorporating ART
and CTX use along with age, sex and geographical location, the adjusted odds ratio for ART
use was 0.47 (95% CI 0.17–1.31) and for CTX use 0.92 (95% CI 0.31–2.71). When the ART
treated group were further sub-divided by year since treatment started, there was a significant
trend to decreased prevalence of CFA with increasing time on treatment; 25.3% no treatment
(n = 265), 15.2% year 1 treatment (n = 59), 13.6% year 2 treatment (n = 44), 10.0% year 3 treat-
ment (n = 30) and 0% year 4 treatment (n = 9), (p<0.01 χ2 for linear trend). This relationship
persisted after adjustment for age, gender and reporting group. In the HIV-positive individuals
with detectable CFA, the geometric mean concentration of CFA was not significantly different
between those off and on ART, 647 vs. 512 Ag/ml respectively, GMR 1.27, 95% CI 0.76–2.08
(Fig 2), nor did the GMC differ by ART duration category 647, 392, 762, 516 & 0 Ag/ml for no
treatment, year 1, 2, 3 & 4 of treatment respectively.
Table 2. Baseline characteristics of study 2 participants by HIV status.
A
Characteristic HIV-positive (n = 411)# HIV-negative (n = 7452)# OR (95% CI†) Adjusted OR (95% CI)*
Age group
15–29 years 77 (18.7%) 3793 (50.9%) - -
30–39 years 159 (38.7%) 1480 (19.9%) 5.29 (4.00–6.99) 5.35 (4.04–7.07)
40 years and above 175 (42.6%) 2179 (29.2%) 3.96 (3.01–5.20) 4.02 (3.06–5.29)
Sex
Female 269 (65.5%) 4201 (56.4%) - -
Male 142 (34.5%) 3251 (43.6%) 0.68 (0.55–0.84) 0.72 (0.58–0.89)
CFA status
Negative 325 (79.1%) 5663 (75.9%) - -
Positive 86 (20.9%) 1789 (24.0%) 0.84 (0.66–1.07) 0.86 (0.67–1.10)
B
Characteristic HIV-positive HIV-negative GMR (95% CI) Adjusted GMR (95% CI) *
CFA GMC, Ag/ml (95% CI) 630 (511–778) 839 (799–882) 0.75 (0.60–0.94) 0.62 (0.38–1.02)
A) The association of age group, gender and circulating ﬁlarial antigen (CFA) with HIV positivity. Adjusted Odds Ratio (OR) derived from logistic
regression model. B) Geometric mean concentration (GMC) of CFA in those CFA positive, Geometric Mean Ratio (GMR) derived from linear
regression model.
# 2 HIV-positive and 26 HIV-negative with incomplete data;
†CI—conﬁdence interval;
* Adjusted for age, sex, and reporting group
doi:10.1371/journal.pntd.0003825.t002
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Table 3. The association of circulating filarial antigenaemia (CFA) prevalence with HIV and antiretroviral therapy (ART) status andmajor potential
confounding socio-demographic characteristics in the 7,863 study 2 participants.
Characteristic N (%) CFA prevalence (%) OR (95% CI#) aOR (95% CI)
HIV and ART status
HIV-negative 7452 (94.8) 1789 (24.0) Ref* Ref
HIV-positive—no ART 265 (3.4) 67 (25.3) 1.07 (0.81–1.42) 1.20 (0.90–1.62)
HIV-positive—ART 142 (1.8) 18 (12.7) 0.46 (0.28–0.76) 0.50 (0.30–0.84)
Gender
Male 3392 (43.1) 995 (29.3) 1.69 (1.52–1.88) 1.77 (1.59–1.98)
Female 4470 (56.9) 880 (19.7) Ref Ref
Age group
Age 15–29 years 3870 (49.2) 896 (23.2) Ref Ref
Age 30–39 years 1639 (20.9) 440 (26.7) 1.22 (1.07–1.39) 1.24 (1.08–1.43)
Age 40 years and above 2354 (29.9) 539 (22.9) 0.99 (0.87–1.11) 0.95 (0.84–1.09)
Mosquito net ownership
0 197 (2.5) 46 (23.4) Ref -
1 945 (12.0) 254 (26.9) 1.21 (0.84–1.73) -
2 1817 (23.1) 461 (25.4) 1.12 (0.79–1.58) -
3 1835 (23.3) 430 (23.4) 1.00 (0.71–1.42) -
4 2854 (36.3) 640 (22.4) 0.95 (0.67–1.34) -
unknown 215 (2.7) - - -
Educational achievement
Nil 277 (3.6) 83 (30.0) Ref Ref
Primary 5493 (71.3) 1379 (25.1) 0.78(0.60–1.02) 0.71 (0.54–0.93)
Secondary 1886 (24.5) 377 (20.0) 0.58 (0.44–0.77) 0.55 (0.41–0.75)
Tertiary 45 (0.6) 8 (17.8) 0.51 (0.23–1.13) 0.52 (0.22–1.19)
Unknown 2 (0.0) - -
Water supply
Bore hole 3755 (47.7) 1037 (27.6) Ref Ref
Tap to house 1082 (13.8) 105 (9.7) 0.28 (0.23–0.35) 0.30 (0.24–0.37)
Shared tap 835 (10.6) 127 (15.2) 0.47 (0.38–0.57) 0.48 (0.39–0.59)
Covered well 999 (12.7) 303 (30.3) 1.14 (0.98–1.33) 1.16 (0.99–1.35)
Open well 572 (7.3) 167 (29.2) 1.08 (0.89–1.31) 1.06 (0.87–1.30)
Lake 456 (5.8) 106 (23.3) 0.79 (0.63–1.00) 0.77 (0.61–0.97)
Unknown 11 (0.1) - - -
Housing type
Burnt brick 5750 (73.1) 1328 (23.1) Ref
Unburnt brick 678 (8.6) 169 (24.9) 1.11 (0.92–1.33) 1.00 (0.83–1.21)
Mud 1087 (13.8) 299 (27.5) 1.26 (1.09–1.46) 1.03 (0.88–1.20)
Grass/bamboo 167 (2.1) 49 (29.3) 1.38 (0.98–1.94) 1.14 (0.81–1.62)
Other 18 (0.2) 2 (11.1) 0.42 (0.10–1.81) 0.43 (0.10–1.91)
Unknown 163 (2.1) - - -
Crude and adjusted Odds Ratios (OR) derived from a logistic regression model. Data on reporting group are not shown in the table but adjusted models
include this as a potential confounder along with the other signiﬁcant variables in the crude analysis.
#CI—conﬁdence interval:
*Reference category
doi:10.1371/journal.pntd.0003825.t003
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Discussion
We present data from two separate studies undertaken in Karonga district, northern Malawi.
In both studies a high LF and HIV prevalence was measured with HIV co-infection rates of
2.6% and 4.6% among those who were CFA positive and 15 years and older. We found no evi-
dence that HIV is associated with an increased risk of LF infection. Initial findings from study
1, a clinical trial not powered to definitively test the impact of HIV on LF infection, revealed a
tendency to lower CFA and microfilarial density in the HIV-positive adults. Subsequent inves-
tigation of these parameters in the much larger population sample revealed a tendency to lower
CFA prevalence in the HIV-positive group, attributable to significantly lower CFA prevalence
in the ART treated sub-group, a finding that persisted following adjustment for key potential
confounders and showed a significant trend to lower CFA prevalence with duration of ART
use. There was no significant effect of CTX therapy, when analysed in a multivariable model.
CFA concentration was also persistently lower in the HIV-positive group although at a level of
uncertain clinical or public health significance.
Fig 2. Box plot of Circulating Filarial Antigen (CFA) concentration distribution (on logarithmic scale) by HIV and antiretroviral treatment (ART)
status for study 2 participants. The boxes show the median value and the interquartile range. The whiskers include all values within 1.5 times the
interquartile range with outliers shown as points. Comparison of CFA concentrations by group HIV- vs. HIV +/ART- (p = 0.22): HIV- vs. HIV+/ART+ (p = 0.05):
HIV+/ART- vs. HIV+/ART+ (p = 0.28), derived from a linear regression model adjusted for age, gender and reporting group.
doi:10.1371/journal.pntd.0003825.g002
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Previous studies have reported divergent findings with some showing an association be-
tween LF and HIV infections but these have tended to be small samples and in selected popula-
tions [6–8]. In contrast to these studies, our second study had a larger sample taken from a
whole population survey, including a high proportion of the at-risk population in an area with
high prevalence rates of LF and HIV. The findings in relation to ART use are novel and we are
unaware of other studies that have investigated this association. Individuals receiving ART
may represent a select group of the HIV-positive population who have better health seeking be-
haviour, may be more educated, live in better accommodation and/or may live in close proxim-
ity to health providers. However, as this work was undertaken in the context of a demographic
survey we were able to investigate these potential confounders by adjusting for reported educa-
tional status, housing quality, access to clean water and geographic location. The finding of
ART associated with a lower CFA prevalence appears robust.
An explanation for these findings remains less clear and merits further work. Residual con-
founding or an unrecognised selection bias remains possible, but seems unlikely given the high-
ly significant lower CFA prevalence with duration of ART therapy. The crude association of
CTX with lower CFA prevalence seems adequately explained by concomitant use of ART, and
there is no evidence to support either sulphonamides or trimethoprim, the components of
CTX, as effective antifilarial agents. If LF infection adversely impacts on the success of ART
therapy, then over time the prevalence of CFA positivity in this group will reduce as the LF/
HIV co-infected die. There is no evidence from the Malawi national HIV programme that out-
comes from ART treatment are worse in regions of the country endemic for LF compared to
those with low LF prevalence. Helminth infections have been linked to increased viral load in
non-ART treated individuals [21] but not to evidence of faster HIV progression [22]. Similarly,
LF infection had no significant effect on HIV disease progression in a study ofW. bancrofti
and HIV coinfections in south India [23]. Altered diagnostic accuracy of the Og4C3 ELISA in
the presence of ART has not been reported. ART has been rarely linked to false negative HIV
results in children and adults but this is more likely to be due to low levels of virus and/or anti-
body than a direct inhibitory effect. The reduction in CFA prevalence by ART treatment dura-
tion and the antigen capture nature of the Og4C3 ELISA would be difficult to explain by ART
inhibition of the assay. Immune reconstitution as a result of ART does not adequately explain
our finding either as there is a similar prevalence of CFA in the HIV-negative and the HIV-
positive untreated. There is no precedent for immune recovery following ART leaving the im-
mune system in a more competent state than an HIV-negative person. ART treatment is an im-
precise proxy marker of duration of HIV infection. If the natural history of LF in the HIV-
positive is a steady fall in antigenaemia could this explain the association? We do not have ac-
curate seroconversion dates for the majority of this population so are not able to fully consider
this possibility. However with ART use the “natural history” of HIV is dramatically altered and
it might be expected that any tendency to lower antigenaemia with time would also be altered
and this would be inconsistent with our findings. The most plausible explanation for this find-
ing is a direct filaricidal activity of the major ART agents. We are unaware of any data on the
effect of Lamivudine, Stavudine or Nevirapine on helminths. Further evaluation of these mole-
cules as antihelminthics would be appropriate.
Of the other factors associated with CFA positivity all have been reported previously, pro-
viding reassurance that the epidemiology of LF disease in Karonga is not unique and results are
generalizable to other similar regions. One surprise was the lack of association with bed net
ownership. However most households possessed bed nets limiting the power of any compari-
son, and during this survey we did not specifically ask about usage, or condition of the nets,
thus limiting the value of this finding. More detailed evaluation of this will be needed in
future work.
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Both of our studies had some degree of selection bias, but it is unlikely that this has funda-
mentally altered our findings. In study 1, we targeted villages known historically to have a high
prevalence of LF infection. If participation by HIV-positive individuals was reduced because of
perceived stigma associated with an HIV test, we may have had reduced power to identify an
association between LF and HIV. However, a similar finding in the much larger study 2 pro-
vides consistency. In study 2, we know HIV-positive adults were under-represented. Adults
who knew their status from earlier HIV testing studies or through routine service provision in
the district, declined participation [20]. However it is difficult to see a mechanism whereby LF
co-infection would disproportionately lead to non-participation by HIV-positive adults and in
particular ART treated HIV-positive adults thereby obscuring the true association.
More females than males were included in both studies. This may represent the easier access
to females at the time of recruitment since females are more likely to be at home. Although we
know men are more likely to be infected with LF in this population, we do not think this
under-representation has meaningfully affected the LF/HIV association. Sub-group analyses
showed similar odds ratios for the LF/HIV association by gender in study 2 suggesting no
major effect modification.
The measurement of our exposure (HIV) and outcome endpoints (LF status) were based on
accurate and well described tests and we do not believe these have introduced significant bias
into the study. We used different tests for assessment of circulating filarial antigen in the two
studies with different sensitivities and specificities, the ICT card test with sensitivity and speci-
ficity reportedly close to 100% and the Og4C3 ELISA test with 100% sensitivity and specificity
of at least 94% [24–26]. There was some disparity between these two tests identified in study 1.
This is consistent with previous studies that have reported overall agreement between the ICT
and Og3C4 tests but different sensitivities and specificities [24,25]. In study 2, we were not able
to assess MF counts due to the use of a stored sample collection. Whilst we cannot categorically
rule out an association between MF density and HIV, data from study 1 showed a positive cor-
relation between CFA levels and MF density. Previous studies have also shown a positive corre-
lation between CFA levels and MF density [26,27]. This implies that the CFA relationship will
broadly apply to MF counts.
In summary, we did not demonstrate a significant detrimental association between LF and
HIV in these studies that will have a negative impact on plans to eliminate lymphatic filariasis.
However ART treated adults had significantly lower CFA prevalence, a finding that merits fur-
ther careful evaluation to exclude an adverse impact of LF on HIV, or the potential of antiretro-
virals as molecules with antihelminthic properties.
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Background: In Africa, albendazole and ivermectin are currently used in combination for annual mass drug
administration (MDA) for lymphatic filariasis (LF) elimination. Rapid and sustained clearance is desirable for public
health impact and elimination of LF. Increasing the dose and/or frequency of albendazole and ivermectin treat-
ment may be more effective in clearing microfilariae than standard MDA.
Methods:We conducted a randomised controlled open label trial in northern Malawi comparing three modified
treatment groups to standard dosage of ivermectin and albendazole in adults with confirmed circulating LF anti-
gen andmicrofilaria. Participants were followed-up every 6months for 2 years for repeatmicrofilarial counts and
safety assessments.
Results: A total of 1851 adults were screened and 70 with microfilarial counts.80 microfilariae/ml were rando-
mised. All treatment groups achieved a significant reduction of microfilariae levels by 12- and 24-months of fol-
low-up. Doubling the standard dose and administering it twice yearly showed a non-significant tendency towards
faster and more complete clearance. There were no serious adverse reactions.
Conclusions: In this small study, all regimens effectively cleared microfilaria. Standard treatment may be
adequate in settings like Malawi but not in all endemic settings and larger studies are required to demonstrate
benefit of higher dosages.
[ClinicalTrials.gov identifier: NCT01213576].
Keywords: Albendazole, Clinical trial, Ivermectin, Lymphatic filariasis, Malawi, Microfilaria
Introduction
Lymphatic filariasis (LF) remains one of the leading causes of dis-
ability in tropical areas.1 Most cases of LF, and all cases in Africa,
are caused by the filarial nematode, Wuchereria bancrofti, with
more than 120million persons affected globally and up to one bil-
lion persons at risk of infection.2 In response to this, WHO
launched the Global Programme to Eliminate Lymphatic
Filariasis (GPELF) in 2000, aiming to eliminate LF through annual
mass drug administration (MDA) using single-dose albendazole
(400 mg) and ivermectin (150–200 mg/kg) annually for 4–6
years to affected populations in Africa.3,4 Rapid and sustained
clearance is desirable for public health impact and the ideal
annual dosing regimens remain unclear with documented ‘hot
spots’ of new transmission remaining in areas that have received
MDA and reports of individuals who remain microfilaria (mf) posi-
tive despite treatment.5
Higher annual doses or more frequent dosing regimens might
have the potential to achieve a successful and accelerated out-
come of mass treatment programmes. This could be at a lower
overall cost to national programmes by achieving critical pro-
grammatic milestones much earlier.6 However, available data to
guide and support such a large programmatic shift are limited.
A randomised clinical trial conducted in Giza, Egypt reported
that multi-dose diethylcarbamazine and albendazole treatment
was more effective than single dose treatment for reducing and
clearing LF microfilaraemia.7 In a study that compared repeated
annual and semi-annual doses of ivermectin and diethylcarba-
mazine for prevention of W. bancrofti filariasis in French
# The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
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Polynesia, the efficacy of ivermectin was shown to bemuch higher
when given twice-a-year rather than annually.8 Another study
conducted in Haiti suggested that high doses of ivermectin may
have longer lasting suppressive effects on LF microfilarial levels.9
Similarly, in Mali, a high dose, biannual treatment with albenda-
zole and ivermectin was shown to be more effective than the
standard dose regimen in suppressing microfilariae.10
In Malawi, the districts of Karonga in the north, and Chikwawa
and Nsanje in the south are historically known to be endemic for
LF11,12 and recent surveys have shown that this infection has
spread more widely than previously thought.13 We undertook a
study in Malawi to investigate whether higher and/or more fre-
quent doses of albendazole and ivermectin were more effective
in eliminating W. bancrofti microfilariae than the current WHO–
approved regimen in an African setting where previous exposure
to LF treatment regimens had been limited or absent.
Materials and methods
This was a randomised, four-arm, open-label, clinical trial. The
study took place from January 2009 to March 2012 in 16 villages
in a pre-defined study area close to the Songwe River in the north
of Karonga district of northern Malawi. This area was known to be
highly endemic for W. bancrofti infection and no mass treatment
intervention had been undertaken prior to commencement of this
study. The trial was registered with Clinical trial.gov, number
NCT01213576.
Study participants
Eligible participants were all adults aged between 18 and 55 years
living within the study area who understood and signed the
informed consent, were willing to undergo night time blood draw-
ing every 6 months for 2 years, had haemoglobin levels ≥9 g/dl
and microfilarial levels .80 microfilariae/ml. Exclusion criteria
were pregnancy, lactation and history of taking albendazole or
ivermectin for any reason within the previous 6 months or a
known allergy to either drug.
Study procedures
At the initiation of the study, field study personnel explained pro-
cedures at village sensitisation meetings. Recruitment was then
done through house-to-house visits. Consenting, eligible indivi-
duals were initially screened for circulating filarial antigenaemia
(CFA) using the Immunochromatographic (ICT) card test (Binax,
Portland, ME, USA).14 The ICT card test was administered accord-
ing to the manufacturer’s instructions with measurements read
at 10 minutes and if two lines were visible in the viewing window
that individual was recorded positive for CFA. Individuals whose
samples produced faint lines were recorded as weakly positive
and deemed as positive individuals for subsequent investigations.
Individuals who were positive for CFA by the ICT card test and
consented to provide a night blood sample were evaluated with a
brief medical history and physical examination and visited at their
households between 22:00 and 02:00 hours for collection of two
venous ‘night blood’ samples. One EDTA sample was used for full
blood count, including eosinophils and the other, a sodium citrate
sample, was used for microfilaria measurement by the
Nucleoporemembrane filtration technique15 expressed as density
of microfilariae (mf) per ml of blood.
Randomisation
Participants who fulfilled the eligibility criteria underwent further
informed consent and were assigned to study treatment groups
using a computer-generated randomisation list. An independent
investigator pre-generated the list, which had an allocation ratio
of 1:1:1:1 and restricted block sizes of four. Study field personnel
enrolled and allocated participants to the treatment groups using
allocation letters on the randomisation list consecutively for each
individual recruited into the study. The study field personnel kept
the allocation list in a field site locker and no blinding was
employed since the trial design was open-label.
Interventions
Eligible participants were randomly allocated to the four treat-
ment study arms (see Figure 1): the standard regimen of single
dose albendazole (400 mg) and ivermectin (200 mg/kg)
once-yearly (control group [SDA]), a twice-yearly standard regi-
men (SDT), a high-dose regimen of albendazole (800 mg) and
ivermectin (400 mg/kg) given either once-yearly (HDA) and the
same given twice-yearly for a period of 2 years (HDT).
Study drugs were taken orally under direct observation by field
staff to ensure compliance and to record any immediate side
effects in the 30 minutes post-ingestion. The study team made
scheduled visits once a day for 7 days to a pre-defined place
within the village to review any individual who reported adverse
events post-treatment. Adverse events were self-reported and
assessed according to pre-defined clinical criteria. These were
recorded on an adverse event form and, if considered severe or
life threatening, was referred appropriately to the nearest health
facility.
Follow-up
Participants were followed-up every 6 months for 2 years, under-
went clinical assessment, venepuncture for full blood count and
night blood microfilarial counting and received subsequent
study drug administration as appropriate. In addition to the clin-
ical assessment done at each follow-up visit, information was col-
lected on filarial related clinical manifestations such as fever,
lymphoedema, lymphangitis, hydrocoele and skin rash.
Individuals with missed appointments remained in the study
until 24 months and were actively traced at each follow-up
appointment.
Sample size
The primary study endpoint was a difference in the clearance rate
of W. bancrofti microfilaraemia, expressed as microfilariae per ml
of blood (mf/ml), at 12 months. Based on data comparing single
and multi-dose regimens for the treatment of lymphatic filaria-
sis,7,16 we assumed that the standard annual therapy would
clear microfilaraemia in approximately 25% of subjects at
1 year whereas multi-dose therapy should give 75% clearance.
The sample size needed to detect this difference by Fisher’s
exact test with two-sided alpha level of 0.05 and power equal
T. T. Tafatatha et al.
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to 80% was 20 per group. Taking 15% attrition at each visit into
account, we planned to recruit 30 subjects per each study arm
(120 planned in total).
Data management and statistical analyses
Participant information was collected onto paper record forms.
Forms were transported to the project headquarters in
Chilumba, Karonga district, where they were checked, coded,
double entered and verified usingMicrosoft Access 2007 software.
All statistical analyses were done using STATA 12.0 (Stata
Corporation, TX, USA). The difference in clearance proportions
between the intervention treatment arms and the comparison
group was examined using the Fisher’s exact test and the log
rank test where appropriate.
The analysis used the last observation carried forward and
intention-to-treat approaches to deal with participants who did
not take all the intended treatments during the study.
Results
A total of 1851 individuals were screened and 70 participants
were found to be eligible for randomisation into the four treat-
ment arms of the study (Figure 1). Rates of missed appointments
were similar in all the treatment groups overall. In the
twice-yearly arms, this led to five missed treatments in SDT and
one in HDT in the first year. Recruitment ceased before the
planned sample size was achieved after the national MDA pro-
gramme for lymphatic filariasis commenced in the study location
in October 2009.17
Figure 1. Flow diagram of study participants of the clinical trial. This figure is available in black and white in print and in colour at Transactions online.
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Demographic and baseline characteristics were similar
between the treatment groups except for higher baseline micro-
filarial count levels in the annual standard dose treatment group
(Table 1).
In the intention to treat analysis, all the treatment groups
achieved significant reduction of microfilariae levels after alben-
dazole and ivermectin treatment by 12 months of follow-up.
Microfilarial clearance was 83% (15/18) for SDA, 82% (14/17)
for HDA, 72% (13/18) for SDTand 100% (17/17) for HDT treatment
doses, respectively. There was no statistically significant differ-
ence between high versus standard dose or between twice-yearly
versus once-yearly dosing of albendazole and ivermectin
(Table 2). In a post-hoc analysis, we compared all participants
with available data at 12 months who had received a single
dose (i.e., those in the single dose arms plus those in the
twice-yearly arms who failed to receive their second dose) versus
those who received two doses. In total, 35 received one dose, 29
received two doses and 6 did not have 12 months data available.
Microfilarial clearance was observed in 31 of 35 (89%) and 28 of
29 (97%), respectively. This was not significantly different, p¼0.38
(Fisher’s exact test).
While the difference inW. bancroftimicrofilarial clearance rate
tended towards significance in the high dose twice-yearly group
at 12 months, this again did not achieve statistical significance.
The high dose twice-yearly treatment group achieved complete
clearance of microfilaraemia at 12 months of follow-up without
any subsequent recurrence of microfilaraemia, while the other
treatment doses took up to 18months to achieve complete clear-
ance of microfilaraemia (Figure 2).
Twenty-two participants (31%) reported seven different
adverse events at various times in all treatment groups. Most of
these were mild to moderate in intensity and included fever,
headache, joint pains and abdominal pains (all typically asso-
ciated with treatment of microfilaraemia). Two cases of malaria,
one of pneumonia and a case of acute bacterial meningitis, which
resulted in the death of the patient, were admitted to hospital for
treatment, and were not considered treatment related. All other
symptoms were treated conservatively and did not result in hos-
pital admission.
At baseline, filarial related clinical manifestations were reported
in 8 (11%) of the participants for lymphoedema, 6 (9%) for lymph-
angitis, 12 (17%) for fever, 4 (6%) for hydrocoele and none for ele-
phantiasis and skin rash, respectively. There was no difference in
these clinical manifestations between subjects in the four treat-
ment groups of the study. During follow-up, there were no new
cases of lympoedema, lymphangitis, elephantiasis and skin rash.
Fever was reported by four individuals (6%) at 6 months and one
(1%) at 12 months, while two new cases of hydrocoele were
reported at 6 and 12 months, respectively. Eosinophilia (absolute
eosinophil count .500/ml) was present in 68 (97%) patients (see
Table 1) at baseline and no patient was found with eosinophilia
during follow-up, indicating a significant reduction after treatment.
Table 1. Baseline demographic and clinical characteristics for each treatment group in the clinical trial
Characteristic Annual standard
dose (n¼18)
Annual high
dose (n¼17)
Twice-yearly standard
dose (n¼18)
Twice-yearly high
dose (n¼17)
Age, median (range), years 32.5 (21–50) 31 (20–53) 27.5 (18–55) 35 (20–54)
Male sex (%) 15 (83.3) 11 (64.7) 11 (61.1) 10 (58.8)
Microfilarial count, geometric mean (95% CI),
mf/ml
464.7 (250.1–863.4) 338.7 (198.7–577.4) 204.5 (145.4–287.8) 264.7 (175.0–400.4)
Eosinophil count, geometric mean (95% CI),×103
cells/ul
1.3 (1.0–1.7) 1.4 (1.0–1.9) 1.6 (1.1–2.1) 1.1 (0.9–1.5)
Haemoglobin level, geometric mean (95% CI),
g/dl
13.7 (13.1–14.2) 13.2 (12.7–13.6) 13.2 (12.1–14.4) 12.4 (11.6–13.4)
Table 2. Number of participants with complete clearance of microfilaraemia by treatment group and month of follow-up
Treatment group 6 monthsa 12 monthsb 18 months 24 months
Annual standard dose 12/18 (67%) 15/18 (83%) 15/18 (83%) 17/18 (94%)
Annual high dose 13/17 (77%) 14/17 (82%) 17/17 (100%) 17/17 (100%)
Twice-yearly standard dose 13/18 (72%) 13/18 (72%) 14/18 (78%) 14/18 (79%)
Twice-yearly high dose 14/17 (82%) 17/17 (100%) 17/17 (100%) 17/17 (100%)
a p¼0.42: high versus standard dose regimens at 6 months.
b p¼1.00: twice annual versus single annual dose regimens at 12 months (Fisher’s exact test).
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Discussion
In this study, we found high levels of microfilarial clearance from
both the standard MDA treatment and experimental arms after
12 months, with additional clearance in all arms at 24 months.
The twice-yearly high dose albendazole (800 mg dose) and iver-
mectin (400 mg/kg) treatment regimen had a non-significant ten-
dency to faster clearance of microfilaraemia compared to the
WHO-recommended annual standard dose albendazole 400 mg
single dose and ivermectin 200 mg/kg treatment regimen, without
any increase in adverse events.
Our findings are consistent with available historic and contem-
porary trials of anti-filarial agents in other settings.8–10 A rando-
mised controlled clinical trial conducted in Mali just prior to our
study also reported that the higher dose twice-yearly treatment
regimen was more effective than the standard dose annual regi-
men.10 This trial was conducted in an area where there had been
considerable previous exposure to ivermectin for onchocerciasis
as well as a number of rounds of MDA for LF elimination and
infected subjects with adequate microfilarial levels were difficult
to find. Our study endorses, and adds to, the findings in Mali
since it had three intervention groups compared with the stand-
ard regimen andwas conducted in a setting of high LF-endemicity
with no known previous exposure to LF treatment or MDA for LF
elimination.
The response to standard treatment wasmuch better than the
expected 25% and 75% at 12 and 24 months, respectively and
this was a contributory reason for failure to achieve a definitive
outcome in this study. The sample size calculations were based
on findings emerging from data comparing single and multi-dose
regimens for the treatment of LF.7,16 The reduced response to
standard treatment in the Mali study may be due to the selection
of less sensitive strains as a consequence of previous exposure to
LF treatment. With the excellent response to standard treatment
in our study, a much larger cohort will be needed to investigate
these dosing schedules further. However, future studies similar
to this are likely to prove increasingly difficult to undertake with
the introduction and increased coverage of MDA.
The principal limitation of this study was the failure to recruit
adequate numbers of participants. Recruitment did not reach
the protocol target due to lower numbers of potential subjects
with the target microfilaraemia of .80 microfilariae/ml and
only 70 were randomised into the study. Recruitment was also
discontinued following the rollout of the albendazole/ivermectin
national MDA programme in the study area in October 2009.
Figure 2. Kaplan-Meier plots for the four treatment arms of the Songwe clinical trial. p¼0.38: annual standard versus annual high dose; p¼0.40: annual
standard versus twice-yearly standard dose; p¼0.16: annual standard versus twice-yearly high dose (log rank test). This figure is available in black and
white in print and in colour at Transactions online.
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Other limitations of the study were a relatively high rate of missed
follow-up appointments compounded by a series of earthquakes
in late 2009 that affected the ability of field workers to reach
potential subjects.
A reduction in LF incidence is likely to have contributed to lower
than expected recruitment. The study site in the Songwe River
area of Malawi was chosen because prior work in the area had
shown a high prevalence of LF antigenaemia (46%) and microfi-
laraemia (30.8%) some 10 years previously.18 During the screen-
ing process for this study, the prevalence of LF was lower,
suggesting a reduction in the incidence of new infections during
this period. A similar trend was observed in Zambia, a neighbour-
ing country to Malawi, where LF prevalence decreased from 33.3
to 14.8% between 2003 and 2011.19 This was attributed to a
decrease in LF transmission following intensive vector control
activities, including the distribution of bed nets. Our study area
had not been subject to MDA for LF and there was no previous
distribution of albendazole for soil-transmitted nematodes.
Migration of patients from the area can also be discounted, as
can significant changes in climatic conditions and vegetation
cover. However, as described in Zambia, there has been a scale-up
ofmalaria control interventions in Malawi with 55%of households
in rural areas reported owning at least one insecticide-treated
mosquito net.20 Thus vector control may account for some, but
not all, of the LF decline observed in our study area. We were
unable to further confirm this through entomological data or
through reports of a decline in filarial-related clinical manifesta-
tions. It is possible that the decline in LF has been ongoing for
many years unnoticed, and that the disease may already have
been declining before the implementation of MDA.
Conclusions
All four treatment doses were effective in clearing lymphatic filar-
iasis microfilariae and these findings are consistent with results
from historic and contemporary trials of anti-filarial agents.
Although these findings did not reach statistical significance due
to low numbers, they provide additional high quality data on the
treatment of LF from an LF-endemic area and indicate that stand-
ard treatment may be adequate for national LF programmes in
settings with similar epidemiology and treatment history to
Malawi. Publication of these results will make them accessible
for a future meta-analysis. While larger studies would be required
to demonstrate the benefit of higher andmore frequent regimens
definitively, these are likely to be increasingly challenging and
expensive to undertake at the required scale.
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